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Developments in high throughput screening and combinatorial chemistry have 
contributed to the unprecedented success of the pharmaceutical industry over the last 
twenty years, leading to a multitude of blockbuster compounds that revolutionized 
treatment for a variety of clinical indications.  This success, particularly in drug 
discovery, has been tempered by an increased number of moieties exhibiting delivery 
limitations due to molecular structure.  One of the most pressing areas of pharmaceutical 
research today is addressing the reduced aqueous solubility of developmental chemical 
entities in pharmaceutical pipelines, which has been estimated to affect up to 90% of such 
compounds.  Current technologies have focused on maximizing dissolution rates or 
equilibrium solubilities of such compounds using platforms such as microemulsions, 
polymorph engineering, particle size reduction, and complexation.  While these 
technologies have been shown to improve oral bioavailability for a number of 
compositions, further improvement can be achieved by developing new production and 
 ix
formulation technologies for amorphous systems.  Within the frame work of this 
dissertation, two unique technologies for bioavailability enhancement were investigated; 
formulation with concentration enhancing polymers to provide extended durations of 
supersaturation and the development of a novel fusion based solid dispersion production 
process based on thermo-kinetic mixing, termed KinetiSol® Dispersing, for the 
production of amorphous solid dispersions.  Studies of solid dispersions containing 
concentration enhancing polymers prepared by ultra rapid freezing showed the ability of 
these formulations to provide improved oral bioavailability of itraconazole when 
compared to the currently marketed product, which is a conventional hydrophilic solid 
dispersion.  KinetiSol® Dispersing was also extensively studied within this work and 
shown to be a viable platform for the production of hydrophilic solid dispersions, 
plasticizer free solid dispersions and solid dispersions containing heat sensitive active 
ingredients.  In a culminating study, KinetiSol® Dispersing was utilized for the 
production of amorphous solid dispersions containing concentration enhancing polymers 
for improved oral bioavailability of itraconazole.  Ultimately, this body of work 
demonstrated that concentration enhancing polymers could provide improved oral 
bioavailability for poorly water soluble compounds, while KinetiSol® Dispersing could 
be used for the production of such compositions, thereby presenting novel technologies 
for addressing future development of poorly water soluble active ingredients. 
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Chapter 1:  Current Formulation and Processing Technologies for the 
Production of Amorphous Solid Dispersions 
1.1 INTRODUCTION 
 
The development of computational chemistry and high throughput screening has 
allowed for substantial progress in the way drug substances are developed, moving R&D 
efforts from remote areas of the world where compounds were once tediously collected 
and analyzed to the bench-top laboratory where thousands of chemical compounds can be 
engineered and rapidly assessed for potential activity in the human body.  High 
throughput screening has resulted in a multitude of new chemical entities (NCE) capable 
of treating a variety of disease states, however many of these compounds have also 
shown a substantial decrease in oral bioavailability over their predecessors, hindering the 
development of orally administered compositions.  A variety of molecular properties 
have been identified in association with low bioavailability, including: high molecular 
weight (> 500), log P values greater than 5, the number of hydrogen bond donors present 
on the molecule exceeding 5 and 10 or more hydrogen bond acceptor sites on the 
molecule (1).  Additionally, the number of rotatable bonds on a drug molecule, generally 
when greater than 10, has also been correlated with reduced oral bioavailability as a 
result of the entropic penalty associated with associated with achieving conformations 
necessary to facilitate absorption (2). Specifically for oral delivery, Biopharmaceutics 
Classification System (BCS) class II poorly water soluble compounds have been shown 
to exhibit bioavailability relative to the dissolution rate of the drug product, with 
increased dissolution rates providing improved oral bioavailability (3,4).  It has been 
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reported that 40 – 70% of new chemical entities (NCEs) in development, can be 
classified as BCS II compounds, having solubility issues (5,6) which limit oral 
bioavailability.  Of these compounds, it has been estimated 15 – 30% can exhibit some 
improvement in dissolution rate through modification of the drug crystal structure (7).  
Additionally, it is estimated that a further 20% of developmental compounds exhibit a 
combination of solubility and permeability limitations that impact oral bioavailability, 
indicating that upwards of 90% of developmental compounds are affected by solubility 
limitations (8). 
 
Over the last decade, there has been an explosion of new technologies and 
formulation strategies capable of addressing poor oral bioavailability due to low aqueous 
solubility, including: crystal engineering, co-crystal formation, nanoparticle production, 
cyclodextrin complexation and amorphous formation.  Each of these processes seeks to 
maximize the dissolution rate through modification of the intermolecular interactions 
and/or reduction of surface area which often results in supersaturation, or the ability of a 
formulation to provide drug concentrations in excess of the equilibrium solubility.  
Ultimately, however, these formulations eventually return the drug concentration to its 
equilibrium solubility due to the thermodynamic instability associated with this state 
which can result in incomplete and variable oral bioavailability.  An emerging field of 
research focuses on the maintenance of supersaturation to provide improved oral 
bioavailability of pharmaceutical compositions.  This technique exploits unique 
interactions of drug and polymeric stabilizers to provide longer durations and elevated 
concentrations of drug in solution to thereby improve oral absorption.  While very 
preliminary studies have shown this to be a viable technique, additional research in this 
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field is necessary to truly establish the utility for oral bioavailability enhancement and 
also provide a more detailed scientific understanding of the underlying mechanism. 
 
In addition to new formulation technologies pioneered to address aqueous 
solubility limitations, processing technologies have also been developed to produce stable 
amorphous compositions providing dissolution and product stability benefits.  While 
many technologies have focused on particle size reduction to provide increased surface 
area, a select group of processes have been developed to regulate the crystal structure of 
the active ingredient to alter the thermodynamic properties of the material and enhance 
dissolution rate.  While these technologies have established themselves amenable to 
production in both R&D and commercial manufacturing environments they also present 
significant disadvantages such as the requirement for potentially toxic solvents and the 
need for elevated processing temperatures.  As such, there is also a continued need for the 
development of new technologies capable of effectively producing amorphous solid 
dispersions without the negative attributes associated with current technologies.  
 
This introductory section describes the underlying mechanisms for solubility 
enhancement from supersaturatable systems, as well as current applications of solid 
dispersion systems for bioavailability enhancement.  It also presents an overview of the 
currently available production techniques, highlighting advantages and disadvantages of 
each.  Utilizing this a backdrop, it also presents current literature related to concentration 
enhancing polymers and thermo-kinetic mixing to provide an understanding of those 




1.2 PROCESSING TECHNOLOGIES FOR AMORPHOUS COMPOSITIONS 
 
1.2.1 Solid State Properties of Amorphous Systems 
 
Pharmaceutical materials can be described by a variety of physicochemical 
properties, including: chemical structure, crystal structure and particle morphology.  The 
chemical structure of a compound refers to the particular atomic composition of the 
molecule, which can be combined in large clusters of molecules which present a 
macroscopic three dimensional structure.  Within these clusters the intermolecular 
spacing is referred to as crystal structure.  In many compounds, this arrangement presents 
both long range and short range order, resulting in specific interactions between the 
molecules within the ensemble.  Such structures are commonly referred to as crystal 
lattices and are present in seven basic forms, regardless of whether they are organic or 
ionic crystals.  Out of these seven basic structures, organic molecules may also present 
different packing configurations within the crystal lattice, thereby expanding on the 
number of possible configurations for arrangement.  For a given molecule, multiple 
configurations may be possible, and such materials are referred to as polymorphic forms.  
Each polymorphic form also presents a different long and short range order resulting in 
different intermolecular interactions and variable thermodynamic properties of the 
system, specifically free energy.  As a general rule of thermodynamics systems always 
attempt to achieve the lowest free energy state and the variation of free energy within the 
different crystal forms establishes a most stable polymorphic form and then metastable 
polymorphic forms having higher free energies.  It is important to note that the specific 
 5
crystal structure which is most stable may only be so under a given set of conditions, and 
deviation outside of those conditions would establish other forms as the most stable.  This 
behavior is referred to as enantiotropic behavior, while a crystal form which is most 
stable over all conditions is referred to as monotropic.  Free energy of a crystal form is 
also directly related to the apparent solubility of the compound, true density of the 
substance and melting point of the material, such that higher free energy systems exhibit 
a lower melting point, reduced density and greater apparent solubility.  Application of 
polymorphic form selection has been well illustrated throughout the history of the 
pharmaceutical industry for a variety of applications, including: morphological control, 
stability and solubility.  While a theoretical potential exists for such system, they have 
generally shown only limited solubility improvements while being hampered by 
thermodynamic instability.  As a result, the pharmaceutical industry has not extensively 
embraced pharmaceutical polymorph screening for oral bioavailability enhancement. 
 
Material properties of pharmaceutical compounds can be further manipulated to 
control properties, particularly solubility, by eliminating long and short range order 
associated with the crystal structure to create an amorphous material.  Since amorphous 
forms lack coherent long range order associated with a crystal form, the material is 
presented in the highest free energy state and can provide the greatest apparent solubility 
and dissolution rate, often providing significant increases in such metrics.  Generation of 
an amorphous form also results in dramatic changes in the physical properties of such 
materials.  Unlike the crystalline counterparts which are characterized by well defined 
melting points, amorphous materials are actually considered supercooled liquids below 
such transition points and exhibit a glass transition temperature where the equilibrium 
properties of the material, such as enthalpy and volume, deviate from that of the 
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supercooled glass, as shown in Figure 1.1.  In such systems, properties such as solubility, 
molecular mobility and vapor pressure are enhanced relative to the crystal state.  While 
improvements in solubility can offer the potential to enhance oral bioavailability, greater 
molecular mobility and elevated free energy can drive phase transformations and it is this 
instability that has been viewed by the pharmaceutical industry as one of the greatest 
drawbacks in the development of such systems. 
 
Resulting from the solubility benefits provided by these systems, extensive 
research has been conducted investigating the fundamental mechanisms of 
recrystallization and polymorphic conversion, as well as techniques for improving the 
overall stability of such compositions.  While recrystallization is predicted to occur as a 
result of the thermodynamic instability of the system, the rates of such transformations 
are determined by the kinetics associated with such processes, specifically activation 
energy and molecular mobility which may hinder such phenomena.  Relaxation rates of 
pharmaceutical systems have been described using the Vogel-Tammann-Fulcher (VTF) 
equation which provides an Arrhenius type relation for molecular relaxation as a function 
of temperature (9).  Further understanding of molecular motion within such systems is 
also expressed using the Williams-Landel-Ferry (WLF) equation which describes the 
temperature dependence of viscosity in such systems (9).  In both relationships, the 
strong dependence of properties influencing molecular mobility on temperature indicates 
that controlling the environmental conditions can regulate recrystallization rates.  As 
shown in Figure 1.1, as the supercooled liquid line is extrapolated past the glass transition 
temperature the line will intersect the enthalpy of the crystalline form which denotes the 
Kauzman temperature where configurational entropy of the system reaches zero (9).  
Utilizing the WLF equation, an approximate temperature of 50 K below the glass 
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transition temperature will provide a situation in which all molecular motion is essentially 
stopped and recrystallization is no longer possible (10,11).  Using this result, one 
approach to stabilizing such systems has been to store them under special conditions 
where this rule can be maintained.  It is important to realize however, that such behavior 
may be impacted by environmental conditions, such as moisture uptake, which can help 
to plasticize the material and provide greater molecular motion.   
 
An alternative approach, which is much more common for pharmaceutical 
products today, is the development of amorphous solid dispersions, which combine the 
active ingredient and one or more carrier materials which can stabilize the amorphous 
form through specific interactions or a general increase in glass transition temperature 
(12).  In the most common form, this material creates a solid solution in which the drug 
substance is homogeneously distributed within the carrier matrix, yielding a single glass 
transition temperature during solid state characterization.  The behavior of such miscible 
forms is governed by the Gordon-Taylor equation in a two component situation which is 
actually a special case of the multicomponent Fox equation (13).  Interestingly, when the 
drug and carrier exhibit a synergistic interaction, such as hydrogen bonding, positive 
deviation in the Gordon-Taylor relationship is observed which results in elevated glass 
transition temperatures (14).  In addition to the benefits provided by such systems for 
elevating the glass transition temperature, benefits in dissolution rate can also be 
achieved through the establishment of polymer dissolution rate limited release systems, 
which are described in subsequent sections. 
 
The production of amorphous active ingredients and amorphous solid solutions 
are generally accomplished by one of four basic techniques, including: precipitation from 
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solution, vapor condensation, milling/compaction and supercooling of a melt (9).  In 
three of the four schemes, the drug and optional carrier materials are dispersed in a 
molecular state and then applied through processing to render a solid amorphous form.  
For milling/compaction processes however, the amorphous form is produced by the 
introduction of high amounts of energy that drive the formation of molecular disorder 
within the system to form an amorphous material.  While this method has been shown to 
provide the capability for amorphous material production, this class of unit operation is 
not commonly used for the production of such systems, but rather serves as a common 
example for the unintended conversion of crystalline material to amorphous material.  
For pharmaceutical production methods, amorphous systems are most commonly 
intentionally created using supercooling of a melt and precipitation from solution 
schemes which are commonly referred to as fusion processing and solvent processing 
respectively (15). 
   
1.2.2 Solvent Processing 
 
Solvent processing techniques for the production of amorphous pharmaceutical 
systems are currently the most popular mode of manufacture for such products and 
consist of a variety of unit operations including: fluid bed coating, spray drying and 
particle engineering.  While the specifics of each operation vary substantially, the basic 
principle is the same.  Drug and optional carrier materials are dissolved into an 
appropriate solvent, ranging from a supercritical fluid to common organic solvent and 
mixed to develop a homogeneous solution.  That solution is then applied by a process in 
order to rapidly remove the solvent on a time scale where molecular mobility cannot 
induce recrystallization.  By inhibiting the molecular motion and preventing 
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recrystallization it is possible to develop an amorphous form, capable of providing 
enhanced oral bioavailability. 
 
Fluid bed coating is the most common commercial method of amorphous form 
production and several currently marketed products are available based on this 
technology, including: Sporanox® (16) and Prograf® (17). In both cases the drug and 
hydroxypropyl methylcellulose carrier are dissolved in an organic solvent system which 
is layered onto multiparticulate cores.  While this technology platform is capable of 
rendering an amorphous form and also provides benefits in using existing production 
capabilities, it suffers from requirements for potentially toxic solvents, as well as the need 
for extended drying periods at elevated temperatures to ensure complete solvent removal. 
 
Another technology for solvent based production of amorphous pharmaceutical 
systems is spray drying.  Similar to fluid bed coating, the drug and appropriate carriers 
are dissolved in a common solvent and sprayed into a chamber to rapidly remove the 
liquid phase.  Unlike fluid bed coating, the droplets are sprayed through an atomizing air 
nozzle and directly into a drying chamber, whereas in fluid bed coating, the droplets are 
sprayed onto the pellet surface forming a film on the substrate.  By processing the 
droplets directly into the air stream, it is possible to control not only the amorphous 
nature of the particles but the particle morphology.  Extensive studies have been 
conducted to identify the critical variables for controlling such properties and ultimately 
it has been shown to be related to the relationship of decreasing droplet size and diffusive 
molecular flow within the system, which can be described by the Péclet number (18,19).  
Through careful optimization of the processing conditions it is possible to produce 
particles having maximized specific surface areas, capable of further improving 
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dissolution, solubility and oral bioavailability.  This technology has also been extensively 
applied to the development of systems for pulmonary delivery, specifically the 
production of large porous particles (18-20).  In addition to the obvious drawbacks 
associated with solvent use during processing, the low bulk density of the resulting 
material can also have significant issues on downstream processing during compression 
and encapsulation (21).  When preparing solvent systems for such applications, the 
loading of material into solution may be a limiting factor due to viscosity or atomization 
considerations and as a result are generally less than 20% w/w during most conventional 
processing which results in an inherently low density (21).  While process optimization 
can facilitate the production of formulations with increased densities and many new spray 
drying systems allow for production under pressurized environments, most products are 
still produced having bulk properties which can negatively impact downstream 
processing.  This presents a need for additional post processing to increase density using 
techniques such as roller compaction or slugging.  Another critical aspect of spray drying 
process control focuses around the optimization of drying rates to prevent phase 
separation (22).  During the drying process, solvent is removed which results in the 
formation of concentration gradients for the components dissolved within the particles.  
Varying drying rates relative to the differing material solubility can lead to phase 
separation.  Control of such issues during production is another critical area of 
development, since these issues may result in reduced dissolution rates and poor product 
stability. 
 
Particle engineering technologies have also been researched extensively, 
providing another viable platform for the production of pharmaceutical materials having 
well controlled physical and morphological properties (23-25).  Three major sub classes 
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for such technologies are: supercritical fluid technologies, anti-solvent processes and 
cryogenic production, each providing its own unique advantages for the manufacture of 
such materials.   
 
Supercritical fluid technologies utilize solvents maintained under conditions of 
temperature and pressure above the critical point, allowing for common materials such as 
carbon dioxide to be used as a solvent.  As a result of the supercritical and often non-
toxic nature of the solvent employed, removal is often rapid and complete, only requiring 
a return of the material to ambient conditions.  Unfortunately, supercritical fluids 
generally exhibit only minimal solubility for pharmaceutical materials, which can limit 
the applicability of this technology (26).  As a result, many of the technologies using 
supercritical fluids for pharmaceutical applications rely on it for the extraction of residual 
solvents, spurring the development of anti-solvent processes.   
 
In anti-solvent processes for pharmaceutical applications, the drug and carrier are 
dissolved in a solvent that is miscible with a second non toxic solvent system.  The 
drug:carrier solution is then added into the second solvent, where the miscible toxic 
solvent diffuses into the solvent, while the drug:carrier mixture which exhibits extremely 
low solubility precipitates to form a particle.  The particles can then be isolated and 
further dried to remove any residual toxic solvent remaining.  This technology has also 
been effectively used to produce amorphous systems.  Kim et al. (27) recently applied 
supercritical anti-solvent processing techniques to produce amorphous formulations of 
atorvastatin calcium to provide enhanced oral bioavailability.  Their results showed that 
such technologies could be applied to the production of amorphous systems and provided 
significant improvements for oral bioavailability in a rat model.  In another study by 
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Vaughn et al. (28,29) using evaporative precipitation in aqueous solutions, an antisolvent 
technique using an aqueous environment, substantially amorphous danazol particles were 
produced leading to in vitro supersaturation and enhanced oral bioavailability compared 
to a physical mixture of drug and carrier in a murine model.  One negative attribute of 
such production techniques is the relatively long time scales for diffusion of the solvent 
in the bulk antisolvent and the dynamics of drug and carrier concentration which occur as 
a result.  As highlighted by Vaughn et al., such processes can result in partially crystalline 
material which can compromise the long term stability and negatively impact dissolution 
rates of such systems.  During optimization it is essential to identify processing 
conditions and formulation variables such as stabilizers which can impact the amorphous 
nature of the finished product. 
  
Cryogenic processes are a type of solvent process that utilizes significant changes 
in temperature to produce amorphous systems by exposing the drug:carrier loaded 
solvent to significantly reduced temperatures that result in rapid freezing of the material.  
Rapid freezing is designed to occur on time scales comparable to the precipitation 
kinetics of the drug and carrier in solution, preventing phase separation.  Additionally, 
drying conducted by lyophilization limits molecular motion as a result of the low 
temperatures used during processing.  Furthermore, the absence of external heat required 
to drive off the solvent phase presents additional benefits for the production of 
amorphous particles containing heat sensitive high value compounds such as proteins and 
peptides.  Based on this general principle, a variety of specific types of techniques have 
been utilized to produce amorphous forms, including: spray freeze drying (SFD) (30), 
spray freezing into liquids (SFL) (25) and thin film freezing (TFF) (31).  Utilizing such 
technologies Vaughn et al. (32) produced amorphous itraconazole particles dispersed in a 
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matrix of polyethylene glycol 800 and poloxamer 188 by SFL.  Similarly, Overhoff et al. 
(33) demonstrated the applicability of TFF for the production of amorphous 
danazol:polyvinylpyrrolidone solid dispersion particles which exhibited high specific 
surface.  Application of such technologies to the production of protein formulations was 
also demonstrated by Engstrom et al. (30), again using TFF, where engineered particles 
provided high specific surface area and also effectively maintained the activity of the 
model macromolecule. 
 
1.2.3 Fusion Processing 
 
An alternative to solvent based processing; fusion processing involves the melting 
of drug and carrier material, followed by subsequent mixing and cooling to produce an 
amorphous solid dispersion.  Although historically not as accepted as solvent processing, 
this class of manufacturing processes has become increasingly more common, with the 
commercially available Kaletra® formulation produced using hot melt extrusion for oral 
bioavailability enhancement (34).  Unlike solvent processing technologies, only a few 
variations of the process are currently used in pharmaceutical research and production, 
including: hot spin mixing, fluidized bed melt granulation and hot melt extrusion (15,35-
39). 
 
Fluidized bed melt granulation and hot spin mixing are two forms of fusion 
processing that have been reported in research literature however have currently found 
little application in pharmaceutical production.  In a recent study by Walker et al. (40) 
fluidized bed melt granulation was utilized to produce amorphous compositions of 
ibuprofen by granulating for a predetermined time at an elevated temperature of 100oC.  
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While applicable for this particular formulation, compositions containing high melting 
point drugs or high viscosity polymers may exhibit limitations under the current process 
design.  Modifications to the process for incorporation of melt spraying may also be 
limited due to the high viscosity of polymer melts or temperatures required for flow and 
atomization.  In another series of studies, hot spin mixing was utilized for the production 
of amorphous systems.  This technology functioned by combining the drug and carrier 
into a rapidly spinning heated vessel, allowing the material to melt and then ejecting 
material into a cooling tower.  While little information was provided on the exact setup of 
the process, it was shown to be an effective platform for the production of solid 
dispersions containing testosterone (41), dienogest (42) and progesterone (43). 
 
Hot melt extrusion is the pharmaceutically preferred method of fusion based solid 
dispersion production and is based on polymer melt extrusion which has been in use for 
over a century.  First applied to pharmaceutical compositions in the 1970’s, hot melt 
extrusion has shown utility in a variety of applications including, bioavailability 
enhancement (34), device manufacture (44) and controlled release systems (45-47). 
 
Based on the equipment utilized for polymer processing, melt extruders typically 
consist of one or more rotating screws which convey material through a heated barrel, 
providing intermixing of materials and generation of additional heat due to shear and 
friction, ultimately forcing material through a shaped die located the end of the unit to 
produce a rod-like structure.  A schematic diagram of an extruder is presented in Figure 
1.2.  Pharmaceutical extruders are derived from two basic designs based on the number of 
screws within the unit.  Single screw extruders, as the name indicates, contain only one 
screw and are commonly used for pumping material through the extruder barrel.  As a 
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result of the single screw design, minimal flow perturbations are present along the flow 
pattern and less mixing is achieved than in other configurations.  Additionally, these 
designs also may be subject to flow stagnation along interfacial surfaces, particularly 
along the melt:screw interface (48,49).  In some cases, specific mixing elements may be 
included on the screw to increase the frequency of flow discontinuities and improve 
convective mixing (48,49).    This can also result in prolonged residence times and 
increased potential for material degradation.  Twin screw extruders are the other common 
form of pharmaceutical extruder and are designed with either co-rotating or counter 
rotating screws, each of which provides unique benefits to production.  For counter 
rotating designs, increased convective mixing occurs as a result of the opposite direction 
of motion which generates intersecting flow patterns inside the barrel.  Co-rotating 
designs provide less convective mixing than the counter rotating equipment as a result of 
the similar flow direction at the screw intermeshing, however this also provides for a 
material removal action along the screw which is commonly termed “self wiping” (50).  
As a result, residence and hold-up times inside twin screw extruders can be minimized 
relative to the single screw contemporaries.  Additional optimization of mixing and 
material flow can be controlled using different elements for the screw.  Screw elements 
refer to interchangeable segments of the screw which are designed to provide different 
functions, such as kneading elements for enhanced mixing or conveying elements for 
greater material throughput.  Process optimization of material feed rates, screw speeds 
and zone temperatures can all contribute to residence times; however these values 
generally range from 30 seconds to 10 minutes based on extruder configuration and scale. 
 
Similar to solvent based compositions, fusion based compositions are intended to 
be produced as a single homogeneous phase to improve dissolution and reduce 
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recrystallization potential due to molecular mobility.  Proper preformulation 
identification of drug:carrier miscibility is essential for the development of a successful 
formulation.  Solubility parameters provide an indication of interaction energies 
associated with the mixing of different materials based on the molecular structure of the 
components.  Greenhalgh et al. (51) successfully applied Hildebrand solubility 
parameters to predict the miscibility of ibuprofen in a variety of hydrophilic carriers and 
results indicated a strong correlation between observed behavior and that predicted by 
theory.  Similar results have also been obtained for melt extruded compositions 
containing indomethacin (52) and lacidipine (53).  Other screening techniques have also 
proved vital in the development of melt extruded systems.  Applications of differential 
scanning calorimetry and hot stage microscopy have both been shown to provide valuable 
information about the behavior of drug:carrier combinations at elevated temperatures, 
specifically providing information about degradation, miscibility, drug solubility within 
the carrier and recrystallization potential upon cooling (53-56).  Extrapolation of results 
observed in these small scale experiments can frequently be correlated to fusion 
processing behavior, although false negatives may occur due to the inability to 
approximate shear effects present in hot melt extrusion.  Even with careful examination 
of the formulation requirements, processing of certain types of materials may be difficult 
by melt extrusion, including: the production of solid dispersions using polymers with 
high melt viscosity and the production of heat sensitive components.   
 
The stability of such formulations is again a function of the glass transition 
temperature and specific interactions between the drug and carrier.  Unlike many solvent 
processes, melt extrusion frequently requires the addition of a plasticizer to facilitate 
production by lowering the glass transition temperature to reduce melt viscosity (36-38).  
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This reduction affects the material under both elevated and room temperature conditions, 
increasing the molecular mobility of the finished product.  In a recent study by Miller et 
al. (57), a 20% plasticizer loading was required to achieve flow of the itraconazole and 
Eudragit® L100-55.  Plasticization at this level reduced the glass transition temperature to 
approximately 50oC, making it unlikely that the formulation would have adequate shelf 
life upon storage.  In another study by Bruce et al. (58), melt extruded compositions of 
guaifenesin and Acryl-Eze, a pre-plasticized form of Eudragit® L100-55, exhibited 
extensive surface recrystallization, due in part to the reduced glass transition temperature 
and greater molecular mobility.  It is important to note that in this case, the polymer was 
further plasticized by the presence of the drug substance within the solid dispersion. Due 
to the negative impact of the plasticizer on the solid state properties of the finished 
product, studies have also been conducted using temporary plasticizers such as 
supercritical fluids.  Verreck et al. examined the applicability of supercritical carbon 
dioxide as a temporary plasticizer for a variety of compositions to provide higher finished 
product glass transition temperatures and also process at reduced temperatures to improve 
the potency of heat sensitive compositions (59-61).  Another technique to facilitate 
processing of temperature sensitive active ingredients is to control the feedstock 
characteristics of the active ingredient.  Through polymorphic selection it is possible to 
identify active forms with lower melting points, ultimately achieving the lowest possible 
processing temperature through use of the amorphous form.  Lakshman et al. (62) 
successfully demonstrated the applicability of such an approach, however many logistical 
issues may need to be addressed in order for such an approach to be commercially viable. 
 
Even with the potential drawbacks associated with the addition of processing aids 
and degradation due to elevated temperatures, hot melt extrusion has been extensively 
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utilized for the production of amorphous solid dispersions for enhanced oral 
bioavailability, with some of the earliest uses of this technology for pharmaceutical 
applications being traced back to the 1970’s (15).  To date, a multitude of publications 
have been presented documenting improvements in dissolution rate as well as 
bioavailability enhancement in animal models and human subjects.  Hülsman et al. (63) 
utilized hot melt extrusion for the production of the production of 17-β estradiol in a 
matrix of polyvinylpyrrolidone and Gelucire® 44/14 which provided a 30 fold increase in 
dissolution rate.  Nimodipine solid dispersion were also produced by melt extrusion and 
shown to provide improved in vitro dissolution rates as well as oral bioavailability in 
beagle dogs (64,65).  In another example of melt extrusion technology R103757, an 
experimental compound exhibiting low aqueous solubility, was prepared as an 
amorphous solid dispersion in HPMC 2910 and provided improved in vitro dissolution 
rates (66).  Oral bioavailability studies in healthy volunteers showed that solid 
dispersions provided enhanced bioavailability, although the greatest improvement was 
provided by a cyclodextrin based complex formulation.  Itraconazole, another poorly 
water soluble compound, has also been extensively studied using the melt extrusion 
platform.  In a series of studies by Six and co-workers (67-70), solid dispersions of 
itraconazole and several candidate polymers were prepared and evaluated for dissolution 
enhancement and oral bioavailability in human subjects.  Results showed that all solid 
dispersions could provide improved dissolution rates compared to the commercial 
multiparticulate formulation of Sporanox®, however bioavailability studies in healthy 
volunteers showed no statistically significant improvement.  Subsequent studies by Miller 
and co-workers (57,71,72) indicated that the reason for this disparity was the formulation 
design which targeted supersaturation to the stomach instead of the upper small intestine.  
Meltrex® is another example of a product produced using melt extrusion to provide 
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improved oral bioavailability.  This commercially marketed product, indicated in the 
treatment of human immunodeficiency virus, contains the poorly water soluble drugs 
ritonavir and lopinavir (73) and increases oral bioavailability lopinavir through a 
combination of solubility enhancement and preferential metabolism of ritonavir.  Using 
this platform, a significant reduction in pill burden and removal of strict low temperature 
storage requirements were obtained when compared to the original soft gelatin capsule 
formulation.  These examples highlight the capabilities of fusion based solid dispersions 
to provide improved oral bioavailability. 
 
1.2.4 Thermo-Kinetic Mixing for Pharmaceutical Applications 
 
Thermo-kinetic mixing is a novel high energy compounding process that has been 
applied in a number of industrial applications over the last thirty years, including dye 
dispersal, polymer recycling and composite production.  This technology utilizes a series 
of rapidly rotating blades to process the drug and polymeric carrier through a 
combination of kinetic and thermal energy without the aid of external heating sources 
resulting in rapid heat buildup within the material, intense mixing and extremely short 
processing durations.  During production under this process, temperature profiles can be 
characterized by two distinct stages: a frictional stage during which time material motion 
builds up heat; and a working stage at which time the material exhibits a rapid change in 
temperature due to intense mixing and changes in viscoelastic material properties (74).  
By accurately controlling the temperature through real time computer controlled 
monitoring it is possible to prevent excessive overheating of the material (75).  
Frequently utilized as an alternative to hot melt extrusion, it provides several key 
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advantages for polymer processing.  First, the process provides an extremely short 
duration of heating, limiting the thermal history of the material.  This can potentially 
provide faster manufacturing times for the production of pharmaceutical compositions, as 
well as reduced thermal burden for heat sensitive compositions.  For applications in 
polymer recycling, it allows for the recovery of waste plastic streams by converting them 
to a material feed having predictable quality properties.  Most recently it has been used in 
polymer research for producing nanoscale composites of wood:polymer (75,76)  and 
organoclay:polymer (74,77) mixtures.  In a study by Gopakumar and Pagé they 
demonstrated that the shear and intense material agitation provided an order of magnitude 
greater mixing in the production of organoclay nanocomposites (77).  This increased 
mixing provides another potential benefit of this technology for pharmaceutical 
production, in that enhanced mixing may translate into improved homogeneity of the 
compositions.  Following on the work presented by Miller (78) demonstrating proof of 
principal for the application of this technology to pharmaceutical production, one of the 
major research initiatives investigated within this dissertation will be the development of 
thermo-kinetic mixing for the production of amorphous pharmaceutical systems. 
 
1.3 FORMULATION TECHNOLOGIES FOR AMORPHOUS COMPOSITIONS 
 
1.3.1 Mechanisms for Achieving Supersaturation 
 
The current development of formulations capable of achieving supersaturation has 
been focused primarily on the development of metastable polymorphic forms, 
nanomaterials and solid dispersions, each of which are capable of achieving high 
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solubilities due to inherent kinetic and thermodynamic properties of the system.  Solid 
dispersions have recently gained significant popularity for the production of 
pharmaceuticals and can be defined as an intimate mixture of one or more active 
ingredients in an inert carrier or matrix at solid state prepared by thermal, solvent, or a 
combination thereof of processing techniques (79).  By developing these compositions it 
is possible to create formulations with the smallest possible drug domains, the individual 
molecules dispersed within a solid carrier, which are termed solid solutions.  With solid 
dispersions it is possible to maximize the solubility enhancement while increasing 
physical stability through proper selection of excipients when compared to polymorphic 
screening.   
 
One of the most frequently cited properties of these systems is the dissolution 
rate, which is increased due to the enhancement of surface area.  As particles decrease in 
size, the total surface area required for the same amount of mass increases significantly.  
According to the Noyes Whitney equation, the dissolution rate will change in proportion 
with the surface area.  Additionally, changes in metastable equilibrium solubility have 
also been reported due to decreases in particle size.   According to the Ostwald-
Freundlich equation, the solubility of a material is proportional to the exponential inverse 
of the particle diameter, as shown below, where S is the saturation solubility of the 
material, S∞ is the saturation solubility of an infinitely large particle, γ is the interfacial 
tension, M is the compound molecular weight, r is the particle radius, ρ is the density, R 
is a gas constant and T is the temperature (80).  By developing smaller particles, an 
enhancement in the overall magnitude of kinetic solubility can be achieved in addition to 










T R ρr 
M   γ2
eSS         Equation 1.1 
 
Crystal structure of the material is the other major property frequently cited in the 
literature for solubility enhancement.  Pharmaceutical APIs may exist in a variety of 
crystal structures, commonly referred to as polymorphs, as well as amorphous forms 
which lack any type of long or short range order associated with a crystalline material.  
When examining the dissolution process, it can actually be viewed as two separate and 
discrete steps: dissociation of the solute molecules from the crystal lattice and solvation 
of solute molecules.  Modifications of the crystal structure can be used to reduce the 
intermolecular interactions and facilitate the dissolution of the drug substance.  
Ultimately, these forms offer transient solid state properties and will eventually transition 
to the thermodynamically stable form of the drug substance.  Detailed polymorphic 
screening and formulation optimization can be used however to provide compositions 
which are stable for pharmaceutically relevant timescales.   
 
As previously mentioned, an extensive portfolio of technologies has been 
developed to exploit these mechanisms of solubility enhancement.  Particle size reduction 
processes, including “top-down” and “bottom-up” technologies, maximize surface area to 
exploit the kinetic and thermodynamic advantages offered by size reduction.  Molecular 
complexation techniques and solid solutions reduce the intermolecular interaction to 
facilitate dissociation while providing the theoretically smallest possible structure for 
dissolution, i.e. the individual drug molecule.  Additionally, formulation techniques such 
as the incorporation of hydrophilic polymers and surfactants have been shown to further 
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enhance the dissolution rate through improved wetting of microscopic drug domains 
within the composition. 
 
Traditional dissolution testing is conducted under sink conditions, meaning that 
the amount of material added to the vessel is three to five times less than that required to 
saturate the media within the vessel (4).  By operating under these conditions, it ensures a 
sufficient driving force for drug release throughout the testing phase in order to mimic 
conditions found in vivo during the dissolution and absorption process.  Additionally, 
operating under sink conditions allows for convenient mathematical assumptions 
facilitating modeling of the release process.  Furthermore, traditionally manufactured 
crystalline dosage forms lack the requisite thermodynamic and kinetic forces for 
supersaturation, eliminating the need for examination under these conditions.  Solid 
dispersions are capable of supersaturating their environment, necessitating testing under 
these conditions.  Typically, supersaturated dissolution testing is conducted under similar 
conditions to sink testing, however the amount of drug added to the vessel is several fold 
the amount required for saturation of the media, allowing the formulation, provided it has 
the underlying properties, to supersaturate the media.  Additionally, due to the presence 
of small particle precipitation which may occur during the testing period filter sizes are 
frequently smaller than those used under sink conditions.  It is generally assumed that the 
particle size cutoff for cellular uptake is 200 nm, so frequently 0.2 μm PVDF or PTFE 
filters are employed to reduce crystallization on the filter membrane while minimizing 
particle size.  Utilizing this testing procedure it becomes possible to ascertain the 
dissolution rate kinetics associated with a formulation, as well as its ability to provide and 
maintain supersaturation over prolonged periods of time.  In the following sections, 
examples of in vitro supersaturation are presented along with the resulting enhancement 
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in bioavailability to illustrate the utility of solid dispersions and supersaturation for 
enhanced therapeutic performance. 
 
1.3.2 IMMEDIATE RELEASE SUPERSATURATION FROM HYDROPHILIC CARRIERS 
 
According to the BCS system class II compositions exhibit solubility limited 
bioavailability making both the compositional equilibrium solubility and the rate at which 
it is achieved restrictive steps in the oral absorption process.  In order to improve the 
bioavailability of these drugs many formulations, both investigative and commercial, 
have been developed to provide enhanced dissolution rates.  By formulating the solid 
dispersion with hydrophilic excipients capable of rapid dissolution rates, the drug 
dissolution rate will become a function of the dissolution rate of the carrier polymer, 
allowing for enhanced dissolution rates and the potential for supersaturation.  Several 
commonly used materials for this application include: hydroxypropyl methylcellulose 
(HPMC), polyvinylpyrrolidone (PVP), low molecular weight polyethylene glycol (PEG), 
vinylpyrrolidone vinylacetate (PVPVA) and Eudragit® E100. Numerous publications are 
available in the literature focusing on the dissolution rate enhancement resulting from 
novel solid dispersion formulations to provide improved bioavailability or faster onset of 
action, however only a paucity of these papers examined the ability of these compositions 
to supersaturate and correlated this behavior to performance in an animal model or 
human subjects.  In recent years the importance of supersaturation in achieving improved 
bioavailability has emerged as a critical design factor for formulation development. 
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Tacrolimus, which is currently marketed under the trade name Prograf®, is 
produced as a solid dispersion using a dichloromethane solvent based coating process.  
Yamashita et al. (81) examined the potential of producing solid dispersions using a 
thermal processing technique using hydrophilic excipients including HPMC, PVP and 
PEG.  In vitro results exhibited substantial supersaturation similar to those produced by 
compositions using the solvent based production process.  These results, presented in 
Figure 1.3, were well correlated with in vivo plasma levels measured in cynomolgus 
monkeys which showed similar pharmacokinetic profiles between formulations produced 
using the two manufacturing processes and a substantial improvement over unprocessed 
crystalline tacrolimus. 
 
Similar approaches have also been described to develop compositions for 
improved bioavailability of other currently marketed solid dispersions as well.  Six et al. 
(68) investigated the ability to produce solid dispersions of itraconazole and several 
hydrophilic excipients using hot melt extrusion, characterizing compositions for in vitro 
dissolution behavior and in vivo pharmacokinetic performance in healthy male 
volunteers.  Dissolution testing was conducted under non-sink conditions (equilibrium 
solubility of itraconazole = 4 – 12 μg/ml) by placing 100 mg itraconazole capsules in 500 
ml of simulated gastric fluid without pepsin and conducting testing at 100 rpm.  As 
shown in Figure 1.4, all compositions provided substantial levels of supersaturation; 
however the commercial formulation exhibited the slowest dissolution rate.  Surprisingly, 
pharmacokinetic data generated in human trials showed that HPMC based compositions 
provided the greatest AUCs compared to formulations of Eudragit® E 100 – PVPVA and 
Eudragit® E 100, however substantial inter-subject variability was observed in all groups.  
Additionally, similar Cmax and Tmax values were observed in vivo, which contradicts what 
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one would anticipate from the in vitro data.  The in vivo performance of itraconazole 
formulations were most likely strongly effected by the solubility properties of 
itraconazole, which exhibits orders of magnitude lower solubility in more neutral 
conditions similar to those observed in the upper small intestine, making it an interesting 
model drug for other advanced solid dispersion technologies such as site specific 
supersaturation and stabilized supersaturation using concentration enhancing polymers.       
 
1.3.3 SITE TARGETED SUPERSATURATION USING MODIFIED RELEASE POLYMERS 
 
While the enhancement in dissolution rate can provide improved oral 
bioavailability by achieving the equilibrium solubility faster or providing higher 
metastable equilibrium solubility values, these formulations may not provide the greatest 
improvement in bioavailability.  Weakly basic drugs may be ionized at gastric pH where 
hydrophilic compositions will dissolve and release the drug.  Upon transition to the upper 
small intestine, the pH rises and the drug may become partially or completely unionized, 
resulting in a rapid precipitation of dissolved drug.  Furthermore, most drugs are 
primarily absorbed in the upper small intestine, where the substantial surface area 
provided by the villi and microvilli facilitate transport across the membrane.  
Compositions which supersaturate the gastric environment for short durations may also 
be subject to partial or complete precipitation, achieving only equilibrium solubility prior 
to entering the upper small intestine and negating the tremendous advantages provided by 
solid dispersions.   In these cases, it would be prudent to target supersaturation to the 
upper small intestine, which is commonly achieved by using pH responsive carriers.  
These carrier materials are insoluble at gastric pH; however upon entering the upper 
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small intestine, the pH change will trigger ionization of the carboxylic acid functional 
groups on the polymer chain resulting in dissolution.  As with the hydrophilic solid 
dispersions, correct formulation and processing can produce compositions whose 
dissolution rate is governed by that of the polymeric material, resulting in significantly 
improved dissolution rates, supersaturation and enhanced bioavailability. 
 
Although a less commonly reported technique for the production of solid 
dispersions, the use of enteric carriers has been reported for at least 20 years to improve 
bioavailability.  In the development of HO-221, a novel anticancer agent, Kondo et al. 
(83) reported the use of micronization technology to enhance the oral bioavailability of 
the drug in mice, dogs and monkeys.  Their results showed that the production of 
submicron particles provided modest improvement in bioavailability (~20% BA), 
although still incomplete.  Additionally, a substantial food effect was observed indicating 
a potential partial solubilization due to bile salts.  This group further investigated the use 
of solid dispersions of hydrophilic and enteric polymers produced by a coprecipitation 
process for enhanced oral bioavailability, with results presented in Figure 1.5.  Using 
hydroxypropyl methylcellulose phthalate (HP-55), in vitro supersaturated dissolution 
testing conducted at pH 6.5 and with a modified pH change method showed significant 
levels of supersaturation.  Compositions produced using hydrophilic excipients also 
achieved substantial levels of supersaturation however these systems exhibited 
precipitation after sixty minutes which reduced levels of drug in solution during the later 
stages of testing.  In vivo studies in beagle dogs revealed a substantial improvement in 
bioavailability of the solid dispersions compared to micronized drug, with hydrophilic 
compositions providing approximately 60% bioavailability and enteric compositions 
providing nearly complete bioavailability.  The researchers hypothesized that the 
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improvement in oral bioavailability of the enteric compositions was due to the site 
targeting of drug release to the upper small intestine, where the drug had been previously 
been shown to be primarily absorbed. 
 
Using a similar approach, Miller and coworkers (71) formulated solid dispersions 
of itraconazole with Eudragit® L100-55 and Carbopol 974P a mucoadhesive agent.  Since 
itraconazole is a weakly basic agent having a pKa of ~ 3.7, it is ionized at gastric pH 
however exhibits a rapid decrease in apparent solubility at pH values representative of the 
upper small intestine.  By formulating compositions capable of site specific 
supersaturation with high viscosity stabilizers it was hypothesized that in vivo 
bioavailability could be improved over traditional hydrophilic solid dispersions of 
itraconazole.  Analytical characterization showed that the amorphous enteric 
compositions were capable of supersaturation, as presented in Figure 1.6; however the 
maximum concentration achieved in vitro decreased with increasing levels of Carbopol.  
This was attributed to the high viscosity of the polymer, acting to slow the dissolution 
rate upon pH change.  Incorporation of Carbopol 974P at a 20% polymer loading also 
exhibited the longest duration of in vitro supersaturation via a combination of hydrogen 
bonding interactions and high viscosity stabilization.  In vivo testing in Sprague-Dawley 
rats demonstrated that the composition containing 20% Carbopol 974P also provided the 
greatest AUC, suggesting that the maximum concentration achieved was secondary to the 
ability to maintain supersaturation for physiologically relevant time scales.  Furthermore, 
the high variability of the itraconazole:L100-55 composition observed in vivo was 
attributed to the inability to stabilize supersaturation, highlighting the importance of 
maintaining supersaturation for enhanced performance.   
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1.3.4 CONCENTRATION ENHANCING POLYMERS FOR PROLONGED DURATIONS OF 
SUPERSATURATION 
 
The importance of maintaining levels of supersaturation has been clearly 
illustrated in the previous examples, where decreasing levels of solubilized drug can 
result in incomplete and highly variable bioavailability.  By developing formulations with 
materials capable of inhibiting precipitation from supersaturation, termed concentration 
enhancing polymers, it is possible to improve the bioavailability of poorly water soluble 
compounds.  Concentration enhancing polymers provide increased levels of drug in 
solution in excess of the normal equilibrium solubility through either physical, chemical 
or a combination thereof of interactions with drug molecules that inhibits precipitation 
(83).  Using these materials, several formulations have demonstrated substantial 
improvements in oral bioavailability. 
 
Although not studied for solid dispersions, Gao and co-workers (84,85) developed 
supersaturatable self emulsifying drug delivery systems (s-SEDDS) utilizing 
concentrations enhancing polymers for the delivery of paclitaxel and an experimental 
compound PNU-91325.  In these studies, s-SEDDS compositions containing HPMC E5 
as a concentration enhancing polymer were developed to provide drug supersaturation 
and precipitation inhibition.  Results from both studies showed substantial inhibition of 
precipitation, with HPMC levels of 5% providing significantly longer durations of 
paclitaxel supersaturation.  When in vivo performance of paclitaxel s-SEDDS 
formulations was assessed in vitro and in a rat model (presented in Figure 1.7), oral 
bioavailability increased from 0.9% in conventional SEDDS compositions to 9.5% 
through the use of HPMC as a concentration enhancing polymer.  An additional increase 
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in oral bioavailability was achieved when co-administered with cyclosporine A, most 
likely due to its inhibitory effects of CYP3A4. 
 
Concentration enhancing polymers have also been applied to solid dispersion 
formulations.  In a recent patent the use of these materials in formulating compositions of 
a low solubility glycogen phosphorylase inhibitor were detailed (86).  Amorphous 
compositions of the drug were prepared by spray drying using a variety of excipients, 
including HPMC, PVP, hydroxypropyl methylcellulose acetate succinate (HPMCAS) and 
cellulose acetate phthalate (CAP).  In vitro supersaturated dissolution testing was 
conducted to assess the performance of these materials by adding excess material to 
dissolution vessels containing a phosphate buffer solution having a pH of 6.5.  Testing 
showed that spray dried powders containing CAP produced the greatest magnitude of 
supersaturation, however precipitation was observed.  Compositions of HPMCAS 
showed the greatest level of stabilization, as presented in Figure 1.8, with no decrease in 
concentration observed for compositions of the 1:3 drug:polymer ratio.  In vivo testing of 
this composition as an orally administered powder showed a significant increase in 
bioavailability compared to the crystalline drug which can be attributed to the substantial 
in vitro AUC observed during testing. 
 
In another study by Guzmán et al. (87), the application of concentration 
enhancing polymers was studied for oral bioavailability enhancement of celecoxib, a 
poorly water soluble compound marketed under the trade name Celebrex®.  Target 
concentration enhancing polymers were identified using a high throughput screening 
technique incorporating light scattering and yielded numerous potential candidates.  
Interestingly, the ability of these materials to inhibit precipitation was related to the CMC 
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of the material.  Additionally, addition of hydroxypropyl cellulose (HPC) was shown to 
enhance stabilization.  When lead compositions consisting of TPGS and HPC, as well as 
formulations with Pluronic F127 and HPC, were dosed in a canine model rapid and near 
complete absorption was observed.  In a similar stud by Overhoff et al. (88), solid 
dispersions of tacrolimus were prepared using surfactant based materials and shown to 
inhibit precipitation while also providing enhanced oral bioavailability in a rat model. 
 
By incorporating materials to inhibit precipitation of the supersaturated state, 
several researchers have successfully improved the oral bioavailability of poorly water 
soluble compounds.  While these studies have demonstrated success, the utility of this 
formulation technique for itraconazole has not been fully examined.  Additionally, many 
questions still remain regarding the utility of this technique for compounds such as 
itraconazole which exhibit a strongly pH dependent solubility and extensive oral 
bioavailability variability due to solubility issues and metabolism.  As part of this 
dissertation, the applicability of formulation of itraconazole solid dispersions with 
concentration enhancing polymer will be investigated, focusing on methods for 










1.4 CONCLUDING REMARKS 
 
With the increasing number of poorly water soluble compounds in developmental 
portfolios, the importance of supersaturatable compositions will continue to grow.  Over 
the last several decades solid dispersions capable of achieving supersaturation have 
emerged as a viable technology to address the ever expanding number of poorly water 
soluble drugs through kinetic and thermodynamic mechanisms of solubility enhancement.  
Formulation of these compositions with hydrophilic polymers has been shown to be a 
highly effective way for improving the bioavailability and onset of action for a number of 
compounds.  Additionally, the use of enteric polymers and concentration enhancing 
polymers have been shown to enhance bioavailability by more effectively targeting and 
maintaining supersaturation at the site of absorption.  Using these formulation techniques 
for the development of poorly water soluble compounds will continue be an effective 
way of enhancing product bioavailability. 
 
 As a complement to formulation technologies, manufacturing processes 
must also grow to meet the challenges of the next generation of pharmaceutical 
compounds.  While current solvent and fusion based techniques have shown to be 
capable of producing such compositions, these methods still present significant 
limitations during development and production.  By applying thermo-kinetic mixing to 
the development and production of such systems, it is hoped that improved 
manufacturing can be achieved while providing the production flexibility to process a 
wider range of materials without concern for thermal degradation or residual solvent 
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Figure 1.1 Schematic diagram illustrating the differences in enthalpy and volume for 
crystalline and glassy solid as a function of temperature.  Reproduced with 
permission from Hancock and Zografi,  1997. Characteristics and 
Significance of the Amorphous State in Pharmaceutical Systems, J. Pharm. 





Figure 1.2 Schematic diagram of a hot melt extruder illustrating critical equipment and 
process aspects.  Reproduced with permission from Follonier et al, 1995. 
Various Ways of Modulating the Release of Diltiazem Hydrochloride from 
Hot-Melt Extruded Sustained Release Pellets Prepared Using Polymeric 





Figure 1.3 Supersaturated dissolution profiles of thermally processed tacrolimus solid 
dispersions (Left) and in vivo plasma profile comparing solvent based and 
thermally processed solid dispersions (Right). Legend: (•) 
Tacrolimus:HPMC, (▲) Tacrolimus:PVP, (♦) Tacrolimus:PEG 6000, (○) 
Crystalline Tacrolimus.  Reproduced with permission from Yamashita et al, 
2003. Establishment of new preparation method for solid dispersion 





Figure 1.4 Supersaturated dissolution profile of itraconazole solid dispersions (top) and 
pharmacokinetic data from human studies (bottom).  Sporanox® ( ), HPMC 
extrudate (■), Eudragit® E100 extrudate ( ), and Eudragit® E100-
PVPVA64 extrudate (●). Reproduced with permission from Six et al, 2003. 
Clinical study of solid dispersions of itraconazole prepared by hot-stage 





Figure 1.5 Supersaturated profiles for hydrophilic coprecipitates at pH 6.5 (A), enteric 
coprecipitates under modified pH change conditions (B) and in vivo plasma 
profiles measured in beagle dogs (C).  (○) HP-55, (■) PVP, (□) 
copolyvidone and (○) micronized HO-221.  Reproduced with permission 
from Kondo et al, 1994. Improved oral absorption of enteric coprecipitates 





Figure 1.6 - In vitro supersaturation dissolution profiles and in vivo data for itraconazole 
solid dispersions. Reproduced with permission from Miller et al, 2008. 
Targeted Intestinal Delivery of Supersaturated Itraconazole for Improved 




Figure 1.7 In vitro supersaturation dissolution profiles and in vivo plasma profiles for 
paclitaxel formulations developed to provide extended durations of 
supersaturation. Reproduced with permission from Gao et al, 2003. 
Development of a Supersaturable SEDDS (S-SEDDS) Formulation of 
Paclitaxel with Improved Oral Bioavailability, J Pharm Sci  92(12):2386 – 





Figure 1.8 In vitro supersaturation profiles (top) and in vivo pharmacokinetic data from 
human trials (bottom) for developmental solid dispersions.  Adapted from 
data presented in Crew et al., Pharmaceutical Compositions of a Sparingly 
Soluble Glycogen Phosphorylase Inhibitor, United States Patent US 
7,235,260 B2  
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Chapter 2:  Research Objectives 
2.1 OVERALL OBJECTIVE 
 
With the increasing number of poorly water soluble compounds under 
development in today’s pharmaceutical market, there is a tremendous need for the 
development of processing and formulation technologies to provide enhanced oral 
bioavailability.  The primary objectives of this work were to develop novel formulation 
and processing technologies to address these needs, specifically: to investigate the utility 
of concentration enhancing polymers for improved oral bioavailability of itraconazole 
while simultaneously developing a proprietary version of thermo-kinetic mixing, termed 
KinetiSol® Dispersing, for the production of amorphous solid dispersions. Within this 
overall framework, research was divided into five major studies evaluating concentration 
enhancing polymers and/or unique applications of KinetiSol® Dispersing for fusion 
processing of solid dispersions.   
 
In the first research study, described in Chapter 3, the application of concentration 
enhancing polymer solid dispersions to provide enhanced oral bioavailability was 
studied, which presented a novel formulation approach that had not previously been 
investigated for itraconazole.  Solid dispersion formulations for this study were prepared 
using ultra rapid freezing, a cryogenic manufacturing process, using cellulose acetate 
phthalate and polyvinyl acetate phthalate.  These materials were then characterized for 
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solid state properties and in vitro dissolution behavior to select lead compositions for oral 
bioavailability testing.  The lead engineered particle composition was then tested for oral 
bioavailability enhancement against the commercially available solid dispersion 
formulation, Sporanox®, using a Sprague Dawley rat model. 
 
Subsequent studies shifted the focus to demonstrating the applicability of 
KinetiSol® Dispersing for the production of amorphous solid dispersions.    In the second 
study of this work, presented in Chapter 4, the application of KinetiSol® Dispersing was 
examined using a model system of itraconazole and HPMC E5 which had previously 
been developed using hot melt extrusion.  In the previously reported studies with the melt 
extruded composition, phase separation was identified during thermal characterization 
which presented an ideal situation to test the increased mixing potential of thermo-kinetic 
mixing.  Compositions were produced using KinetiSol® Dispersing and compared to 
equivalent material prepared by hot melt extrusion.  Formulations were characterized for 
solid state behavior, in vitro dissolution performance and oral bioavailability 
enhancement using a Sprague Dawley rat model.   
 
In Chapter 5, the applicability of KinetiSol® Dispersing to the production of 
plasticizer free compositions was studied and compared to solid dispersions produced by 
hot melt extrusion which required a plasticizer.  Using a formulation of itraconazole and 
L100-55, melt extruded compositions required 20% triethyl citrate to achieve the 
necessary flow characteristics to facilitate production, however lowered the glass 
transition temperature to approximately 50oC which would prove detrimental to 
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amorphous stability.  Formulations produced using both manufacturing methods were 
studied for solid state characteristics, in vitro dissolution behavior and amorphous 
stability under accelerated conditions. 
 
In Chapter 6, KinetiSol® Dispersing was applied to the production of solid 
dispersions containing a temperature sensitive active ingredient, hydrocortisone.  In 
fusion processing, one of the primary negative attributes of the process is the extensive 
exposure of material to elevated temperatures which can impact product potency and 
therapeutic efficacy.  Since residence time at elevated temperature and cycle times during 
KinetiSol® Dispersing are incredibly short, typically less than 5 and 30 seconds 
respectively, this can provide significant benefits to the processing of such materials.  
Within this study, methods for carrier selection were examined for use in the production 
of hydrocortisone solid dispersions.  Ideal solid dispersions were prepared by hot melt 
extrusion utilizing a design of experiments to evaluate the effect of processing parameters 
on product potency.  After identifying the affect of melt extrusion process parameters, 
solid dispersions were prepared using KinetiSol® Dispersing to investigate the ability of 
the process to improve potency due to the shortened residence times and reduced 
processing temperatures.    
 
 To provide a culminating study, continuing to develop the applications of 
KinetiSol® Dispersing while expanding on the knowledge of concentration enhancing 
polymers for improved oral bioavailability of itraconazole, advanced solid dispersions 
with concentration enhancing polymers were prepared using KinetiSol® Dispersing.  
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Prior to production, screening studies were undertaken to examine the stabilization 
properties of potential polymers based on molecular structure of the materials.  Once 
identified, prototype formulations incorporating the concentration enhancing polymer 
were prepared using KinetiSol® Dispersing.  Additional formulations were also prepared 
incorporating Carbomer 974P to investigate the behavior of that material for oral 
bioavailability enhancement.  During testing, compositions were investigated for solid 
state properties as well as in vitro dissolution behavior in surfactant free and biosimilar 
media.  Lead compositions were then examined for bioavailability performance in a 
Sprague Dawley rat model and compared to previous studies to assess improvement 
relative to the marketed product. 
 
 Based on the cumulative work conducted in this dissertation, results were 
extrapolated to the performance of these technologies for poorly water soluble 
compounds.  It is hoped that the results presented within this study help to improve 
formulation strategies for such compounds, while also providing a fundamental 
background for the continued development of KinetiSol® Dispersing as a platform for the 
production of amorphous solid dispersions. 
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Chapter 3:  Amorphous Compositions Using Concentration Enhancing 
Polymers for Improved Bioavailability of Itraconazole 
3.1 ABSTRACT 
 
Amorphous engineered particle compositions of Itraconazole (ITZ) and potential 
concentration enhancing polymers, cellulose acetate phthalate (CAP) and polyvinyl 
acetate phthalate (PVAP), were produced by ultra-rapid freezing to investigate the effect 
of these polymers on the bioavailability of ITZ solid dispersions.  X-ray diffraction 
analyses of engineered particle compositions were shown to be amorphous.  Modulated 
differential scanning calorimetry demonstrated that ITZ:CAP engineered particle 
compositions exhibited a strong correlation with the Gordon-Taylor relationship while 
ITZ:PVAP formulations exhibited positive deviations from predicted values attributed to 
hydrogen bonding interactions between the drug and polymer.  Energy dispersive 
spectroscopy mapping demonstrated that the drug was homogenously distributed within 
all compositions supporting the miscibility of the drug with the polymers.  Scanning 
electron microscopy imaging of the particles demonstrated that the material existed in 
two general forms, discrete particles of approximately 5μm and larger aggregates in 
excess of 30μm, with engineered particle compositions having approximately 15 times 
higher measured specific surfaces areas compared to micronized ITZ.  In vitro 
supersaturated dissolution results showed that all compositions provided significantly 
lower levels of supersaturation in acidic media and greater extents of supersaturation in 
neutral media compared to Sporanox® Pellets. ITZ:CAP formulations provided the 
greatest degree and extent of supersaturation in neutral media.  Dissolution data were 
fitted to an exponential relationship based on a simplified model of particle growth, 
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allowing for the determination of drug half life in solution for evaluation of stabilization 
behavior.   1:2 ITZ:CAP showed superior in vitro performance compared to all other 
engineered particle compositions and was selected for in vivo testing.  Although not fully 
elucidated, data indicated that the stabilization mechanism was due to interactions 
between the drug and polymer, primarily attributed to steric hindrance resulting from the 
molecular weight of the polymer chain and chemical composition of the polymer 
backbone relative to position of hydrogen bonding sites.  In vivo testing conducted in 
Sprague-Dawley rats (n = 6) demonstrated a significant improvement in oral 
bioavailability from the 1:2 ITZ:CAP (AUC = 4,516 ± 1,949 ng·hr/mL ) compared to the 
Sporanox® Pellets (AUC = 2,132 ± 1,273 ng·hr/mL) (p ≤ 0.05).  Additionally, the more 
rapid onset of action indicated superior targeting of the upper small intestines, and the 
prolonged half-life suggested the utility of CAP to maintain supersaturated 
concentrations, in vivo.  These results demonstrated that amorphous compositions of ITZ 
and enteric concentration enhancing polymers provided improved bioavailability due to 




Itraconazole (ITZ) is a weakly basic triazole antifungal agent indicated in the 
treatment of both local and systemic fungal infections however successful treatment of 
infections is often complicated by its low aqueous solubility resulting in variable 
absorption and plasma concentration. (3, 4)  Classified as a BCS class II compound, (5) 
ITZ has a strongly pH dependent solubility (pKa ~ 3.7) with reported solubilities in 
acidic and neutral media of approximately 4 μg/ml and 1 ng/ml respectively (6).  While 
limited by poor aqueous solubility, the highly lipophilic nature of the compound (c log P 
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= 6.02) (6) allows for high permeability of intestinal membranes.  In order to maximize 
bioavailability and reduce in vivo variability, unique strategies for delivery of the 
marketed products have been utilized, including cyclodextrin complexation (7) and 
amorphous solid dispersion technology (8). 
 
Sporanox®, the trade name of the currently marketed form of ITZ, is available in 
three formulations; a multiparticulate capsule, a 2-hydroxypropyl-β-cyclodextrin 
complexed oral solution and a solution for i.v. infusion.  The capsule formulation is 
currently produced by drug layering of ITZ and hydroxypropyl methylcellulose (HPMC) 
onto sugar spheres using a methylene chloride:ethanol cosolvent system and is capable of 
providing rapid drug release in acidic media (9, 10).  While this composition is able to 
provide adequate plasma levels for prophylaxis, it has shown both significant inter- and 
intra- subject variability (8, 11).  ITZ pharmacokinetics have also been shown to be 
strongly affected by several factors including dose, diet and disease state, further 
complicating treatment.  The dose dependent pharmacokinetics of ITZ have been well 
documented in the literature for both animal models (12) and human subjects (8), with 
higher doses providing non-dose proportional increases in bioavailability.  Furthermore, 
administration of Sporanox® capsules in the fasted state (8) or with neutralizing agents 
such as antacids (13) has been shown to negatively affect bioavailability, while 
administration in conjunction with acidic beverages such as Coca-Cola has resulted in 
improved blood levels due to the pH dependent solubility of ITZ (14).  The cyclodextrin 
based formulation was developed, in part, to address these issues.  In human trials with 
healthy volunteers the oral solution was shown to minimize the food effect and was also 
able to improve the bioavailability by 37% compared to the capsule based formulation 
(4).  Recent studies have shown that the ability of the cyclodextrin complexes to improve 
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bioavailability may be a function of the ability of these materials to maintain solubility 
values in comparison to more conventional formulations which exhibit a decrease in drug 
concentration (15).  This formulation, however, does suffer from several side effects 
associated with the use of cyclodextrins which can reduce patient compliance, including: 
poor taste, stomach pain and diarrhea (11).   
 
Although the oral solution has been able to address issues associated with limited 
and variable bioavailability, interest still exists in developing a solid dosage form with 
enhanced pharmacokinetic properties, including enhanced bioavailability and reduced 
variability.  In an attempt to improve the bioavailability of ITZ solid dosage forms, 
numerous strategies have been investigated, including: cyclodextrin complexed solid 
formulations (16), capsule based self emulsifying systems (17), engineered particle 
compositions(18-20), and amorphous solid dispersions produced by melt extrusion (2, 
21-24) or spray drying (25).  While these systems have provided excellent dissolution 
properties in acidic conditions, the effect on bioavailability was either not assessed in an 
animal model or demonstrated limited improvement with no significant reduction in 
variability.  In a study conducted by Miller and co-workers, limited bioavailability 
enhancement was observed from a system of engineered particles contained in a 
hydrophilic matrix designed to maximize supersaturation in acidic conditions (26).  In 
vitro supersaturated dissolution testing conducted under USP Method A enteric 
conditions demonstrated that upon pH change ITZ rapidly precipitated from the media, 
suggesting limited levels of drug available for absorption in the later stages of the GI 
tract.  The authors hypothesized that the poor performance was due to the targeting of 
supersaturation to the low pH environment of the stomach (26).  In a subsequent study, 
solid dispersions of ITZ and enteric polymers were produced and compared to solid 
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dispersions containing ITZ and hydrophilic polymers to study the bioavailability of 
compositions designed to provide supersaturation in neutral media.  Although substantial 
variability was observed for the enteric solid dispersion, this work demonstrated that 
improved in vitro neutral media supersaturation correlated with improved in vivo plasma 
levels (27).  The variable plasma profiles observed for the enteric solid dispersion were 
hypothesized to be the result of the short duration of neutral media supersaturation.  
Eudragit® L100-55 begins to dissolve at a pH of approximately 5.5 and has been reported 
to dissolve at a slower rate than enteric polymers containing phthalate groups (28), which 
may result in variable efficiency in targeting the upper small intestine.  Furthermore, the 
rapid in vitro precipitation of ITZ observed from these compositions suggests a lack 
stabilizing function for the polymer which may also have contributed to variable 
performance.     
 
The traditional development strategy for poorly water soluble compounds has 
long identified increased dissolution rates under sink conditions with improved 
bioavailability (29); however a number of researchers have begun investigating the use of 
concentration enhancing polymers to decrease precipitation rates and maintain 
supersaturation.  By definition, concentration enhancing polymers provide increased 
levels of drug in solution in excess of the normal equilibrium solubility through either 
physical, chemical or a combination thereof of interactions with drug molecules that 
inhibits precipitation.  Several examples for both solid and liquid phase formulations 
incorporating concentration enhancing polymers have been discussed recently in 
literature, providing significant improvements in bioavailability (30-32).  In the work of 
Gao and coworkers, HPMC was incorporated as an additive in self emulsifying drug 
delivery system (SEDDS) formulations to increase the duration of supersaturation in vitro 
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for PNU-91325 and paclitaxel.  The improved duration of supersaturation was correlated 
with improved bioavailability in animal models for both molecules.  Vandecruys et al. 
used a screening technique to determine which compositions provided improved 
solubilities and increased durations of supersaturation in vitro for a developmental 
compound (32).  Lead compositions selected based on solubility performance were tested 
in animal models and demonstrated enhanced bioavailability.  In addition to published 
research papers, a number of companies have used this strategy to enhance the 
bioavailability of developmental compounds as described in the patent literature (33-35).  
Similar to the research papers, the addition of concentration enhancing polymers 
provided increased in vitro AUC values which were correlated with enhanced 
bioavailability.  Melt extruded compositions of ITZ, L100-55 and varying levels of 
Carbomer 974P were also investigated by Miller et al., for their application as a high 
viscosity stabilizing polymer and also potential mucoadhesive agent (36).  Results 
showed that the 20% Carbomer compositions provided the greatest duration of 
supersaturation and was also shown to provide the greatest improvement of in vivo AUC, 
suggesting that prolonged durations of supersaturation in neutral media provide enhanced 
bioavailability. 
 
Based on the success of other researchers on enhanced ITZ bioavailability by 
maximizing neutral media supersaturation (27, 36), it was hypothesized that the 
formulation of ITZ with concentration enhancing polymers could further improve 
bioavailability by increasing the amount of drug available for absorption in the later 
stages of the GI tract. The purpose of this study was to investigate the effect of enteric 
polymers containing phthalate groups on the bioavailability of ITZ enteric solid 
dispersions.  For this work CAP and PVAP were selected due to their lower pH of 
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ionization (pH 5), more rapid polymer dissolution rate (28) and potential to function as a 
concentration enhancing polymer (33).  To study the effects of these polymers, 
amorphous compositions were manufactured using ultra rapid freezing (URF) particle 
engineering technology (37, 38) and characterized for their solid state properties by XRD, 
mDSC, Fourier transform infrared spectroscopy (FTIR), SEM, specific surface area 
analysis, transmission electron microscopy and EDS.  In vitro dissolution testing was 
used to assess the performance of the compositions by evaluating the degree (Cmax), 
duration (t1/2) and extent (AUCdissolution) of supersaturation.  Based on the in vitro 
performance, the lead composition was dosed orally to Sprague Dawley rats and 
compared to Sporanox® pellets for evaluation of the relative oral bioavailability 
enhancement.   
    
3.3 MATERIALS AND METHODS 
 
3.3.1 Materials 
Itraconazole, BP was purchased from Hawkins, Inc. (Minneapolis, MN). 
Cellulose acetate phthalate (Cellacefate) was purchase from Spectrum Chemical 
Manufacturing Corporation (Gardena, CA).  Polyvinyl acetate phthalate (pHthalavin® 
2138 clear) was donated by Colorcon®, Inc. (West Point, PA).  Sporanox® capsules (Lot 
# 6MG457) were purchased from Janssen Pharmaceutica Products, L.P. (Titusville, NJ).  
Empty size 9 porcine gelatin capsules were purchased from Torpac®, Inc. (Fairfield, NJ).  
1,4-Dioxane was purchased from Fischer Chemical Co. HPLC grade acetonitrile was 
purchased from EMD chemicals (Darmstadt, Germany). All other chemicals utilized in 





3.3.2.1 Ultra Rapid Freezing 
 
Samples of engineered particles were prepared using a thin film freezing 
technique.(37-40) Measured quantities of ITZ and enteric polymer (CAP or PVAP) were 
dissolved in 1,4 Dioxane to produce a 1% w/v solution and slowly feed as discrete 
droplets onto a chilled rotating drum maintained at approximately -60oC. The frozen 
material removed from the drum by a scraper blade, collected and dried using a Virtis 
Advantage Lyophilizer operated in a three stage drying program presented in Table 3.1. 
 
3.3.2.2 X-Ray Diffraction 
 
XRD testing was conducted using a Philips Model 1710 X-ray diffractometer 
(Philips Electronic Instruments Inc., Mahwah, NJ).  Samples of powder were placed into 
channeled stages and the diffraction profile was measured from 5o to 50o using a 2θ step 
size of 0.05o and dwell time of 3s. 
 
3.3.2.3 Modulated Differential Scanning Calorimetry 
 
Modulated Differential scanning calorimetry testing was performed using a TA 
Instruments Model 2920 DSC (New Castle, DE) and analyzed using TA Universal 
Analysis 2000 Software. Prior to testing, polymer samples were preheated at 90oC for 15 
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minutes using a model MF-50 moisture balance (AND Company Ltd. Encino, CA.) to 
remove excess residual moisture and weighed to 15 ± 2 mg in aluminum crimped pans 
(Kit 0219-0041, Perkin-Elmer Instruments, Norwalk, CT). Engineered particle samples 
were accurately weighed to 5 ± 1 mg in aluminum crimped pans.  Testing was performed 
at a ramp rate of 10 °C/min from 5 to 215 °C using a modulation temperature amplitude 
of 0.5 ºC and a modulation period of 40 s under nitrogen purge at a flow rate of 40 
mL/min. 
 
3.3.2.4 Fourier Transform Infrared Spectroscopy 
 
Individual materials, physical mixtures and URF processed powders were 
analyzed by FTIR to evaluate potential interactions.  Individual materials and physical 
mixtures were triturated in a mortar and pestle prior to pellet preparation.  Physical 
mixtures of components were prepared by geometric dilution using a glass mortar and 
pestle.  Samples for FTIR analysis were prepared by weighing approximately 4 mg of the 
material for analysis, mixing with 250 mg of dried KBr for approximately 2 minutes in a 
mortar and pestle, and compressing the mixture under vacuum with a compression force 
of 10 tons using a 13 mm diameter round flat face punch for three minutes to produce a 
pellet compacts.  Samples were analyzed using a Thermo Mattson Infinity Gold FTIR 
with Spectra-Tech Thermal ARK module from 400 – 4000 cm-1 in transmission mode 
equipped with a KBr beamsplitter and DTGS detector having a resolution of 1cm-1.  Each 
presented spectrum is the average of 64 scans. 
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3.3.2.5 Brauner Emmett Teller Specific Surface Area Measurements 
 
Specific surface areas were measured using a Nova 2000 v.6.11 (Quantachrome 
Instruments, Boynton Beach, FL) with a nitrogen adsorbate gas.  Powder samples of 
approximately 25 mg were placed into the sample bulb, degassed for a minimum of three 
hours at room temperature and measured using a six point pressure profile ranging from 
0.05 - 0.30 psia.  Specific and total sample surface areas were calculated from the BET 
model using NOVA Enhanced Data Reduction Software v. 2.13. 
 
3.3.2.6 Scanning Electron Microscopy 
 
Prior to imaging, samples were mounted onto aluminum stages using double sided 
carbon tape and sputter coated using a Pelco® Model 3 sputter coated equipped with an 
Au source for 20s.  Particle morphologies were evaluated by SEM using a Hitachi S-4500 
scanning electron microscope (Hitachi, Ltd., Tokyo, Japan) operated at an accelerating 
voltage of 10kV. 
 
3.3.2.7 Transmission Electron Microscopy and Energy Dispersive Spectroscopy 
 
Samples were prepared by dispersing powder samples onto a 200 mesh copper 
grid coated with a carbon support film (Electron Microscopy Sciences, Hatfield, PA). 
Imaging and EDS were conducted using a JEOL 2010F transmission electron microscope 
(JEOL USA, Inc., Peabody, MA) equipped with a HAADF STEM detector, Oxford 
spectrometer and GATAN digital imaging system operated at 200kV. 
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3.3.2.8 Supersaturated Dissolution Testing 
 
Supersaturated dissolution testing was performed based on the USP XXIX 
method A enteric dissolution test using a VK 7010 dissolution apparatus (Varian, Inc., 
Palo Alto, CA) operating at 50 rpm paddle speed and VK 8000 autosampler (Varian, Inc., 
Palo Alto, CA).  An equivalent amount of 37.5 mg ± 0.4 mg of ITZ (~10x 0.1N HCl 
media equilibrium solubility) was weighed, prewetted with 15 mL of preheated (37oC) 
0.1N HCl media and added to the dissolution vessel containing 735 mL of 0.1N HCl 
media.  After two hours, 250 mL of 0.2M Na3PO4 solution was added to the dissolution 
vessel to achieve a pH of approximately 6.8.  During testing 5 mL samples were removed 
from the dissolution vessels without replacement after 60, 120, 130, 150, 180, 240, 300, 
360 and 1440 min.  Samples were immediately filtered using 0.2 μm PTFE membrane, 
13mm Acrodisc filters (Pall Corporation, East Hills, NY) to minimize drug adsorption 
and precipitation, immediately diluted in a 1:1 ratio with mobile phase, vortexed mixed 
and transferred into 1 mL vials (VWR International, West Chester, PA) for analysis. 
 
Dissolution samples were analyzed using a Waters (Waters Corporation, Milford, 
MA) high performance liquid chromatography (HPLC) system consisting of dual Waters 
515 Syringe Pumps, a Waters 717 Autosampler and a Waters 996 Photo Diode Array 
extracting at a wavelength of 263 nm.  The system was operated under isocratic flow at 1 
mL/min using a mobile phase consisting of 70:30:0.05 acetonitrile:water:diethanolamine 
equipped with a Phenomenex Luna 5 μm C18(2) 100 Å, 150 mm x 4.6 mm 
(Phenomenex®, Torrance, CA) HPLC column.  Samples collected in the 0.1N HCl media 
and neutralized media were injected in volumes of 50 μL and 200μL respectively during 
 72
testing.  Data were collected and analyzed using Empower® Version 5.0 software.  The 
retention time of ITZ was approximately 6 min.  All analytical tests maintained system 
suitability limits for linearity from 0.024 to 100 μg/mL (r2 ≥ 0.999) and reproducibility of 
replicate injections (% RSD ≤ 2.0%). 
 
3.3.2.9 In Vivo Studies 
 
Institutionally approved in vivo studies were conducted using jugular vein pre-
catheterized CD® IGS Sprague-Dawley rats (Charles River Laboratories, Inc., 
Wilmington, MA) weighing approximately 300 g. Throughout the study the animals were 
stored in individual cages, subjected to 12 hr – 12 hr cycles of light and darkness, with 
access to food and water ad libitum.  The catheters were flushed daily with 300 μL of 50 
U/mL heparinized normal saline. A minimum of 72 hours was allowed for 
acclimatization, after which time the rats were administered the formulations at a dose of 
15 mg ITZ / kg body weight (n = 6). Prior to dosing, formulations of Sporanox® pellets 
were filled into size 9 porcine gelatin capsules to achieve a target dose of 15 mg ITZ / kg 
body weight (n = 6).  Briefly, the contents of ten Sporanox® capsules were emptied and 
weighed (464 mg pellets / capsule), to determine a theoretical potency per pellet mass 
(216 mg ITZ / g pellets).  An equivalent amount of 4.5 mg ITZ was manually filled into 
the body of the capsule to achieve dosing of 15 mg ITZ / kg for a 300 g animal.  Closed 
capsules were dosed by oral capsule dosing syringe (Torpac, Inc., Fairfield, NJ) followed 
by administration of 200 μL of deionized water by oral gavage. Engineered particles 
were dispersed in deionized water prior to dosing at a concentration of 4.5 mg ITZ / 1 mL 
and dosed by oral gavage, providing volumetric doses below 4 mL / kg body weight to 
prevent spontaneous release through the pyloric sphincter (41). Blood samples of 
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approximately 300 μL were collected from the jugular vein catheter at 0, 2, 3, 3.5, 4, 4.5, 
5, 5.5, 6, 8, 12 and 24 hr after dosing, placed into pre-heparinized 1.5 mL microcentrifuge 
tubes and replaced with equal volumes of heparinized saline. Blood samples were 
centrifuged at 3000g for 15 min and the plasma transferred to a clean 1.5 mL 
microcentrifuge tube.  All samples were stored at -20oC until HPLC analysis. 
 
Prior to HPLC analysis, plasma samples were removed from frozen storage, 
allowed to equilibrate to room temperature and a measured volume of plasma was 
transferred to a clean 1.5 mL microcentrifuge tube.  To each microcentrifuge tube, 50 μL 
of 0.3 N barium hydroxide and 50 μL 0.4 N zinc sulfate heptahydrate solutions were 
added.  Samples were then vortex mixed for 30 s and 1 mL of acetonitrile containing 
1200 ng/mL ketoconazole as an internal standard was added to each plasma sample.  
Samples were vortex mixed for an additional 90 s and centrifuged at 3000g for 15 min. 
From each vial the supernatant was extracted, transferred to a clean 1.5 mL centrifuge 
tube and dried in an aluminum heating block (70 °C) under a stream of nitrogen gas. 
Samples were reconstituted with 250 μL mobile phase, vortex mixed for 60 s and 
centrifuged for an additional 15 min.  An aliquot of the supernatant was extracted and 
filled into 150 μL HPLC vial inserts. Samples were analyzed at a wavelength of 263nm 
using the previously described Waters HPLC system equipped with a Phenomenex® Luna 
5 μm C-18(2) 100Å HPLC column (250 mm × 4.6 mm) maintained at a temperature of 
37 °C using a 38:62 0.05M phosphate buffer : acetonitrile mobile phase operated under 
isocratic flow of 1 mL/min.  Sample injection volumes of 100 μL were utilized for testing 
and the retention times of KTZ and ITZ were approximately 5.5 min and 14.7 min, 
respectively.  All analytical tests maintained system suitability limits for linearity (r2 ≥ 
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0.999) and reproducibility of replicate injections (% RSD ≤ 2.0%).  The limit of detection 
and quantitation for ITZ was 10 ng/mL and 30 ng/mL, respectively. 
 
3.3.2.10 Pharmacokinetic Analysis 
 
Plasma data was analyzed with WinNonlin v4.1 (Pharsight Corporation, 
Mountain View, CA) using non-compartmental analysis for extravascular input.  
Specifically, Tmax and Cmax were determined directly from empirical data, AUC was 
calculated by the linear trapezoidal method, and t½ was determined by calculation of the 
lambda z parameter.  For statistical analysis, encapsulated Sporanox® pellets were used as 
the reference formulation. 
 
3.3.2.11 Statistical Analysis 
 
Statistical analyses were conducted by ANOVA with Tukey comparison test or 
Students t-test, as identified in the respective section, using Minitab® Release 14.  For all 








3.4 RESULTS AND DISCUSSIONS 
 
3.4.1 Solid State Characterization 
 
In the development of amorphous compositions for enhanced bioavailability, 
several solid state properties are critical for product success including; the amorphous 
nature, drug-polymer miscibility and product surface area. 
 
Drug-polymer miscibility is essential for the stability of amorphous 
pharmaceutical compositions, as immiscibility can result in the formation of concentrated 
drug domains that may be prone to post production recrystallization.  The miscibility of 
these pharmaceutical systems can be assessed by a variety of techniques including the use 
of the Gordon-Taylor equation (42), presented in equation 1, wherein the 
physicochemical properties of the drug and the polymer are used to calculate the 
theoretical glass transition temperature of the mixture, with; Tgi indicating the glass 
transition temperature of component i, wi indicating the weight fraction of component i in 
the mixture, ρi indicating the true density of component i and Δαi indicating the change in 


















As values for Δαi are not readily available for many materials, K is often 







                                               
      Equation 3.2 
By comparison of the calculated glass transition temperatures to the observed 
glass transitions temperatures, the miscibility of the system can be assessed based on the 
correlation of the values.  The observed glass transition values of engineered particle 
compositions were determined by mDSC as the midpoints of the observed transitions in 
reversing heat flow shown in Figure 3.1.  In all cases, only a single transition was 
observed indicating that the systems existed as a single phase.  All compositions below 
80% drug loading did not exhibit an ITZ melting endotherm, further supporting the 
existence of a single drug-polymer phase.  Compositions of 80% drug loading did exhibit 
a melting endotherm; however, prior to this event a recrystallization exotherm was 
observed in standard heat flow suggesting that the melting endotherm was due in part to 
recrystallization during the analysis.  Standard heat flow also exhibited several broad 
endotherms during the initial phase of the testing not present in the reversing heat flow.  
These transitions were attributed to relaxation of the material, which is kinetically limited 
preventing these transitions from appearing in the reverse heat flow profiles.  To further 
evaluate the miscibility, the calculated and observed glass transitions temperatures for 
ITZ:CAP and ITZ:PVAP compositions were plotted as a function of ITZ weight fraction, 
as shown in Figure 3.2.  Compositions of ITZ:CAP showed an acceptable correlation (r2 
= 0.984) with the predicted glass transition values indicating drug and polymer 
miscibility.  The observed glass transition temperatures of the ITZ:PVAP compositions 
demonstrated a lower correlation (r2 = 0.920) and consistent positive deviation of the 
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Gordon-Taylor relationship, indicating either hydrogen bonding interactions between the 
drug and polymer or immiscibility of the drug polymer system (44). 
 
The potential interactions between ITZ and PVAP were investigated further using 
FTIR, as shown in Figure 3.3.  ITZ has numerous potential hydrogen bonding sites which 
may interact with enteric polymers such as PVAP, including the C=O group which 
functions as a hydrogen bond acceptor.  Examination of the FTIR spectra for ITZ 
indicated an intense C=O stretch located at 1700 cm-1, while a broader, less intense peak 
was observed for PVAP at 1735 cm-1.  The spectra for the 1:2 ITZ:PVAP physical 
mixture was similar to the additive profiles of the individual components with the 
intensities of the peaks in proportion to their concentration in the mixture, indicating that 
a simple admixture of the components did not induce a change in molecular interactions.  
Analysis of the 1:2 ITZ:PVAP engineered particle compositions showed a decrease in 
intensity and a broadening of the C=O stretch and a decrease in the C-H bond intensity 
compared to the physical mixture suggesting possible hydrogen bonding which may be 
responsible for the positive deviation observed in the Gordon-Taylor analysis.    
 
ITZ has previously been reported to be immiscible with several polymers, 
including Eudragit® EPO, resulting in observable phase separation (22).  Although only 
single glass transitions were observed by mDSC, EDS mapping was conducted to 
evaluate the qualitative distribution of ITZ in the composition by tracking the distribution 
of Cl, an atom unique to ITZ.  EDS mapping of engineered particle compositions, 
presented in Figure 3.4, yielded a homogeneous distribution of ITZ with no observed 
regions of phase separation supporting the conclusion of acceptable drug-polymer 
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miscibility.  It can also be seen that as the ITZ concentration increased, the intensity of 
the Cl signal also increased. 
 
By producing amorphous compositions, the ability to effectively supersaturate 
aqueous media can be readily attained due to the thermodynamic reduction in the heat of 
fusion.  To assess the amorphous nature of the compositions produced pXRD testing was 
conducted and the diffraction profiles are presented in Figure 3.5.  ITZ exhibited several 
strong characteristic crystalline peaks at 2θ = 14.4o, 17.5o, 20.4o, 23.4o, 25.3o and 27.1o.  
Both polymers used for production of the engineered particles demonstrated amorphous 
halos, supported by an absence of melting endotherms during mDSC testing, which 
indicated their amorphous nature.  Diffraction patterns of the engineered particle samples 
showed amorphous halos with an absence of the characteristic crystalline ITZ peaks, 
indicating that the ITZ was in an amorphous state.  This was also supported by the mDSC 
analysis in which only a single glass transition temperature with no melting endotherm 
was observed for compositions below 80% ITZ loading. 
 
The surface area and morphology of the engineered particles can significantly 
influence the drug release characteristics of the system through both kinetic and 
thermodynamic factors.  It is generally recognized that increased surface area can provide 
enhanced mass transfer during the dissolution process.  To examine the morphology and 
surface area of the particles, SEM and BET analyses were preformed.  SEM imaging of 
the engineered particles, presented in Figure 3.6, revealed two distinct forms for all 
compositions studied; discrete particles of approximately 5 μm and larger particle 
aggregates in excess of 30 μm.  In all cases, the particles exhibited a highly contoured 
surface providing significantly increased surface area compared to micronized powder, 
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providing an order of magnitude increase in surface area, as shown in Table 3.2.  These 
increased surface areas offered the potential for increased dissolution rates in vitro and in 
vivo. 
 
3.4.2 In Vitro Dissolution 
 
To assess the performance of developmental compositions prior to animal testing, 
in vitro dissolution has routinely been used in the pharmaceutical industry.  Dissolution 
studies reported in the literature and also testing recommended by the Food and Drug 
Administration (FDA) (45, 46) has generally been conducted under sink conditions, 
wherein the concentrations are maintained at least three to five times below equilibrium 
solubility.  Numerous articles have correlated the results of these tests to the in vivo 
performance of the formulations; however with amorphous compositions these tests 
neglect the ability of the formulation to supersaturate the dissolution media.  
Supersaturation can occur in vivo as well, necessitating the requirement for evaluation of 
the associated kinetics.  For this study, the dissolution testing was conducted under 
supersaturated conditions in order to evaluate the supersaturation and precipitation 
dynamics of Sporanox® Pellets, ITZ:CAP engineered particles and ITZ:PVAP engineered 
particles. 
 
As discussed previously several recent papers have evaluated the dynamics of 
supersaturation (26, 27, 30-32, 35, 36, 47), however these analyses have focused 
primarily on the area under the curve (AUC), also referred to as extent of supersaturation.  
While this value can provide a general description of the in vivo bioavailability, it does 
not directly assess the stabilizing properties of the polymer.  For the identification and 
 80
characterization of concentration enhancing polymers, the rate of precipitation inhibition 
was identified by calculation of the half life of drug in solution. During the growth phase 
of the precipitation process transport of drug to the precipitate surface is driven by the 









                                                          
    Equation 3.3 
 
where G is the growth rate of the particle, kd is a constant, ΔCS is the difference 
between measured concentration and equilibrium concentration, Cc is the precipitate 
density, α is the volume factor and β is the shape factor (48).  Assuming that the growth 
rate is proportional to the rate of concentration decrease and combining all constants into 
a lumped term, K’, it can be shown that: 
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                                                        Equation 3.4 
 
where Ceq is the equilibrium solubility.  By identifying that C >> Ceq and 
integrating the equation it can be shown that the change in measured concentration 




K'−=                                                                     Equation 3.5 
 
Assuming that the growth phase began at the maximum observed concentration 
and by plotting the dissolution data as an exponential function of the above form, the half 
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life of the formulation can be calculated by linear regression allowing for assessment of 
the polymer stabilizing properties. 
  
Dissolution testing of the Sporanox® pellets, presented in Figure 3.7, illustrated 
the ability of the formulation to rapidly and extensively supersaturate in acidic media, 
achieving near complete supersaturation.  Following pH change, there was a rapid 
precipitation of drug from solution, with an observed t1/2 of 6.7 ± 2.4 min, supporting the 
hypothesis of Miller et al, that the low and variable bioavailability of Sporanox® was due 
to the inability of the formulation to maintain supersaturation in neutral media (26).  
Although Sporanox® pellets contain low viscosity HPMC E5 (9, 10) and HPMC has been 
identified as a concentration enhancing polymer for several compounds (47), the 
viscosity of the material has been shown to significantly influence the supersaturation 
stabilization of ITZ in neutral media (27).  This suggests that a change in HPMC 
viscosity could improve the bioavailability of the commercial product.  
 
Engineered particle compositions were also tested for in vitro dissolution 
performance.  Dissolution profiles presented in Figure 3.8 and Figure 3.9 indicated that in 
all cases the engineered particle compositions provided significantly reduced release in 
acidic media, compared to Sporanox® Pellets due to minimal solubility of the enteric 
polymers in these conditions.  Additional critical formulation metrics are provided in 
Table 3.3.  Following pH change. 1:2 ITZ:CAP and 1:2 ITZ:PVAP compositions showed 
the greatest increase of supersaturation in neutral media for the respective polymer 
classes due to ionization and subsequent dissolution of the enteric polymer, while 
compositions with higher ITZ:polymer ratios exhibited reduced degrees of 
supersaturation.  Although reduced degrees of supersaturation can indicate immiscibility 
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of the system caused by reduced wetting due to regions of hydrophobic drug, results from 
the solid state characterization indicated homogeneous distributions for both polymer 
systems, and this phenomenon was attributed to the higher drug loading which resulted in 
decreased particle wetting limiting the dissolution process.  Differences in the degree of 
neutral media supersaturation were also observed for the CAP and PVAP compositions 
which were attributed to the substantially larger half-life of drug in solution and 
variations in the nucleation behavior of these systems.  During testing both formulation 
types were observed to dissolve upon pH change, however the more rapid precipitation of 
PVAP compositions prevented identification of the true maximum amount of dissolved 
drug due to the short duration of the maximum.  The differences in the measured values 
may also indicate a difference in the nucleation behavior of these systems, however 
insufficient data are available to assess this variation.    Examination of AUCdissolution 
values showed that ITZ:CAP compositions provided statistically significant increases in  
extent of neutral media supersaturation compared to the other test formulations due to the 
prolonged half-life of drug in solution.  Half-life values for CAP based compositions 
were significantly higher than those observed for the other tested compositions indicating 
that CAP was a superior concentration enhancing polymer, although the data does not 
conclusively indicate at which stage of the precipitation process (nucleation or growth) 
the polymer has its greatest effect. 
 
Two mechanisms have been traditionally used to explain the stabilizing 
performance of excipients in supersaturated solutions; hydrogen bonding and steric 
hindrance. Examination of the molecular structure of ITZ revealed numerous hydrogen 
bond acceptor sites that are capable of interacting with the hydrogen bond donor sites of 
the enteric polymers.  The molecular structure of both polymers, presented in Figure 
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3.10, indicated that PVAP has more hydrogen bond donor sites per weight, suggesting 
that the magnitude of hydrogen bonding between the drug and polymer is not the 
mechanism of stabilization.  A qualitative comparison of polymer solutions (2%) shows 
that CAP provides higher viscosities than PVAP (49), suggesting that the stabilization 
may be due to steric hindrance.  Furthermore, the molecular structure of CAP may also 
play a role in the stabilization.  It has been observed that higher viscosities of HPMC, a 
cellulosic polymer, can provide improved stabilization of supersaturated ITZ solutions 
compared to comparable viscosities of PVP, a polymer with a polyalkylene backbone.  
The ability of these excipients, HPMC and CAP, to provide superior stabilization of 
supersaturation may also be due, in part, to the cellulosic polymer backbone which can 
provide additional shielding of ITZ from interactions that could result in recrystallization 
compared to polymers such as PVP and PVAP with a polyalkylene backbone due to 
differences in polymer rigidity. 
 
3.4.3 In Vivo Results 
 
Based on the superior in vitro dissolution performance of the 1:2 ITZ:CAP 
engineered particle composition, this formulation was selected for comparison to 
Sporanox® pellets in a rat model.  After dosing, plasma samples taken during testing were 
analyzed by HPLC and ITZ plasma concentrations were plotted as a function of time as 
shown in Figure 3.11.  Both plasma profiles were analyzed by non-compartmental 
analysis for extravascular administration to determine the appropriate pharmacokinetic 
parameters of the two formulations, as presented in Table 3.4, and the data was analyzed 
statically using the student t-test.  Additional analysis of plasma profile time points was 
conducted using one way ANOVA with Tukey post-hoc testing. 
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Statistically significant differences observed for both AUC0-24hr and t1/2 values 
indicated that the engineered particle formulation, when compared to Sporanox Pellets®, 
provided greater oral bioavailability and suggested that larger concentrations of drug 
were available for absorption in the later stages of the GI tract due to the inhibition of 
drug precipitation, however one cannot rule out a potential contribution of metabolic 
conversion on the improvement of itraconazole bioavailability.  Results also showed no 
statistically significant difference in measured Cmax values, as well as a reduction in 
variability for the test product indicating a potential for increased oral bioavailability with 
a comparable or reduced side effect profile.  Similarly, measured tmax values for the two 
formulations also showed no statistically significant difference, although the test 
formulation did exhibit lower variability.  Statistical analysis of plasma profile time 
points collected from two to five hours during testing showed statistically significant 
differences in mean concentration, with engineered particle compositions providing 
greater concentrations within this time period which suggested superior targeting of the 
upper small intestine.   
 
Comparing the in vitro dissolution results to the in vivo plasma profiles yields 
several interesting findings.  First, the composition with the slower dissolution rate and 
lower overall degree of supersaturation provided the higher oral bioavailability.  These 
results are similar in nature to those reported by Six et al. (2), where in vitro dissolution 
rates did not linearly correlate to differences in oral bioavailability.  Assessment of much 
of the currently available literature teaches that increased dissolution leads to increased 
bioavailability, however the results presented here contradict this hypothesis.  When 
examining the physiological properties of the rat gastrointestinal tract, one sees that the 
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approximate surface area of and residence time in the stomach are significantly lower 
than that of the intestinal tract (1, 50, 51), allowing for increased absorption of drugs after 
transiting through the pyloric sphincter.  In situ perfusion studies of ITZ in Sprague-
Dawley rats demonstrated regional permeabilities and Kobs of approximately 5 x 104 cm/s 
and 1.3 x 10-3 respectively (52). Although the permeability values decreased between the 
duodenum and the ileum, the relatively constant Kobs values suggested that absorption 
occurs throughout the intestine.  Since the interaction of ITZ and CAP provided 
prolonged durations of supersaturation in vitro, it is reasonable to infer that a similar 
effect would occur in the neutral pH and highly permeable environment of the 
intestine(52), resulting in a higher driving force for transport across the intestinal 
membrane thereby improving the absorption and bioavailability of ITZ.  Products 
exhibiting longer durations of absorption, such as modified release tablets, exhibit longer 
in vivo half lives when evaluated by non-compartmental analysis due the combined 
mechanisms of absorption and elimination (53).  Examination of the t1/2 values also 
showed that the ITZ:CAP composition provided an increased half-life, indicative of 
prolonged absorption in the later stages of the intestinal tract.  Based on these results, for 
drugs such as ITZ that exhibit no regional absorption limitations, bioavailability can be 
enhanced by providing greater extents of supersaturation at lower maximal 
concentrations than by maximizing the dissolution rate when the drug substance is prone 
to precipitation under physiological conditions.  
 
Another interesting observation was the statistically significant differences in the 
initial stages of the plasma profile for the two formulations, which suggested improved 
targeting of the upper small intestine by the ITZ:CAP composition.  During testing 
gavage volumes were minimized to prevent spontaneous release through the pyloric 
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sphincter, however variations in gastric emptying associated with the differences in 
dosage form (1) may have contributed to this disparity in performance between the 
formulations, as solid dosage forms have a longer intestinal residence time.  Given the 
absence of a statistical difference observed in tmax values between formulations one can 
infer an underlying performance difference between compositions.  Although the 
Sporanox® Pellets supersaturated the acidic media in vitro, rapid and complete 
precipitation to below the limit of detection was observed upon pH change above the 
pKa.  Analogously, in vivo the Sporanox Pellets® rapidly supersaturate the stomach, 
however the short residence time and minimal surface area limit absorption during this 
stage.  Upon transiting through the pyloric sphincter the supersaturated solution 
encounters pH values above the pKa causing the drug to unionize and rapidly precipitate 
from solution due to the absence of a strong stabilizing polymer.  As a result of the 
precipitation in neutral media, limited and decreasing quantities of drug in solution are 
available to provide a driving force for diffusive transport in the highly permeable upper 
small intestine resulting in incomplete absorption.   Conversely, the ITZ:CAP 
composition provided substantially lower levels of drug release in the acidic media 
representative of the stomach.  When the stomach contents entered the upper small 
intestinal region, the pH increase the ionized enteric polymer allowing for maximal 
supersaturation in the region of highest permeability driving a more rapid increase in 
plasma concentration during the initial stages of the profile.  Similar results have also 
been reported in the literature, for example where the use of enteric coprecipitates and 
intraduodenal administration of PVP coprecipitates resulted in improved bioavailability 
of the developmental drug HO-221 by targeting the upper small intestine (54), further 





Solid state characterization demonstrated that the engineered particles were 
amorphous and provided increased specific surface areas which would provide 
thermodynamic and kinetic advantages during dissolution.  It was also shown that the 
compositions were chemically homogenous with only single glass transitions observed 
over a range of drug loadings, indicating miscibility of the drug-polymer systems studied 
and confirmed by EDS mapping.  In vitro dissolution testing results indicated a reduced 
dissolution rate of the engineered particle systems compared to the Sporanox® Pellets, 
however ITZ:CAP compositions were able to more completely supersaturate the neutral 
pH environment and also provided greater extents of supersaturation due to the 
stabilizing effect of the polymer.  As a result of the site targeting and improved extent of 
supersaturation, a statistically significant two-fold improvement in bioavailability of 
itraconazole was observed over the currently marketed product in a rat model, suggesting 
a potential application of this formulation strategy in humans.  
 
Clearly, these results indicate that the ability to provide enhanced bioavailability 
is dependent on more than the dissolution rate of the compositions and support the 
hypothesis that prolonged durations of neutral media supersaturation correlate with 
improved oral bioavailabilities.  When formulating a poorly water soluble new chemical 
entity (NCE), it is essential to understand the dynamics of supersaturation and the 
regional absorption of the compound.  Drug substances requiring supersaturation to 
improve absorption will ultimately be subjected to precipitation due to the metastability 
associated with the dissolution process.  Identifying and incorporating materials capable 
of decreasing the rate of precipitation can provide increased bioavailability by prolonging 
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the duration of supersaturation.  Furthermore, site targeting of supersaturation using pH 
dependent polymers can be an effective way to provide the maximum driving force in the 
region of highest permeability.  These results highlight the utility of this approach for the 
bioavailability enhancement of itraconazole, and similar strategies have been reported for 
other compounds in the literature, indicating that this technique can be an effective tool to 
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Figure 3.1 mDSC Thermograms.  (a.) Reversing Heat Flow Profile of ITZ:CAP 
Compositions, (b.) Heat Flow Profile of ITZ:CAP Compositions, (c.) 
Reversing Heat Flow Profile of ITZ:PVAP Compositions, (d.) Heat Flow 


































Figure 3.2 Gordon Taylor Relationship for Engineered Particle Formulations.  ITZ:CAP 
Measured Tg (♦), ITZ:PVAP Measured Tg (■), Predicted ITZ:CAP Tg (····), 


























Figure 3.4 TEM Imaging Analysis of Particle Structure. (a.) 1:2 ITZ:CAP, (b.) 2:1 
























Figure 3.6 – SEM Images of Engineered Particle Morphologies. (a. & b.) 1:2 ITZ:CAP, 






























Figure 3.7 Supersaturated dissolution profile of Sporanox® Pellets.  Each vessel (n=3) 
contained 37.5 mg ITZ equivalent corresponding to 10 times the equilibrium 
solubility of ITZ in the acid phase. Testing was conducted for 2 h in 750 ml 
of 0.1 N HCl followed by pH adjustment to 6.8 ± 0.5 with 250 ml of 0.2 M 
tribasic sodium phosphate solution.  Dashed vertical line indicates the time 






























Figure 3.8 Supersaturated dissolution profile of ITZ:CAP formulations.  Key: 1:2 
ITZ:CAP (♦), 1:1 ITZ:CAP (■), 2:1 ITZ:CAP (▲).  Each vessel (n=3) 
contained 37.5 mg ITZ equivalent corresponding to 10 times the equilibrium 
solubility of ITZ in the acid phase. Testing was conducted for 2 h in 750 ml 
of 0.1 N HCl followed by pH adjustment to 6.8 ± 0.5 with 250 ml of 0.2 M 
tribasic sodium phosphate solution.  Dashed vertical line indicates the time 































Figure 3.9 Supersaturated dissolution profile of ITZ:PVAP formulations.  Key: 1:2 
ITZ:PVAP (♦), 1:1 ITZ:PVAP (■), 2:1 ITZ:PVAP (▲).  Each vessel (n=3) 
contained 37.5 mg ITZ equivalent corresponding to 10 times the equilibrium 
solubility of ITZ in the acid phase. Testing was conducted for 2 h in 750 ml 
of 0.1 N HCl followed by pH adjustment to 6.8 ± 0.5 with 250 ml of 0.2 M 
tribasic sodium phosphate solution.  Dashed vertical line indicates the time 










Figure 3.11 In Vivo Plasma Profile. Key: Sporanox® Pellets (♦), 1:2 ITZ:CAP (■).  
Formulations were administered by oral gavage at a dose of 15 mg ITZ / kg 
body weight per rat (n=6). * indicates statistically significant concentration 
difference between test and reference formulation as determined by one-way 













1 24 -20 < 100 -80 
2 36 -5 < 100 -80 
3 12 20 < 100 -80 
 




Composition Surface Area (m2/g) 
ITZ (Unprocessed) 2.90 
1:4 ITZ : CAP 39.83 
4:1 ITZ : CAP 55.91 
1:4 ITZ : PVAP 47.53 
4:1 ITZ : PVAP 61.26 
 




Table 3.3 Summary of In Vitro Dissolution Testing Data with reported maximum 
observed concentrations (Cmax), observed time to achieve maximum 
concentration (tmax), area under the supersaturation dissolution profile for pH 
change testing (AUCdissolution) and observed supersaturation half life (t1/2). 
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381.4 ± 121.8 4.3 ± 0.6 4,516 ± 1,949 9.6 ± 1.9 
 
Table 3.4 Calculated Pharmacokinetic Parameters for Formulations Tested In Vivo 
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Chapter 4:  Fusion Processing of Itraconazole Solid Dispersions by 
KinetiSol® Dispersing: A Comparative Study to Hot Melt Extrusion 
4.1 ABSTRACT 
KinetiSol® Dispersing (KSD) is a novel high energy manufacturing process 
investigated here for the production of pharmaceutical solid dispersions. Solid 
dispersions of itraconazole (ITZ) and hypromellose were produced by KSD and 
compared to identical formulations produced by hot melt extrusion (HME). Materials 
were characterized for solid state properties by modulated differential scanning 
calorimetry and x-ray diffraction. Dissolution behavior was studied under supersaturated 
conditions. Oral bioavailability was determined using a Sprague Dawley rat model. 
Results showed that KSD was able to produce amorphous solid dispersions in under 15s 
while production by HME required over 300s. Dispersions produced by KSD exhibited 
single phase solid state behavior indicated by a single glass transition temperature (Tg) 
whereas compositions produced by HME exhibited two Tgs. Increased dissolution rates 
for compositions manufactured by KSD were also observed compared to HME processed 
material. Near complete supersaturation was observed for solid dispersions produced by 
either manufacturing processes. Oral bioavailability from both processes showed 
enhanced AUC compared to crystalline ITZ. Based on the results presented from this 
study, KSD was shown to be a viable manufacturing process for the production of 
pharmaceutical solid dispersions, providing benefits over conventional techniques 






Advances in combinatorial chemistry and high throughput screening have 
significantly increased the number of developmental “hits” however this has also been 
responsible for a dramatic increase in the number of developmental compounds 
exhibiting poor bioavailability due to limited aqueous solubility (1, 2).  Although the 
percentage of poorly water soluble compounds varies by company pipeline, it has been 
reported to represent approximately 40% of new chemical entities reaching the market 
and upwards of 60% of corporate pipelines (3), indicating a significant demand for 
solubilization technologies to improve oral bioavailability.  Significant development in 
this field has occurred over the last twenty years, particularly in the area of oral delivery 
applications given the predominance of this route of administration for pharmaceutical 
products today.  Currently, the primary technologies which enable enhanced oral 
bioavailability include: nanoparticles (4-6), microemulsions (7, 8), lipid systems (9), 
complexed systems (10, 11) and solid dispersions (12-16).  Of these technologies, solid 
dispersions have received substantial interest in both the academic and industrial arenas, 
with several currently available products employing this technology including: Kaletra® 
(13), Sporanox® (17) and Prograf® (18). 
 
Solid dispersions are defined as dispersions of one or more active ingredients in 
an inert carrier or matrix at the solid state (19) and can provide enhanced dissolution 
properties through a combination of particle size diminution and reduced crystallinity.  
First described in the late 1960’s, early systems typically consisted of a drug dispersed in 
a hydrophilic excipient wherein the active ingredient generally maintained the original 
crystalline properties but was present in a reduced particle size presenting greater surface 
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area for dissolution enhancement.  Additional refinement of processing techniques later 
demonstrated that additional drug release enhancement could be achieved through the 
development of solid solutions (20), which are analogous to a liquid solution having all 
components distributed at a molecular level to provide a single phase.   
 
The production of amorphous solid dispersions can be achieved using a variety of 
manufacturing processes, which can be classified into two major categories: solvent 
production methods and thermal production methods (21).  Both classifications follow a 
similar process, wherein the drug and carrier are transitioned into a state of higher 
molecular mobility, allowed to mix through external forces and processed to a solid state, 
ideally rendering a single phase.  Although similar in principle, each classification 
presents unique advantages and disadvantages.  Solvent based processes, currently more 
common than thermal processes, are performed by dissolving the drug and excipients in a 
common miscible solvent system.  During processing the equipment is generally operated 
at lower temperatures and can be conducted using conventional equipment such as fluid 
bed coaters and spray dryers.  These unit operations however, frequently rely on high 
toxicity ICH limited use solvents such as dichloromethane which can result in the need 
for additional drying steps to prevent batch failure due to excessive residual solvent.  
Thermal production methods are conducted by heating the drug and excipients to a 
molten state and mixing, thereby eliminating the requirement for an organic solvent.  
Processing under these conditions however, exposes materials to extensive thermal 
energy which can result in degradation (22).  Additionally, plasticizers are frequently 
required to achieve the necessary material properties during production which can 
negatively impact the stability of the material through a reduction in glass transition 
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temperature (23-25).  Other issues associated with both classes include low production 
throughput and phase separation of materials. 
 
Multiphase pharmaceutical systems can result from a number of reasons 
including: material immiscibility, inappropriate drying rate and insufficient mixing 
during processing.  This behavior can be characteristic of both solvent processes (26) and 
thermal processes (27).  While enhancements in dissolution rate and oral bioavailability 
can be achieved using these systems, the ability of these compositions to provide 
adequate pharmaceutical shelf life may be compromised.  In a study by Six et al., they 
showed that hot melt extrusion could be utilized to produce amorphous solid dispersions 
of itraconazole and hypromellose (27).  Solid dispersions produced at various drug 
loadings were able to provide improved in vitro dissolution rates relative to amorphous 
and crystalline ITZ.  Additional studies in human volunteers also revealed that this 
formulation provided similar oral bioavailability compared to the commercially marketed 
product, Sporanox® (28).  Solid state characterization of the samples at 40% ITZ loading 
showed two distinct transitions.  The first transition occurred between 60oC and 70oC 
which indicated an ITZ rich phase, while a second transition occurred around 140oC and 
was attributed to a polymer rich phase.  This behavior was attributed to intermolecular 
interactions which were influenced by the presence of residual water and the authors 
were unable to determine processing conditions which could eliminate this behavior (29).  
It is important to note however, that many modern extruders have interchangeable screw 
elements which allow for modification of shear properties within the unit.  
Implementation of screw designs with greater shear characteristics, as well as 
optimization of screw speeds, zone temperatures and feed rates, may have provided 
improved homogeneity of the compositions.   
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KinetiSol® Dispersing (KSD) is a novel high energy mixing process for the 
production of amorphous pharmaceutical solids.  This technology utilizes a series of 
rapidly rotating blades to process the drug and polymeric carrier through a combination 
of kinetic and thermal energy without the aid of external heating sources.  For processing, 
materials are preblended and charged into the product chamber.  During processing, 
material temperatures are monitored in real time using a computer control system and 
automatically discharged when reaching the required endpoint.  Although not currently 
recognized for pharmaceutical production, it is presently applied in other fields and 
provides several potential advantages over other available solid dispersions platforms.  
Classified as a thermal process, this manufacturing platform can provide an order of 
magnitude greater mixing relative to other thermal processes, imparting the potential to 
produce amorphous solid dispersions with improved properties (30).  Additionally, 
production scale equipment currently employed in other industries reach material 
throughputs in excess of 1,000 kg/hr.  Officially considered as a batch unit operation, 
equipment can be configured for batch or semi-continuous operation providing versatility 
and flexibility for the end user.  Although the inability to run in a continuous mode and 
the requirement for immediate post-processing may be perceived as disadvantages, it is 
important to point out that batch processing is still the primary mode of manufacture in 
the pharmaceutical industry and that hot melt extrusion also requires similar post-
processing techniques such as conveyed cooling and in-line pelletization.  
 
In this study it was hypothesized that KinetiSol® Dispersing could be utilized to 
produce solid dispersions having improved physicochemical properties compared to 
materials produced using alternative thermal production techniques while providing 
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enhanced oral bioavailability relative to crystalline drug substances.  Itraconazole, a weak 
base (pKa = 3.7), was selected as the model poorly water soluble drug and exhibits an 
aqueous solubility in acid conditions of approximately 4 - 12 μg/ml (31, 32).  A 
formulation of 33% ITZ loaded solid dispersion in hypromellose E5 was selected based 
on the previously documented phase separation of this formulation when produced by hot 
melt extrusion (27).  Compositions were produced by both hot melt extrusion and 
KinetiSol® Dispersing and characterized for solid state properties, in vitro dissolution 
behavior, potency and oral bioavailability using a rat model.  Results were then compared 
across manufacturing processes and to current industry standards in order to establish the 
viability of KinetiSol® Dispersing for the production of amorphous solid dispersions. 
 




Itraconazole, BP micronized was purchased from Hawkins, Inc. (Minneapolis, 
MN). Hydroxypropyl methylcellulose (HPMC E5) was generously donated by the Dow 
Chemical Company (Midland, MI). Hydroxyitraconazole was purchased from BDG 
Synthesis (Wellington, New Zealand).  HPLC grade acetonitrile was purchased from 







4.3.2.1 KinetiSol® Dispersing (KSD) 
 
KinetiSol® Dispersing was conducted using a custom built compounder designed 
for pharmaceutical processing applications by DisperSol Technologies, L.L.C. (Austin, 
TX).  Briefly, the unit consists of a product containment vessel containing a rotating shaft 
with processing blades extending outward from the shaft.  During operation, the blades 
rotate at a high rotational velocity rapidly processing the material through the 
development of heat generated by shear and frictional motion of product within the 
vessel.  This method of heat generation is unique among fusion possessing technologies, 
and no external heat input is required during production.  Operational temperatures and 
processing speeds were monitored real time through a computer regulated control system 
and the material was automatically discharged upon reaching the target temperature.  For 
production, drug and polymer quantities were accurately weighed and premixed by hand 
in a polypropylene bag for two minutes.  Materials were charged into the compounder at 
room temperature and processed under operational conditions presented in Table 4.1.  
Following discharge the material was quench pressed between two chilled plates and 
ground using an impact mill (Capresso Inc., Closter, NJ).  The powder was further 
comminuted using a glass mortar and pestle.  The powder was then passed through a 60 
mesh (250 micron) screen and use for analysis.  Additional quantities of powder were 
also screened as described in the subsequent section to produce material for particle size 
studies.  In-process temperature profiles were smoothed using a five point mean value 




4.3.2.2 Hot Melt Extrusion (HME) 
 
Hot melt extrusion was conducted using a co-rotating conical (5/14 mm diameter) 
twin screw HAAKE Minilab II Microcompounder (Thermo Electron Corporation, 
Newington, NH) without an external die.  Prior to extrusion, ITZ and HPMC E5 were 
accurately weighed in a 1:2 ratio and premixed in a glass mortar and pestle for two 
minutes.  The ITZ:HPMC E5 powder blend was manually feed into the extruder which 
was maintained at a temperature of 180oC and screw speed of 120 rpm.  In-process 
parameters were measured during extrusion and are presented in Table 4.1.  Following 
extrusion, extrudates were milled using an impact mill (Capresso Inc., Closter, NJ) and 
further ground in a glass mortar and pestle.  The powder was screened through a 60 mesh 
(250 micron opening) sieve to yield a final powder for analysis. 
 
4.3.2.3 X-Ray Diffraction (XRD) 
 
 XRD testing was conducted using a Philips Model 1710 X-ray diffractometer 
with a copper target and nickel filter (Philips Electronic Instruments Inc., Mahwah, NJ).  
Samples of powder were placed into channeled stages and the diffraction profile was 
measured from 5o to 50o using a 2θ step size of 0.05o and dwell time of 3s operated at a 





4.3.2.4 Modulated Differential Scanning Calorimetry (mDSC) 
 
mDSC testing was performed using a TA Instruments Model 2920 DSC (New 
Castle, DE) and analyzed using TA Universal Analysis 2000 Software. Samples were 
weighed to 15 ± 2 mg in aluminum crimped pans (Kit 0219-0041, Perkin-Elmer 
Instruments, Norwalk, CT) and testing was performed at a ramp rate of 10 °C/min from 5 
to 215 °C using a modulation temperature amplitude of 0.5 ºC and a modulation period of 
40 s under nitrogen purge at a flow rate of 40 mL/min.  Amorphous itraconazole was 
assessed by examination of the second run heating cycle following a rapid quench.  
Unprocessed polymer profiles were presented as a second mDSC run to remove thermal 
history of the material. 
 
4.3.2.5 Thermal Gravimetric Analysis (TGA) 
 
Thermal gravimetric analysis was conducted using a Perkin-Elmer 7-Series 
Thermogravimetric Analyzer (Norwalk, CT) operated at a ramp rate of 10 oC/min from a 
temperature of 100oC to 500oC.  Samples were prepared by degassing under desiccated 
vacuum for 72 hours at room temperature prior to analysis and accurately measuring a 
sample of approximately 10 mg.  Data was analyzed using Perkin-Elmer control software 
and plotted using Microsoft Excel. 
 
4.3.2.6 Helium Pycnometry 
 
 123
Powder true densities were measured by helium pycnometry using an AccuPyc 
1330 (Norcross, GA).  An accurately measured quantity of powder was placed into the 
sample cell and analyzed at 19.85 psi (n=3) using high purity helium.  Data were reported 
as the mean of the three analytical measurements. 
 
4.3.2.7 Potency Testing 
 
 Potency testing was conducted by accurately weighing and recording the amount 
of an aliquot of powder equivalent to 10.0 ± 0.1 mg of ITZ and dissolving in 100 ml of 
60:40:0.05 acetonitrile:water:diethanolamine mobile phase.  Dissolved samples were 
filtered using 0.2μm PTFE membrane, 13mm filters (Pall Corporation, East Hills, NY) 
and analyzed using a Waters (Waters Corporation, Milford, MA) high performance liquid 
chromatography (HPLC) system consisting of dual Waters 515 Syringe Pumps, a Waters 
717 Autosampler and a Waters 996 Photo Diode Array extracting at a wavelength of 263 
nm. Samples were injected at 50 μl and the system was operated under isocratic flow at 1 
mL/min using a mobile phase consisting of 60:40:0.05 acetonitrile:water:diethanolamine 
equipped with a Phenomenex Luna 5 μm C18(2) 100Å, 150 mm x 4.6 mm 
(Phenomenex®, Torrance, CA) HPLC column.  Data were collected and analyzed using 
Empower® Version 5.0 software.  The retention time of ITZ was approximately 19 min.  
All analytical tests maintained system suitability limits for linearity (r2 ≥ 0.999) and 
reproducibility of replicate injections (% RSD ≤ 2.0%).  Final reported values were 





4.3.2.8 Supersaturated Dissolution Testing  
 
Supersaturated dissolution testing was performed based on the USP XXIX 
Apparatus II dissolution test using a VK 7010 dissolution apparatus (Varian, Inc., Palo 
Alto, CA) and VK 8000 autosampler (Varian, Inc., Palo Alto, CA) operated at a paddle 
speed of 50 rpm and vessels containing 900 ml of 0.1N HCl media.  An equivalent 
amount of 45.0 mg ± 0.5 mg of ITZ (~10x 0.1N HCl media equilibrium solubility) was 
weighed and added to the dissolution vessel containing 0.1N HCl media heated to 37.0 ± 
0.5 oC.  During testing 5 mL samples were removed from the dissolution vessels without 
replacement after 5, 10, 15, 30, 45, 60, 90 and 120 min.  Samples were immediately 
filtered using 0.2m PTFE membrane, 13mm filters (Pall Corporation, East Hills, NY), 
diluted in a 1:1 ratio with mobile phase, vortexed mixed and transferred into 1 mL vials 
(VWR International, West Chester, PA) for analysis. 
 
Dissolution samples were analyzed using the previously described Waters HPLC 
system operated under isocratic flow at 1 mL/min using a mobile phase consisting of 
70:30:0.05 acetonitrile:water:diethanolamine equipped with a Phenomenex Luna 5 μm 
C18(2) 100Å, 150 mm x 4.6 mm (Phenomenex®, Torrance, CA) HPLC column.  Samples 
were collected in the 0.1N HCl media at a volume of 50 μL during testing.  Data 
collection and analysis was performed using Empower® Version 5.0 software.  The 
retention time of ITZ was approximately 6 min.  All analytical tests maintained system 
suitability limits for linearity from 0.024 to 100 μg/mL (r2 ≥ 0.999) and reproducibility of 
replicate injections (% RSD ≤ 2.0%). 
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4.3.2.9 In Vivo Studies 
 
Institutionally approved in vivo studies were conducted using jugular vein pre-
catheterized CD® IGS Sprague-Dawley rats (Charles River Laboratories, Inc., 
Wilmington, MA) weighing approximately 300 g. Throughout the study the animals were 
stored in individual cages, subjected to 12hr-12hr cycles of light and darkness, with 
access to food and water ad libitum.  The catheters were flushed daily with 300 μl of 50 
U/mL heparinized normal saline. A minimum of 72 hours was allowed for 
acclimatization, after which time the rats were administered the formulations at a dose of 
15 mg ITZ / kg body weight (n = 6). Processed powder samples were dispersed in 
deionized water prior to dosing at a concentration of 4.5 mg ITZ / 400 μl and dosed by 
oral gavage. Blood samples of approximately 300 μl were collected from the jugular vein 
catheter at 0, 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12 and 24 hr after dosing, placed into pre-
heparinized 1.5 mL microcentrifuge tubes and replaced with equal volumes of 
heparinized saline. Blood samples were centrifuged at 3000g for 15 min and the 
measured plasma transferred to a clean 1.5 mL microcentrifuge tube.  To each 
microcentrifuge tube, 50 μl of 0.3 N barium hydroxide and 50 μl 0.4 N zinc sulfate 
heptahydrate solutions were added.  Samples were then vortex mixed for 30 s and 1 mL 
of acetonitrile containing 1200 ng/mL ketoconazole as an internal standard was added to 
each plasma sample.  Samples were vortex mixed for an additional 90 s and centrifuged 
at 3000g for 15 min. From each vial the supernatant was extracted, transferred to a clean 
1.5 mL centrifuge tube and dried in an aluminum heating block (70 °C) under a stream of 
nitrogen gas. Samples were reconstituted with 250 μL mobile phase, vortex mixed for 60 
s and centrifuged for an additional 15 min.  An aliquot of the supernatant was extracted 
and filled into 150 μl HPLC vial inserts. Samples were analyzed at a wavelength of 
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263nm using the previously described Waters HPLC system equipped with a 
Phenomenex® Luna 5 μm C-18(2) 100Å HPLC column (250 mm × 4.6 mm) maintained 
at a temperature of 37 °C using a 38:62 0.05M phosphate buffer : acetonitrile mobile 
phase operated under isocratic flow of 1 mL/min.  Sample injection volumes of 100 μl 
were utilized for testing and the retention times of KTZ, OH-ITZ and ITZ were 
approximately 5.5, 7.5 and 14.7 min, respectively.  All analytical tests maintained system 
suitability limits for linearity (r2 ≥ 0.999) and reproducibility of replicate injections (% 
RSD ≤ 2.0%).  The limit of detection and quantitation for OH-ITZ and ITZ was 10 
ng/mL and 30 ng/mL, respectively. 
 
4.3.2.10 Pharmacokinetic Analysis 
 
Plasma data analysis was conducted using WinNonlin v4.1 (Pharsight 
Corporation, Mountain View, CA) by non-compartmental analysis for extravascular 
input.  Specifically, Tmax and Cmax were determined directly from empirical data, and 
AUC was calculated by the linear trapezoidal method. 
 
4.3.2.11 Statistical Analysis 
 
Statistical analyses were conducted by ANOVA with Tukey comparison test or 
Students t-test, as identified in the respective section, using Minitab® Release 14.  For all 
tests, p ≤ 0.05 was used as the criteria to assess statistical significance. 
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4.4 RESULTS AND DISCUSSION 
 
4.4.1 Production of Solid Dispersions 
 
Solid dispersions of 1:2 ITZ and HPMC E5 were produced by KSD and HME to 
support characterization and bioavailability studies under the processing conditions 
presented in Table 4.1.  For KSD processing, material was first preblended, charged into 
the product container and processed at the specified rotational speed until reaching the 
target temperature at which point the material was discharged, cooled and further 
processed into powder.  During processing operations the in-process computer control 
system logged material temperatures recorded using an in-line infra-red temperature 
probe, which was converted into a temperature profile as shown in Figure 4.1.  
Examination of the profile showed an initial period of constant temperature at which time 
the material temperature was below the sensor limit of detection.  Once material achieved 
the minimum probe display temperature a linear increase in temperature was observed as 
material generated heat through the kinetic energy imparted during processing.  Since all 
heat energy generated during processing was produced from friction and shear, no heat 
transfer from external surfaces was necessary which may provide more uniform heating 
characteristics.  Additionally, higher shear rates provided improved mixing 
characteristics of materials within unit offering the potential to improve the 
physicochemical characteristics of the composite produced.  This unique combination of 
increased shear and material heating may allow KSD to provide processing advantages 
over conventional fusion techniques.  Complete cycle time for batch processing was 
rapid, measuring 14.2 s and material was exposed to elevated temperatures above 150oC 
for less than two seconds, suggesting minimal thermal degradation potential due to heat 
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induced decomposition.  TGA profiles of both ITZ and HPMC E5, presented in Figure 
4.2, indicated that both raw materials exhibited minimal decomposition through 
temperatures of approximately 225oC.  This indicated that these components would be 
stable under thermal processing conditions used for KSD and HME processing.  Product 
potency determined by HPLC and designed to facilitate identification of thermal 
degradation products showed excellent potencies, with measured values within 0.5% of 
target for both manufacturing processes.  Additionally no significant degradation 
products were observed in either the KSD or HME processed chromatograms indicating 
minimal drug decomposition during processing under thermal processing conditions.  
Upon reaching the target temperature endpoint material was discharged and cooled.  
Following milling and sieving, powders were also tested for density differences using 
helium pycnometry.  Materials processed by KSD exhibited a similar true density 
compared to material produced by HME, having reported values of 1.331 g/cc and 1.327 
g/cc, respectively.  While densification has been reported with thermal processing it has 
generally been associated with materials directly post processed into dosage forms such 
as tablets and is typically done in comparison to similar products produced by 
conventional methods which exhibit an inherent porosity.  Thermally processed solid 
dispersion material yielded only slightly higher true density values than that anticipated 
for a physical mixture of the individual components (27), suggesting a minimal 
densification of the material due to processing. Furthermore, differences between the two 
manufacturing processes were determined to be insignificant given the magnitude and 
indicated that KSD processing does not significantly densify material compared to HME.  
 
Elevated processing temperatures associated with thermal solid dispersion 
production techniques can negatively impact final product performance as a result of 
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thermal degradation which may occur during processing.  Preliminary screening of raw 
materials based on thermal stability is a necessary step in the development process.  
Although both the active ingredient and the polymeric carrier indicated acceptable 
thermal stability which enabled processing by KSD and HME, KSD presented several 
unique advantages over HME.  A process comparison indicated that KSD provided a 
significant reduction in material exposure to elevated temperatures as a result of the short 
cycle time and dynamic temperature during processing.  While this did not provide a 
significant improvement in material potency or purity for the thermally stable materials 
used in this study, it may have a significant benefit for drugs or excipients which exhibit 
degradation at elevated temperatures.  Furthermore, the short cycle times exhibited 
during processing in the laboratory scale unit are also characteristic of those for larger 
scale production equipment thereby allowing for enhanced material throughput for 
production scale KSD equipment compared to conventional HME equipment.    
 
4.4.2 Solid State Characterization 
 
Solid state properties of dispersions produced by KSD and HME were 
characterized by XRD and mDSC to assess the amorphous nature and homogeneity.  In 
the XRD profiles, presented in Figure 4.3, ITZ exhibited several strong characteristic 
crystalline peaks.  For solid dispersion profiles these peaks were absent indicating 
amorphous material.  Crystalline ITZ also exhibits a well defined melting endotherm in 
the mDSC total heat profile at approximately 170oC, which was clearly missing from the 
profile for amorphous ITZ as well as the two solid dispersion formulations, as presented 
in Figure 4.4.  This indicated that both solid dispersion processes were able to render the 
drug substance amorphous within the process scale.  Another critical solid state attribute 
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of these dispersions is the homogeneity of the system which can be assessed by 
examining the reversing heat flow profile to determine the glass transitions of the 
components.  As shown in the reversing heat flow profile, amorphous ITZ produced as a 
second heating run during mDSC testing exhibited a glass transition temperature at 
approximately 58.58oC which was followed by secondary rearrangements of the liquid 
crystalline structure.  Temperature differences between previously reported transitions 
and those observed in this study were attributed to the heating rate used during mDSC 
testing.  HPMC E5 is an amorphous cellulosic polymer and exhibited a weak, relatively 
broad glass transition event at 146.78oC.  Solid dispersions produced by HME revealed 
two glass transition temperatures.  The first thermal event, which occurred at 68.37oC, 
was attributed to an ITZ rich domain within the dispersion, while the second event, 
measured at 135.10oC, was ascribed to a HPMC rich phase.  The observed temperatures 
for these events were similar in magnitude to those reported in the study of Six et al. (27) 
when tested using a large sample Setaram conventional DSC.   Interestingly, in their 
study mDSC methods could not detect the two phase profile.  While differences in the 
methods, such as larger sample size and increased heating rate may help to elucidate this 
behavior it is also possible that the phase separation was greater for compositions 
produced on the Haake minilab due to the fixed conveying design of the extruder screws 
which provided reduced mixing.  Although the researchers in the Six study were unable 
to develop HME processing conditions capable of producing a single phase composition, 
their inability to detect this behavior may also indicate improved homogeneity compared 
to melt extruded compositions produced in this study, and suggests that shear and mixing 
efficiency are critical in developing a homogeneous solid dispersion.  Thermal 
characterization results for the KSD processed material exhibited a single broad glass 
transition temperature at 86.02oC indicating enhanced homogeneity compared to HME 
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processed material.  It should be noted however that the measured glass transition value 
is approximately 25oC lower than the calculated glass transition temperature using the 
well known Gordon-Taylor equation (33) with the Simha-Boyer rule (34), although in 
this case the breadth of the transition does include the calculated value.  The most likely 
explanation for this depression in measured glass transition temperature is the presence of 
residual water which functions as a plasticizer during the closed pan mDSC testing 
resulting in a reduction observed value.  Although theoretically possible to calculate the 
composition of each phase using the Gordon-Taylor equation, the plasticizing behavior of 
water present in the solid dispersion prevents this due to the reduction in glass transition 
temperature.  Based on a qualitative assessment, it is evident that due to the duality of the 
HME profile, the KSD process provided improved homogeneity due to enhanced mixing. 
 
KSD processing is employed in a variety of manufacturing fields which require 
intense mixing to produce homogeneous composites.  In order to effectively produce 
composite materials for these applications, a significant amount of shear must be 
imparted into the product to ensure adequate dispersion of the materials.  A similar 
behavior when applied to pharmaceutical compositions is also likely to occur, providing 
an increase in micro and nanoscale mixing, helping to produce more homogenous solid 
dispersions.  This allows KSD processing to reduce phase separation of solid dispersions 
and potentially provides the ability to produce solid dispersions of systems which can not 





4.4.3 In Vitro Dissolution 
 
Resulting from the change in free energy of the system, amorphous solid 
dispersions are capable of providing significantly enhanced dissolution rates relative to 
crystalline material.  In vitro dissolution testing of solid dispersions produced by KSD 
and HME processes, as well unprocessed crystalline ITZ, were characterized under ten 
times equilibrium solubility supersaturated dissolution conditions in acidic media as 
shown in Figure 4.5.  Critical dissolution metrics for each formulation were also 
calculated and presented in Table 4.2.  Crystalline ITZ exhibited limited release during 
the two hour testing period, which is characteristic of previous reports for dissolution in 
acidic media.  Both solid dispersion processes produced material providing enhanced 
dissolution rates relative to the crystalline material.  In both cases, near complete 
supersaturation was achieved within the two hour testing period.  Additionally, 
significantly greater AUDC values were observed for the solid dispersion compositions 
in comparison to the unprocessed API.   
 
Interestingly, KSD processed material provided faster in vitro dissolution rates in 
comparison to the HME processed material.  This difference would not be anticipated to 
be physiologically significant since both compositions achieved complete supersaturation 
within the testing period and ITZ is primarily absorbed from the upper small intestine 
(35, 36) however it does support the solid state observations of increased homogeneity of 
the KSD processed material.  Although the mechanism of drug release from solid 
dispersions is still not largely understood, the dissolution process is believed to occur by 
several different mechanisms (37).  One proposed mechanism for release is the carrier 
controlled release.  For these systems, the dissolution rate of the polymeric carrier 
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governs the rate of drug release, limiting the effect of drug properties provided the 
manufacturing process can sufficiently distribute the active within the carrier.  If the 
active ingredient is not homogeneously distributed in the carrier, different mechanisms of 
release may occur which result in a dissolution profile more dependent on the properties 
of the drug substance.  As described previously, the HME processed material exhibited 
two phase behavior, indicating heterogeneity, which may impact the mechanism of 
release such that domains of higher polymer concentration would provide faster release 
while drug rich regions would exhibit decreased dissolution due to increased hydrophobic 
properties of the system.  For such a system where a greater concentration of drug 
negatively impacts wetting and dissolution rate of the high drug concentration phase, a 
decrease in drug release would be anticipated from the system relative to a homogenous 
system.  Similar behavior was observed in a recent study by Matteucci et al., where 
increasing ITZ loadings in amorphous particles were shown to provide reduced 
dissolution rates (38).  In the KSD system ITZ was homogenously distributed in the 
carrier which would minimize the affect of drug properties on dissolution.  The release 
process in this case would have been carrier controlled and therefore increased over the 
HME processed system due to the more hydrophilic nature of the solid dispersion.  It was 
also possible that the difference in release was due to a difference in particle size.  This 
was investigated by classifying KSD processed material into two particle size fractions: 
125 – 250 μm and < 125 μm.  Particles in each class were tested for in vitro dissolution 
performance, as shown in Figure 4.6.  The results indicated that both particle size 
fractions provided similar release characteristics in terms of the overall magnitude of 
supersaturation, with both particle size class providing superior dissolution rates when 
compared to the HME processed material.  Based on these results, the observation of 
increased dissolution rate for the KSD processed material was attributed to the improved 
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homogeneity of the solid dispersion and supported the solid state characterization 
observations.  Furthermore, dissolution rate increases highlighted the advantage of 
enhanced mixing provided by KSD processing which may lead to compositions with 
improved therapeutic performance. 
 
4.4.4 Oral Bioavailability 
 
It has been reported that solid dispersions can provide enhanced oral 
bioavailability of poorly water soluble compounds in human subjects and animal models 
(15, 21, 39).  The ability of solid dispersions produced using KSD and HME to provide 
increased bioavailability was investigated using a Sprague Dawley rat model where 
compositions were dosed as a suspension by oral gavage.  Following dosing, plasma 
samples were taken periodically, as noted previously, and analyzed for the presence of 
ITZ and the primary metabolite, OH-ITZ.  During the study, one animal in the HME 
group suffered a blocked catheter which could not be recovered.  In accordance with the 
study protocol this animal was removed from the cohort and immediately sacrificed.  All 
other animals successfully completed the study and did not exhibit abnormal behavior.   
The resulting pharmacokinetic profiles were plotted as shown in Figure 4.7 and analyzed 
using pharmacokinetic modeling software to calculate critical formulation metrics, as 
presented in Table 4.3. 
 
Examination of the pharmacokinetic profile of ITZ revealed that both 
compositions exhibited similar mean behavior showing an increase in plasma 
concentration over the initial four hours, followed by a brief plateau which has been 
previously attributed to enterohepatic recirculation (35) and then a final elimination 
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phase.  Both pharmacokinetic profiles for OH-ITZ showed a brief initial delay followed 
by increasing plasma levels due to the progression of metabolic activity in the gut wall 
and liver following absorption of ITZ. Similarly, the mean behavior of OH-ITZ was 
comparable between manufacturing processes with a greater AUC observed in both cases 
for OH-ITZ.  This is characteristic during oral dosing of ITZ, with observed ratios of OH-
ITZ:ITZ being as high as 3:1 in certain cases (40, 41). 
 
A comparison of the two manufacturing processes showed that no statistically 
significant difference was observed, although the high variability of the results in this 
study contributed to the outcome.  It is important to note that orally administered solid 
dispersions of ITZ have been characterized by significant variability in both humans (28) 
and animal models (42-44).  Furthermore, the mean behaviors of the two profiles were 
similar in overall magnitude and provided comparable behavior in vivo.  As noted 
previously, the increased dissolution rate observed for the KSD processed material in 
vitro was not anticipated to provide a substantial difference in oral bioavailability due to 
precipitation of ITZ at elevated pH conditions of duodenum (36).  Comparison of the 
mean AUC of ITZ provided by both manufacturing methods to previously reported AUC 
values of Sporanox® pellets in a Sprague Dawley rat model (45), presented in Table 3, 
demonstrated a comparable magnitude for all formulations.  Examination of the 
pharmacokinetic behavior also yielded similarity of the Sporanox® pellets to the 
amorphous solid dispersions produced by HME and KSD.  This indicated that both solid 
dispersion processes produced amorphous compositions that provided similar in vivo 
behavior to the currently marketed product.  This would be anticipated since both the 
marketed product and the experimentally developed formulations used HPMC E5 as the 
primary stabilizing polymer for the solid dispersion.  This correspondence in polymeric 
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carrier led to a similarity in supersaturation and comparable ability to stabilize 
supersaturation under physiological conditions.   Finally, when compared to crystalline 
ITZ dosed at 30 mg/kg reported by Miller et al. (36) there was a statistically significant 
difference in dose normalized AUC which demonstrated the ability of solid dispersions to 
provide enhanced oral bioavailability in a rat model.  The dissolution limited crystalline 
material, in contrast to the amorphous solid dispersions, lacked the ability to achieve 
supersaturation as a result of the highly ordered crystal structure.  This behavior 
contributed to the lower oral bioavailability observed for the material.  Amorphous solid 
dispersions produced by both manufacturing methods, as well as the commercially 
available Sporanox® pellets, all provided statistically significant increases in dose 
normalized oral bioavailability in comparison to crystalline ITZ.  This indicated that both 
KSD and HME were viable methods for producing solid dispersions to provide enhanced 
oral bioavailability in a rat model and suggested that bioavailability enhancement in 




The growing number of poorly water soluble compounds present in corporate 
pipelines necessitates the development of advanced methods for the production of 
amorphous solid dispersions.  While numerous techniques are currently available, all 
methods exhibit significant disadvantages which limit applicability.  In this comparative 
study, solid dispersions were produced using KSD and HME were shown to provide 
supersaturation of ITZ in vitro that could be correlated to an enhancement in oral 
bioavailability over crystalline ITZ.  Results from this study, when evaluated in the 
context of prior art, suggested that optimization of extrusion properties could increase 
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shear and improve solid dispersion homogeneity.  Furthermore, this study demonstrated 
that KSD processing, a novel solid dispersion process, is capable of providing benefits 
over traditional thermal processing methods such as HME, specifically offering enhanced 
mixing and increased production outputs.  These benefits were correlated to improved 
material characteristics of the solid dispersions produced in this study, including superior 
homogeneity and increased dissolution rate, which supported the hypothesis that KSD 
processing could produce solid dispersion with enhanced physicochemical properties 
while generating greater oral bioavailability compared to crystalline drug substance.   
 
Based on these results, KSD processing can be applied to the production of 
traditional hydrophilic compositions as well as to the development of advanced solid 
dispersions which exhibit phase separation when produced by other methods thereby 
allowing additional production versatility over conventional unit operations.  Other 
applications for this technology include: the ability to produce solid dispersions without 
the aid of a plasticizer, the production of solid dispersions containing thermally labile 
active ingredients and the capability of the platform to produce solid dispersions of 
poorly water soluble compounds and concentration enhancing polymers.  Already 
available for commercial applications in other industries, KSD processing would not be 
negatively impacted by scale-up issues such as changes in processing times or 
temperatures that can be associated with many other developmental technologies.  
Continued development of this technology is necessary to firmly establish this technique 
within the pharmaceutical manufacturing portfolio; however this study establishes KSD 
processing as a viable method for the production of solid dispersions of poorly water 
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Figure 4.1 In-process temperature profile of ITZ:HPMC E5 solid dispersion produced by 




Figure 4.2 - TGA profiles for raw materials used in thermal processing of solid 
dispersions measured using a sample size of ~ 10 mg and temperature ramp 
































Figure 4.5 Supersaturated dissolution profile of HME (▲) and KSD (■) processed solid 
dispersions.  Each vessel (n=3) contained 50.0 μg/ml ITZ equivalent 
corresponding to 10 times the equilibrium solubility of ITZ in the acid 




Figure 4.6 Supersaturated dissolution profile of small particle [< 125 μm] (♦) and large 
particle [125 – 250 μm] (■) KSD processed solid dispersions.  Each vessel 
(n=3) contained 50.0 μg/ml ITZ equivalent corresponding to 10 times the 
equilibrium solubility of ITZ in the acid phase. Testing was conducted for 2 




Figure 4.7 In Vivo Plasma Profile. Key: HME, ITZ (♦), KSD, ITZ (■), HME, OH-ITZ 
(◊), KSD, OH-ITZ (□).  Formulations were administered by oral gavage at a 





Processing Parameters HME KSD 
Batch Size (g) 30 55 
Temperature (oC) 180 180.6 
Torque (N·cm) 45 -- 
Screw/Blade Speed (rpm) 120 2,100 
Processing Time (s) > 300 14.2 
   
Metric HME KSD 
Assay (%) 99.7 99.9 
True Density (g/cc) 1.327 1.331 
Table 4.1 Processing Conditions, Assay and True Density of Batches Produced by HME 




Formulation AUDCacid (μg·min/ml) 
Cmax 
(μg/ml) Cmax/So 
Itraconazole 27 ± 5 0.7 ± 0.1 0.14 ± 0.02 
1:2 ITZ:HPMC (HME) 4,772 ± 91 46.6 ± 0.2 9.31 ± 0.04 
1:2 ITZ:HPMC (KSD) 5,469 ± 130 48.9 ± 1.1 9.78 ± 0.23 
250 – 125 μm 1:2 ITZ:HPMC (KSD) 5,625 ± 50 49.4 ± 0.2 9.88 ± 0.05 
< 125 μm 1:2 ITZ:HPMC (KSD) 5,469 ± 50 49.3 ± 0.5 9.87 ± 0.01 
Table 4.2 In vitro dissolution metrics of batches produced by KSD and HME, with 
reported area under the supersaturation dissolution profile (AUCacid), 





Table 4.3 Calculated pharmacokinetic parameters for KSD and HME processed 
materials.  Values for crystalline itraconazole and Sporanox® pellets are 
reported from references (36) and (45) respectively 
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Chapter 5:  Applications of KinetiSol® Dispersing for the Production of 
Plasticizer Free Amorphous Solid Dispersions 
5.1 ABSTRACT 
 
Thermal manufacturing methods for the production of solid dispersions frequently 
require the addition of a plasticizer in order to achieve requisite molten material flow 
properties when processed by unit operations such as hot melt extrusion.  KinetiSol® 
Dispersing, a rapid high energy thermal manufacturing process, was investigated for the 
ability to produce amorphous solid dispersions without the aid of a plasticizer.  For this 
study itraconazole was used as a model active ingredient, while Eudragit® L100-55 and 
Carbomer 974P were used as model solid dispersion carriers.  Triethyl citrate (TEC) was 
used as necessary as a model plasticizer.  Compositions prepared by KinetiSol® 
Dispersing and hot melt extrusion were evaluated for solid state properties, 
supersaturated in vitro dissolution behavior under pH change conditions and accelerated 
stability performance.  Results showed that both manufacturing processes were capable 
of producing amorphous solid dispersions, however compositions produced by hot melt 
extrusion required the presence of TEC and yielded a glass transition temperature (Tg) of 
approximately 54 oC.  Plasticized and unplasticized compositions were successfully 
produced by KinetiSol® Dispersing, with plasticizer free solid dispersions exhibiting a Tg 
of approximately 101 oC.  Supersaturated in vitro dissolution testing revealed a 
significantly higher dissolution rate of plasticized material which was attributed to the 
pore forming behavior of TEC during the acidic phase of testing.  X-ray diffraction 
testing revealed that under accelerated stability conditions, plasticized compositions 
exhibited partial recrystallization, while plasticizer free materials remained amorphous 
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throughout the six month testing period.  These results demonstrated that KinetiSol® 
Dispersing could be used for the production of amorphous solid dispersions without the 
aid of a plasticizer and illustrated the enhanced solid state stability that can be achieved 




Solid dispersions, first described in the early 1970’s, are defined as the dispersion 
of one or more active ingredients within an inert carrier or matrix prepared by either 
fusion mediated methods, solvent mediated methods or some combination thereof  (1).  
In many early systems the drug was present in the original crystal form, providing 
enhanced dissolution through a reduction in particle size and increase in specific particle 
surface area.  Later generation systems exploited the ability of molecular processing 
mechanisms, such as solvent and thermal processes, to alter the crystal structure of the 
drug to provide an amorphous solid solution in which the drug molecules are 
homogeneously dispersed throughout the carrier to further enhance dissolution (2).  
While crystalline drug substances provide a rigid, ordered structure for molecules, 
amorphous systems are devoid of long range order and exhibit minimal short range 
molecular order which eliminates interaction energies associated with the crystal 
structure.  This also drives an increase in free energy for the amorphous system, making 
it thermodynamically unstable. 
 
Polymorphic conversion and recrystallization of metastable forms result from the 
thermodynamic driving force to minimize free energy, however the time scale over which 
these transformations occur and corresponding activation required for such processes 
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vary based on the specific properties of the system (3).  Since the melting point of the 
polymorphic form has been correlated to magnitude of free energy, systems exhibiting 
lower melting points are considered to be less stable (4-7).  Amorphous forms, also 
commonly referred to as supercooled liquids, do not exhibit a melting point because of 
the lack of coherent crystal structure (6, 8).  Instead these systems exhibit a glass 
transition temperature which indicates the transition of molecular material from a rigid 
glass to a rubbery state.  This form of material represents the highest free energy 
conformation and generally the most thermodynamically unstable system for a given 
active component.  In order to develop stable amorphous forms, active ingredients are 
typically formulated as solid dispersions which can frequently provide improved stability 
over lower free energy metastable crystalline forms through different stabilization 
mechanisms (3). 
 
Formulation of solid dispersions to provide enhanced amorphous stability focuses 
on increasing the activation energy for the transformation, which is achieved by reducing 
molecular mobility.  This is commonly formulated in pharmaceutical systems by two 
methods; specific interactions and confinement.  In the case of specific interactions, drug 
and carrier materials can be selected to exploit molecular interactions such as hydrogen 
bonding thereby reducing mobility.  It is also interesting to note that specific 
intermolecular interactions such as hydrogen bonding also manifest themselves as a 
positive deviation in the Gordon-Taylor equation, providing an elevated glass transition 
temperature relative to the theoretical value (9).  Application of this technique for 
pharmaceutical systems may be limited due to the carrier requirements of developing a 
dosage form, which include a need for rapid dissolution and the potential for site specific 
delivery.  In the case of confinement, it has been well established that molecular motion 
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is minimized when a system is maintained 50 oC below the glass transition temperature 
(10-13).  By developing compositions providing glass transition temperature above 90 oC 
it is possible to minimize molecular motion and prevent recrystallization of 
pharmaceutical systems stored at ambient and accelerated temperature conditions.  
Moisture ingress may present additional problems for these products, due to the ability of 
water to function as a plasticizer for many polymeric systems (14).  For many common 
drug and polymer combinations, theoretical glass transition temperatures will exceed 
90oC at lower drug loadings; however requirements for higher drug loadings and the need 
for plasticizers to facilitate thermal processing can compromise the compositional glass 
transition temperature of the system.  Solubility of the active ingredient within the carrier 
will also play a significant role in the rate of crystallization.  The magnitude of 
supersaturation within the matrix provides a driving force for nucleation and growth 
within the bulk phase (15, 16).  Limiting the degree of supersaturation within the matrix 
can reduce the rate of recrystallization, further helping to ensure an appropriate 
amorphous shelf life for the composition.  Furthermore, the incorporation of additives 
capable of solubilizing the active ingredients can also provide additional benefit in 
maintaining the amorphous state.   
 
Amorphous systems have gained increased popularity in the pharmaceutical 
industry over the last decade as new chemical entities have increasingly exhibited lower 
aqueous solubilities limiting oral bioavailability.  In recent years several new amorphous 
products have been approved to provide enhanced oral bioavailability through the 
thermodynamic benefits provided these systems (17-19).  Even with these benefits 
however, amorphous systems represent a thermodynamically unstable form exhibiting the 
potential to recrystallize during storage.  Numerous examples have been presented, 
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demonstrating the ability of metastable pharmaceutical forms to convert during storage 
when molecular mobility is not limited (10).  Zhou and co-workers studied the correlation 
of critical thermodynamic properties and molecular mobility on the recrystallization 
potential of five pharmaceutical compounds.  Their work demonstrated that compounds 
exhibiting the highest entropic barriers and lowest molecular mobilities were the most 
difficult to recrystallize.  This indicated that configurational entropy as well as molecular 
mobility contribute to recrystallization and provides an indication for why interfacial 
recrystallization occurs prior to bulk recrystallization.  In a recent study by Bruce and co-
workers, guaifenesin and Eudragit® L100-55 matrix tablets were produced by hot melt 
extrusion wherein the active ingredient was shown to plasticize the polymer (20).  
Compositions containing a minimum of 25% guaifenesin provided glass transition 
temperatures of less than 50 oC and also exhibited substantial surface recrystallization on 
storage under ambient and accelerated conditions.  Additionally, the use of hydrophilic 
polymer additives limited the onset and reduced the extent of recrystallization in these 
systems.  
 
In order to enhance the long term stability of amorphous systems, advanced 
formulation and processing technologies have been developed focused on providing 
improved compositional glass transition temperatures.  KinetiSol® Dispersing is a novel 
high energy mixing process that has recently been applied to the production of 
amorphous pharmaceutical systems containing hydrophilic polymers (21).  In this 
process, material is processed within a closed fixed volume chamber containing blades 
rotating at high radial velocities.  As a result the unique geometry, significant macroscale 
flow of the material is not required and materials are exposed to elevated temperatures for 
extremely short durations, potentially allowing for the production of plasticizer free 
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compositions and materials having limited thermal stability.  For this study it was 
hypothesized that KinetiSol® Dispersing could be used for the production of amorphous 
solid dispersions without the aid of a plasticizer and provide enhanced stability properties 
due to the increased glass transition temperature.  Compositions of ITZ and L100-55 
were produced with and without plasticizer using KinetiSol® Dispersing and compared to 
equivalent compositions using hot melt extrusion.  Solid dispersions were also prepared 
containing 20% Carbopol 974P by polymer weight which had previously been shown to 
result in a two phase composition when manufactured by hot melt extrusion using a 
Haake minilab (22) in order to assess the magnitude of mixing between the processes.  
Selected compositions were placed on accelerated stability and evaluated for 
recrystallization over a six month period to assess the stability benefit provided by 
plasticizer free compositions. 
 




 Itraconazole, BP micronized was purchased from Hawkins, Inc. (Minneapolis, 
MN). Eudragit® L100-55 was purchased from Evonik Corporation (Linden, NJ).  Triethyl 
citrate, NF grade and Carbopol 974P were generously donated by Vertellus™ 
Performance Materials (Greensboro, NC) and Lubrizol Advanced Materials Inc. 
(Cleveland, OH), respectively.  HPLC grade acetonitrile and isopropanol were purchased 
from EMD chemicals (Darmstadt, Germany). All other chemicals utilized in this study 





5.3.2.1 KinetiSol® Dispersing (KSD) 
 
KinetiSol® Dispersing was performed using a custom built compounder designed 
for pharmaceutical processing applications by DisperSol Technologies, L.L.C. (Austin, 
TX) as described previously.  For compositions requiring plasticization with TEC, 
formulation polymers and plasticizers were accurately dispensed and mixed in a glass 
mortar and pestle.  Prior to processing materials were accurately weighed, manually 
mixed in a polyethylene bag for approximately 1 minute and charged into the 
compounder.  In-process temperatures and rotational speeds were monitored during 
processing, with material discharged upon achieving the target processing temperature.  
Batch formulations and processing conditions used for manufacture are specified in Table 
5.1.  Following discharge the material was quench pressed between two chilled plates and 
ground using an impact mill (Capresso Inc., Closter, NJ).  The powder was further 
comminuted using a glass mortar and pestle before being passed through a 60 mesh (250 
micron) screen.  In-process temperature profiles were smoothed using a five point mean 
value algorithm and plotted using Microsoft Excel 2003 (Microsoft Corporation, 
Redmond, WA). 
 
5.3.2.2 Hot Melt Extrusion (HME) 
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Hot melt extrusion was conducted using a co-rotating conical (5/14 mm diameter) 
twin screw HAAKE Minilab II Microcompounder (Thermo Electron Corporation, 
Newington, NH) without an external die.  For compositions requiring plasticization with 
TEC, formulation polymers and plasticizers were accurately dispensed and mixed in a 
glass mortar and pestle.  Prior to processing materials were accurately weighed, manually 
mixed in a polyethylene bag for approximately 1 minute.  Powder blends, specified in 
Table 5.1, were manually feed into the extruder which was maintained at a temperature of 
130 oC and screw speed of 300 rpm.  Following extrusion, extrudates were milled using 
an impact mill (Capresso Inc., Closter, NJ) and further ground in a glass mortar and 
pestle.  The powder was screened through a 60 mesh (250 micron opening) sieve to yield 
a final powder for analysis. 
 
5.3.2.3 X-Ray Diffraction (XRD) 
 
XRD testing was performed using a Philips Model 1710 X-ray diffractometer 
(Philips Electronic Instruments Inc., Mahwah, NJ) to assess crystallinity in conjunction 
with thermal techniques.  Samples of powder were placed into channeled stages and the 
diffraction profile was measured from 5o to 50o using a 2θ step size of 0.05o and dwell 
time of 3s. 
 
5.3.2.4 Modulated Differential Scanning Calorimetry (mDSC) 
 
Modulated differential scanning calorimetry testing was conducted using a TA 
Instruments Model 2920 DSC (New Castle, DE) and analyzed using TA Universal 
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Analysis 2000 Software. Prior to testing, samples were weighed to 15 ± 2 mg in 
aluminum crimped pans (Kit 0219-0041, Perkin-Elmer Instruments, Norwalk, CT).  
Testing was performed at a ramp rate of 10 °C/min from 5 to 215 °C using a modulation 
temperature amplitude of 0.5 ºC and a modulation period of 40 s under nitrogen purge at 
a flow rate of 40 mL/min.   
 
5.3.2.5 Hot Stage Microscopy 
 
Characterization of ITZ solubility in the molten carrier was assessed using hot 
stage microscopy.  Polymer samples were prepared by dissolving Eudragit® L100-55 
without plasticizer and with TEC at 20% plasticizer on a dry polymer basis in acetone.  
The solutions were pipetted onto a glass slide and allowed to dry at 25 oC for a minimum 
of 24 hours prior to testing.  Prior to testing ITZ was spread onto the polymer coated 
surface of the slides.  As a control, ITZ was also test spread across an uncoated slide and 
tested.  During testing, an Olympus BX60 microscope (Olympus Corp., Center Valley, 
PA) with Insight QE camera (Diagnostic Instruments, Inc., Sterling Heights, MI) was 
used to visually observe samples while a FP82HT hot stage controlled by a FP 90 central 
processor (Mettler Toledo, Columbus, OH) maintained temperatures at 130 oC.  Images 
were captured under visible light using Spot Advance Software (Diagnostic Instruments, 







5.3.2.6 Titration of Eudragit® L100-55 
 
To assess the functionality of side groups on the Eudragit® L100-55 polymer the 
titration method provided by the manufacturer was adapted.  Samples were tested by 
dissolving the equivalent of 500 mg of polymer into 100 ml of a 60:40 isopropanol:water 
mixture containing phenolphthalein maintained at approximately 50oC.  As a neutralizing 
agent, 0.5N NaOH was added dropwise to the test solution while gently agitated using a 
magnetic stir bar until color change was visually identified.  Methacrylic acid units 
content was calculated using the equation below, VNaOH represents the volume of titrant 
in ml, wsample is the total sample weight and fL100-55 indicates the fraction of Eudragit® 
L100-55 in the sample tested.  Physical mixtures of ITZ and L100-55 were used to verify 






  (%)  UnitsAcid cMethacryli
f⋅
⋅
=     Equation 5.1 
 
5.3.2.7 Scanning Electron Microscopy (SEM) 
 
Particle morphology and pore formation of solid dispersion formulation was 
investigated by SEM.  Samples of selected solid dispersion formulations were placed in 
750 ml of 0.1N HCl media and mixed at 50 rpm as described in the In Vitro Dissolution 
section.  Dissolution media was then filtered using a 0.45 micron nylon filter paper 
(Whatman Corp, Piscataway, NJ).  Material collected on the filter paper was collect and 
dried under vacuum for 24 hours.  Prior to imaging, samples were mounted onto 
aluminum stages using double sided carbon tape and sputter coated using a Pelco® Model 
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3 sputter coated equipped with an Au source for 20s.  Particle morphologies were 
evaluated by SEM using a Hitachi S-4500 scanning electron microscope (Hitachi, Ltd., 
Tokyo, Japan) operated at an accelerating voltage of 10kV.  Samples equilibrated in the 
0.1N HCl media were compared to untreated samples. 
 
5.3.2.8 In Vitro Dissolution 
 
Supersaturated dissolution testing was performed based on the USP XXIX 
method A enteric dissolution test using a VK 7010 dissolution apparatus (Varian, Inc., 
Palo Alto, CA) operated at 50 rpm paddle speed and VK 8000 autosampler (Varian, Inc., 
Palo Alto, CA).  An equivalent amount of 37.5 mg ± 0.4 mg of ITZ (~10x 0.1N HCl 
media equilibrium solubility) was accurately weighed and added to the dissolution vessel 
containing 750 mL of 0.1N HCl media.  After two hours, 250 mL of 0.2M Na3PO4 
solution was added to the dissolution vessel to achieve a pH of approximately 6.8.  
During testing 5 mL samples were removed from the dissolution vessels without 
replacement after 60, 120, 125, 130, 135, 150, 180, 240, 300 and 360 min.  Samples were 
immediately filtered using 0.2 μm PVDF membrane, 13mm filters (Whatman, 
Piscataway, NJ) to minimize drug adsorption and precipitation, immediately diluted in a 
1:1 ratio with mobile phase, vortex mixed and transferred into 1 mL vials (VWR 
International, West Chester, PA) for analysis. 
 
Dissolution samples were analyzed using a Waters (Waters Corporation, Milford, 
MA) high performance liquid chromatography (HPLC) system consisting of dual Waters 
515 Syringe Pumps, a Waters 717 Autosampler and a Waters 996 Photo Diode Array 
extracting at a wavelength of 263 nm.  The system was operated under isocratic flow at 1 
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mL/min using a mobile phase consisting of 70:30:0.05 acetonitrile:water:diethanolamine 
equipped with a Phenomenex Luna 5 μm C18(2) 100 Å, 150 mm x 4.6 mm 
(Phenomenex®, Torrance, CA) HPLC column.  Samples collected in the 0.1N HCl media 
and neutralized media were injected in volumes of 50 μL and 200μL respectively during 
testing.  Data were collected and analyzed using Empower® Version 5.0 software.  The 
retention time of ITZ was approximately 6 min.  All analytical tests maintained system 
suitability limits for linearity from 0.024 to 100 μg/mL (r2 ≥ 0.999) and reproducibility of 
replicate injections (% RSD ≤ 2.0%). 
 
5.3.2.9 Accelerated Stability Studies 
 
Accelerated stability studies were conducted to monitor the solid state stability of 
compositions produced with and without plasticizer.  Approximately 2 g of solid 
dispersion powder was dispensed into a round 30 cc HDPE bottle and induction sealed.  
Proper closure of the induction sealed was verified to prior to placing samples on 
stability.  Sealed HDPE bottles were placed into a closed chamber within a heated oven 
maintained at approximately 40oC.  Within the chamber, a saturated salt solution 
maintained the relative humidity at approximately 75%.  Samples were removed from the 
chamber at predetermined intervals of 1 month, 3 months and 6 months.  Prior to testing, 
samples were allowed to equilibrate to room temperature for a minimum of 24 hours.  





5.4 RESULTS AND DISCUSSION 
 
5.4.1 Manufacturing Process Comparison 
 
The production of solid dispersions containing ITZ, Eudragit® L100-55 and 
Carbopol 974P were successfully prepared by hot melt extrusion (HME) and KinetiSol® 
Dispersing (KSD).  Compositions prepared by HME required the addition of 20% TEC to 
achieve necessary viscoelastic flow characteristics.  Additionally, relatively high motor 
torque loads were observed during extrusion and required production without the use of 
an external die to achieve flow.  This indicated that even at pre-plasticized levels of 20% 
substantial flow resistance was still provided by the formulations.  For KSD processing, 
solid dispersions were able to be produced with or without plasticizer as a result of the 
limited material flow characteristics associated with the process.  For all compositions 
produced manufacturing cycles were extremely short, lasting under 15 s. Another critical 
aspect of the process was the reduced residence time at elevated temperatures, with 
temperatures above 130oC observed for extremely short durations of approximately 1 s, 
as shown in Figure 5.1.  This rapid processing throughput and limited thermal exposure 
can potentially allow for solid dispersion production of thermally labile materials.  As 
shown in Figure 5.2, all materials used in this study exhibited acceptable thermal stability 
by TGA through approximately 150 oC, however significant decomposition of Eudragit® 
L100-55 and Carbopol 974P was observed at higher temperatures.  Eudragit® L100-55 
was used in the study as a model thermally labile material which has been reported to 
degrade at temperatures of approximately 155 oC by decomposition of carboxylic acid 
side chains followed by chain decomposition at temperatures in excess of 180 oC (23). 
Examination of side group functionality for processed compositions was compared to 
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unprocessed polymer samples by a titration method (24).  Titration results, presented in 
Table 5.2, showed that KSD provided similar functional levels to unprocessed polymer 
and material prepared by hot melt extrusion at 130 oC.  This indicated that the rapid 
processing and brief deviations above the degradation onset temperature did not 
significantly affect the physicochemical properties of the polymeric carrier.   
 
Conventional methods for the production of solid dispersions, such as spray 
drying and hot melt extrusion require significant manufacturing trains to provide an 
amorphous intermediate product.  These manufacturing processes also require the use of 
processing aids and additional analytical testing to verify material properties.  KSD has 
been shown to allow for the rapid production of amorphous solid dispersions which can 
potentially reduce manufacturing times.  During manufacturing, 60 g batches were 
produced in less than 15 seconds, representing a significant improvement over 
conventional manufacturing technologies.  As a result of the extended residence times 
and elevated temperatures encountered within hot melt extruders during processing, only 
a limited number of manufacturing conditions can be applied to a specific list of 
thermally stable materials.  During processing temperature deviations above the 
degradation temperature may result in decomposition and potentially unwanted changes 
in material characteristics which can occur over manufacturing time scales.  Although 
many designs for extruders, specifically co-rotating twin screw extruders which have 
been reported to provide residence times of up to 2 minutes (25), attempt minimize 
thermal exposure no current manufacturing technology can provide residence times 
comparable to KSD.  Additionally, scaled-up KSD manufacturing equipment will exhibit 
similar residence times to those observed on the lab scale thereby helping to reduce 
material decomposition and maximize production output.    Furthermore, when compared 
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to spray drying no solvent was required and no additional residual solvent testing is 
required.  During melt extrusion plasticizer was required to lower the Tg and improve 
flow characteristics, however this also results in a reduction in glass transition 
temperature which can potentially compromise the compositional stability.  The 
capability of KSD to provide an effective platform for the production of amorphous solid 
dispersions without the aid of a plasticizer presents unique advantages over current 
techniques.  The ability to produce solid dispersions without the requirement for organic 
solvent or plasticizer represents a substantial improvement over conventional 
technologies and may open up new avenues of formulation by expanding the portfolio of 
processable materials.   
 
5.4.2 Solid State Characterization 
 
The physicochemical properties of a composition will significantly govern the 
pharmacological effect of the product.  For poorly water soluble compounds exhibiting 
dissolution limited oral bioavailability, the production of an amorphous solid dispersion 
has been shown to be a viable manufacturing technique to improve absorption.  
Analytical testing was utilized to identify glass transition events associated with 
amorphous ITZ and polymer to assess the solid state nature of the compositions 
produced.  As shown in Figure 5.3, total heat flow profiles for all compositions revealed 
the absence of an ITZ melting endotherm which suggested that all processed formulations 
were amorphous.  The amorphous nature of these compositions were also confirmed 
using XRD, as shown in Figure 5.4, where the diffraction pattern for crystalline ITZ 
exhibits several strong characteristic peaks while all processed compositions provided 
amorphous halos.  Examination of the glass transition behavior for the compositions 
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produced also provided significant information regarding the performance of the 
manufacturing process.   Pure Eudragit® L100-55 exhibited a Tg at approximately 128 oC  
while amorphous ITZ has a Tg at approximately 62 oC (26).  Using the Gordon-Taylor 
equation the resulting glass transition temperature for an amorphous solid solution of 1:2 
ITZ:L100-55 was calculated to be 103 oC.  Additionally, similar values would be arrived 
for compositions containing the C974 additive since this material exhibits similar 
properties to Eudragit® L100-55.  The addition of plasticizers as a thermal processing aid 
has been extensively reported and the incorporation of these materials into 
pharmaceutical systems results in a reduction in Tg that can facilitate production by 
increasing the free volume of the polymer.  Compositions prepared by HME required the 
aid of a plasticizer to achieve the necessary viscoelastic characteristics for processing; 
however also exhibited a reduced compositional Tg measured at 54 oC.  KSD processing 
allowed for the production of amorphous solid dispersions without the aid of a plasticizer 
and resulted in an amorphous 1:2 ITZ composition having a measured Tg of 101 oC.  This 
value was similar to the calculated glass transition temperature and represented a 
significant increase over the plasticized formulation.  It was further hypothesized that this 
composition would provide a significant stability benefit in comparison to plasticized 
formulations produced by HME.  Formulations were also produced by KSD and HME 
containing the C974 additive.  Similar to the previously reported work of Miller et al., the 
composition produced by HME exhibited a two phase profile which was attributed 
polymer phase separation.  The first transition event, observed at 56 oC results from an 
L100-55 prominent region, while the second event at approximately 137 oC was 
attributed to a C974 rich domain.  Although slightly higher than the measured Tg for 
C974, the similarity in Tg onset on the broad nature of the transition suggest that it is 
associated with the C974 component of the dispersion.  Interestingly, composition 
 172
produced by KSD processing exhibited only a single Tg indicating increased polymer 
inter-mixing of the composition.  Previous reports have demonstrated the ability of KSD 
processing to improve the homogeneity of solid dispersions due to the enhanced mixing 
of the process (21) and it is believed that the single phase material produced here is also 
attributed to this behavior. 
 
During the production of amorphous solid dispersions, all batches produced by 
HME were processed below the melting point of ITZ and compositions prepared by KSD 
only briefly exceeded, if at all, the melting of ITZ before being quench pressed between 
chilled metal plates.  This indicated that the drug may have significant solubility in the 
carrier at temperatures at or above 130 oC.  To test this hypothesis, samples of ITZ were 
layered onto slides pre-coated with L100-55 and visually examined for drug dissolution.  
Images, presented in Figure 5.5, were taken following heating to the target temperature of 
130 oC and following a 15 minute incubation period.  In all cases, no significant 
dissolution of the drug in the molten carrier was observed.  This indicated that at this 
temperature the drug dissolution process in the carrier was limited and may result from 
the high molecular weight of Eudragit® L100-55, which has been reported to be 
approximately 250,000 (27).  Similar studies have also shown that preformulation studies 
such as hot stage microscopy may not accurately capture behavior of systems produced 
by thermal techniques dependent on a mixing component (28).  This behavior also 
suggested that the shear generated during processing may help to dissolve the drug within 
the carrier due to an increase in convective mixing.  Greater mechanical energy present 
during both HME and KSD processing may also further reduce the particle size of the 
micronized drug resulting in an increase in surface area for dissolution.  Since processing 
of the solid dispersion was dependent on the shear generated during processing it also 
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stands to reason that KSD processing may provide benefits over HME for solubilizing 
active ingredients within molten carriers below the melting point due to a combination of 
particle size reduction and increased convective mixing.   
 
5.4.3 In Vitro Dissolution Behavior 
 
Amorphous solid dispersions provide significant improvements in dissolution 
rates over crystalline materials due to the reduced enthalpy of the system.  In vitro 
dissolution testing under pH change conditions was conducted to assess the performance 
of systems prepared by HME and KSD, with resulting profiles presented in Figure 5.6.  
For solid dispersions of ITZ:L100-55 produced without plasticizer minimal release in the 
acidic phase was observed, however only minor increases in supersaturation were 
observed following pH change.  Compositions prepared by HME required the use of 
TEC, a water soluble plasticizer, and provided significantly greater neutral media 
dissolution rates.  In order to further investigate the cause of the reduced dissolution rates, 
an additional batch was produced using KSD processing containing TEC (20% dry 
polymer weight).  In vitro dissolution testing was performed on this batch and exhibited 
similar behavior to that produced by HME, indicating that the presence of plasticizer 
facilitated dissolution following pH change.  Previous studies of melt extruded solid 
dispersions have demonstrated that the presence of water soluble plasticizers such as TEC 
can favorably impact drug release rates due to the pore formation caused by dissolution 
and pore formation (29, 30).  As shown in Figure 5.7, pore formation within the solid 
dispersion was assessed by scanning electron microscopy prior to and immediately 
following immersion in acidic buffer.  Prior to immersion, all samples exhibited similar 
continuous surfaces, free of recrystallized ITZ and showing no pores throughout.  
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Following two hour incubations in acidic media, plasticizer free compositions still 
exhibited a smooth, continuous surface however; solid dispersions containing TEC 
showed the formation of small micron to submicron pores along the exterior of the 
particles.  As a result of the pore formation within the particles a larger surface area is 
present at the time of pH change thereby increasing the dissolution rate.  Additionally, 
previous studies have suggested that the enthalpy of solvation for ITZ is more favorable 
in acidic media than in neutral media (26).  Pore formation which occurs while particles 
are exposed to the acidic environment may also facilitate solvation of inaccessible ITZ, 
further improving dissolution rates. 
 
The effect of C974P, a high viscosity mucoadhesive polymer, on the dissolution 
rate was also examined for compositions produced by HME and KSD.  As shown in 
Figure 5.6 and Table 5.3, limited ITZ dissolution was observed in the acidic environment 
for the HME processed compositions however solid dispersions prepared by KSD 
exhibited an increased dissolution rate.  As discussed previously, solid state 
characterization of the two compositions revealed that the HME processed material 
exhibited a dual phase nature, while the solid dispersion prepared by KSD exhibited a 
single and more homogenous phase.  In HME processed material, it was further 
suggested that the two domains were indicative of an ITZ:L100-55 phase and a second 
C974P phase.  Since C974P does not provide enteric protection, formulations prepared by 
KSD which were more homogenous, also would provide reduced enteric protection.  
Following neutralization, both compositions showed muted neutral media dissolution 
behavior compared to the plasticized compositions produced without C974P.  This 
reduced dissolution behavior was attributed to the presence of C974P in the formulation 
which reduced diffusion rates to the bulk media due to the high viscosity of the material.  
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Additionally, reduced dissolution rates for the C974P composition prepared by KSD can 
be attributed to the absence of TEC, which was previously shown to function as a pore 
forming agent in the solid dispersion.  
 
During the production of amorphous solid dispersions, processing aids may be 
required depending on the manufacturing technique employed, leading to changes in 
material properties.  These additives may also impact in vitro and potentially in vivo 
performance, as was indicated by the presence of TEC which functioned as a pore 
forming agent in the acidic environment.  Since KSD does not require the addition of 
processing aids such as TEC, it would be possible to select similar agents which provide 
pore forming functionality without having to reduce the Tg of the solid dispersion.  
Performance variations between the processes also led to differences in physical 
properties of solid dispersions which impacted the drug release characteristics of the 
materials.  The development of more homogeneous compositions appeared to reduce the 
enteric protection provided by the formulation, thereby increasing acidic release of ITZ.  
It is possible that the observed differences in drug release would result in changes to oral 
bioavailability, however this was not assessed as part of this study.  Ultimately, when 
developing solid dispersions of poorly water soluble drugs which exhibit dissolution 
limited oral bioavailability formulation scientists will be required to balance dissolution 
requirements with physicochemical requirements to ensure appropriate potency and 
stability.  Using the KSD platform, it is possible to provide more flexibility and 
versatility in formulation and process development to the pharmaceutical scientist which 
is not available using current thermal processing techniques. 
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5.4.4 Amorphous Stability 
 
One of the most challenging aspects for the development of amorphous 
pharmaceutical systems is the ability to provide for pharmaceutically relevant stability.  
The stabilization of amorphous systems is provided by two basic mechanisms: limitation 
of molecular mobility within the system and the establishment of favorable drug-carrier 
interactions.  Since KSD processing did not require the addition of plasticizer it was 
possible to produce solid dispersions providing significantly higher Tg values compared 
to those prepared by HME.  In order to investigate the hypothesis that plasticizer free 
compositions could provide greater amorphous stability compared to plasticized material 
prepared by HME samples were packaged, stored under accelerated and periodically 
monitored by XRD, as shown in Figure 5.8.  Crystalline ITZ exhibits several strong 
characteristic peaks, shown as dashed line within the figure.  After production, both KSD 
and HME processed materials were shown to be amorphous.  During stability testing, 
HME processed material which exhibited a Tg of approximately 54 oC showed a gradual 
growth of ITZ characteristic peaks over time which indicated recrystallization during 
storage.  KSD processed material, having a Tg of 101 oC, did not exhibit peak growth 
over time and suggested a more stable formulation.  Since Tg is directly related to 
molecular mobility, reduced molecular motion within the plasticizer free KSD processed 
composition was responsible for the improvement in amorphous stability.   
 
The ability of KSD to produce solid dispersions without the aid of a plasticizer 
presents significant benefits for improving the stability of pharmaceutical compositions 
through reduced molecular motion.  While it was demonstrated that plasticizers can 
provide secondary functions to improve dissolution, alternative materials can also be 
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added to formulations providing similar dissolution functionality without reducing the Tg 
of the composition.  Similarly, alternative methods such as spray drying could be used to 
produce solid dispersions however these would be subjected to secondary issues such as 
residual solvent testing and low material density.  Since KSD processing provides the 
ability to process without the aid of a plasticizer or solvent, which results in a significant 
improvement in compositional stability, this manufacturing technology represents a 




During formulation development specific critical product attributes, such as solid state 
properties, dissolution and stability must be balanced in order to develop a successful 
product.  Current technologies for production are limited due to the requirements for 
solvents and processing aids which can negatively impact product quality.  KSD 
processing was shown to be a viable platform for the production of advanced 
multicomponent solid dispersions without the aid of plasticizers and provided several 
critical advantages over HME, including the ability to manufacture without a plasticizer 
and enhanced mixing during processing.  These advantages translated into improved 
physicochemical properties of the solid dispersion, specifically resulting in improved 
homogeneity of the solid dispersion and elevated compositional Tgs which provided 
enhanced accelerated stability.  While it is possible that modification of extruder 
processing conditions could improve homogeneity, no alteration of the extrusion process 
would allow for production with unplasticized Eudragit® L100-55.  Therefore, by 
applying KSD processing to the manufacture of solid dispersion formulations which 
require Tg lowering processing aids to facilitate production by other techniques, it is 
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possible to achieve greater developmental flexibility leading to formulations with 
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Figure 5.5 Hot stage microscopy images of ITZ on various film samples taken 




Figure 5.6 Supersaturated dissolution profile of KSD and HME processed compositions.  
Key: ITZ:L100-55, KSD (♦),ITZ:L100-55, 20% TEC, KSD (■),ITZ:L100-
55, 20% TEC, HME (□), ITZ:L100-55:C974P, KSD (▲),ITZ:L100-
55:C974P, HME (Δ).  Each vessel (n=3) contained 37.5 mg of ITZ 
equivalent corresponding to 10x acid phase equilibrium solubility.  Testing 
was conducted for 2 hr in 750 ml of 0.1 N HCl media followed by pH 
adjustment to approximately 6.8 by addition of 0.2M tribasic sodium 
phosphate solution.  Dashed vertical line indicates pH change.  Dashed 




Figure 5.7 SEM images of ITZ:L100-55 solid dispersions prior to and following 2 hr 





Figure 5.8 XRD patterns of HME and KSD process ITZ:L100 solid dispersions measured 
over six months accelerated stability at 40oC/75%RH.  Samples were stored 







Formulation ITZ L100-55 Carbomer 974P TEC 
ITZ:L100-55 (KSD) 3 6 -- -- 
ITZ:L100-55, 20% TEC 
(KSD) 3 5 -- 1 
ITZ:L100-55, 20% TEC 
(HME) 3 5 -- 1 
ITZ:L100-55:C974 (KSD) 3 4 1 1 
ITZ:L100-55:C974, 20% 












ITZ:L100-55 (KSD) 3,000 158.1 14.1 
ITZ:L100-55, 20% TEC (KSD) 3,000 162.2 9.3 
ITZ:L100-55:C974P (KSD) 3,000 176.9 8.4 





Description Methacrylic Acid Units (%) 
L100-55 (unprocessed) 48.6 
ITZ:L100-55 (physical mixture) 48.2 
ITZ:L100-55 (KSD) 47.4 
ITZ:L100-55:TEC (HME) 47.3 




Table 5.3 In vitro dissolution metrics for KSD and HME processed compositions 
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Chapter 6:  Fusion Production of Solid Dispersions Containing a Heat 




Many techniques for the production of solid dispersions rely on elevated 
temperatures and prolonged material residence times which can result in decomposition 
of temperature sensitive components.  In this study hydrocortisone was used as a model 
temperature sensitive active ingredient to study the effect of formulation and processing 
techniques as well as characterize the benefits of KinetiSol® Dispersing for the 
production of solid dispersions.  Preformulation studies were conducted using differential 
scanning calorimetry and hot stage microscopy to identify optimum carriers for the 
production of amorphous solid dispersions.  After identification, solid dispersions were 
prepared by hot melt extrusion and KinetiSol® Dispersing, with material characterized by 
x-ray diffraction, dissolution and potency testing to evaluate physicochemical properties.  
Results from the preformulation studies showed that vinylacetate: vinylpyrrolidone 
(PVPVA) copolymer allowed for hydrocortisone dissolution within the carrier at 
temperatures as low as 160oC, while hydroxypropyl methylcellulose required 
temperatures upward of 180oC to facilitate solubilization.  Low substituted 
hydroxypropyl cellulose, a high glass transition temperature control showed that the 
material was unable to solubilize hydrocortisone.  Manufacturing process control studies 
using hot melt extruded compositions of hydrocortisone and PVPVA showed that 
increased temperatures and residence times negatively impacted product potency due to 
decomposition.  Using KinetiSol® Dispersing to reduce residence time and facilitate 
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lower temperature processing, it was possible to produce solid dispersions with improved 
product potency.  This study clearly demonstrated the importance of carrier selection to 
facilitate lower temperature processing, as well as the effect of residence time on product 
potency.  Furthermore, KinetiSol® Dispersing provided significant advantages over hot 
melt extrusion due to the reduced residence times and lower required processing 





Manufacturing techniques for the production of solid dispersions have gained 
increasing popularity as the number of poorly water soluble compounds has increased.  
Two unit operations which have gained significant popularity for this application are 
spray drying (1-3) and hot melt extrusion (4-6).  During spray drying, the drug and carrier 
are dissolved in a common miscible solvent, sprayed into a drying chamber and the 
solvent evaporated from the system to produce solid dispersion.  In hot melt extrusion the 
drug and carrier are processed under significant agitation at elevated temperatures, 
yielding solid dispersions upon cooling.  While solvent based systems such as spray 
drying have been employed successfully in the production of amorphous solid 
dispersions, this technique involves the use of potentially toxic solvents, presenting 
substantial issues in terms of residual solvents.  In some cases it may be necessary to 
process at elevated temperatures and provide continued drying.  Similarly, hot melt 
extrusion requires the use of substantially elevated temperatures which pose limitations 
for thermally sensitive active ingredients and carriers alike.  While elevated processing 
temperatures are widely acknowledged as a significant limitation to current production 
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technologies (7), only limited studies have been undertaken to characterize the 
decomposition of thermally sensitive materials in pharmaceutical systems. 
 
During the extrusion process, degradation of materials results from thermal and 
mechanical factors which occur during processing.  In many polymer processing studies, 
degradation has been reported to occur via thermal mechanisms (8, 9) and it is well 
known that degradation rates of many pharmaceutical active ingredients increase at 
elevated temperatures (10).  In a recent study by Repka and co-workers, hot melt 
extrusion was investigated as a method of producing clotrimazole films for the treatment 
of oral candidiasis (11).  Although the authors concluded that the manufacturing process 
was a viable method for the production of such films, degradation of clotrimazole to (o-
chlorophenyl) diphenyl methanol resulted in product potencies of approximately 93%.  In 
another study by Repka and co-workers, films of hydrocortisone and chlorpheniramine 
maleate were prepared in hydroxypropyl cellulose to assess the effect of the active 
ingredient on the physico-mechanical properties of the films (12).  Results showed that 
films prepared containing chlorpheniramine maleate provided acceptable product 
potencies, while formulations containing hydrocortisone exhibited increased 
decomposition at elevated temperatures.  During processing, the researchers concluded 
that hydrocortisone degraded at elevated temperatures due to oxidation to a D-
homosteroid.  This behavior indicated that increases in thermal exposure due to increased 
temperatures accelerated decomposition.  One strategy to reduce processing temperatures 
is through the incorporation of a plasticizer, which is frequently employed to facilitate 
manufacturing of thermally sensitive actives and carriers (13-15). In a recent study by 
Verreck et al., supercritical carbon dioxide was used as a temporary plasticizer to 
facilitate production of p-amino salicylic acid at lower temperatures (16).  Compositions 
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produced without the supercritical fluid required the use of elevated temperatures which 
resulted in greater decomposition compared to plasticized formulations which provided 
up to 95% product potencies. 
 
For many cases, thermal degradation of a material is primarily related to 
cumulative exposure which is a function of temperature and duration.  In order to 
minimize thermal degradation of pharmaceutical components under elevated 
temperatures, techniques incorporating suitable formulation design to limit degradation 
and appropriate process optimization to reduce thermal exposure may be utilized.  Many 
systems manufactured by hot melt extrusion require temperatures above the glass 
transition temperature of the carrier and melting point of the active ingredient to facilitate 
processing.  It is also possible to render an amorphous solid dispersion by processing 
below the melting point of the active ingredient by selecting carriers capable of 
solubilizing the drug substance within the molten carrier.  This behavior, however, is not 
universal to all drug:carrier combinations, but rather depends on the interplay of the 
pair’s physicochemical properties.  Solubility parameters have been extensively used to 
predict the miscibility of such compositions (17) and in many cases miscibility can also 
imply solubility of the drug within the polymeric matrix.  In order to exploit this 
synergistic behavior it is critical to identify appropriate combinations at an early stage 
using preclinical characterization techniques.  In several studies reported by Forster and 
co-workers, a variety of preclinical characterization techniques were utilized to assess 
drug:carrier compatibility (18, 19).  Solubility parameters provide a preliminary 
indication of the interaction between the drug and carrier based on the chemical 
composition of the materials.  It is generally accepted that interaction parameter 
differences of less than 7 MPa1/2 will lead to favorable interactions between the 
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components, while differences greater than 10 MPa1/2 will lead to unfavorable behavior 
and phase separation.  Although this provides an indication of the behavior of the system 
and can be used to identify potential combinations which may process favorable 
interactions, it does not directly quantify the behavior of such systems under conditions 
analogous to production.  In order to assess the behavior under thermal processing 
conditions, hot stage microscopy and differential scanning calorimetry have been applied 
to assess processability of drug:carrier physical mixtures (18).  Mixtures of the drug and 
carrier can be visually assessed using hot stage microscopy to image drug dissolution 
within the carrier, as well as recrystallization of the drug from the polymer upon cooling.  
Similarly, differential scanning calorimetry can be used to assess drug:carrier 
compatibility.  The heating process applied during DSC testing is analogous to the 
thermal exposure the materials experiences during processes such as hot melt extrusion.  
Regulation of the heating rate can control the recovery of materials during testing, such 
that slower heating rates allow for greater duration of drug dissolution in the carrier.  This 
behavior has been shown to limit the ability to detect crystalline material in a solid 
dispersion and is a major reason for using a secondary “cold” method such as x-ray 
diffraction in the assessment of crystal content.  However, application of DSC to physical 
mixtures can provide an indication of drug dissolution rate within the carrier and can be 
used to identify optimum compositions. 
 
Processing of solid dispersions below the active ingredient melting point has also 
been well established as a method to produce amorphous compositions.  Trey et al. (20), 
successfully prepared hot melt extruded films of itraconazole and hydroxypropyl 
cellulose at 155oC, below the melting point of itraconazole.  Similar behavior has also 
been reported by Miller et al. for systems of itraconazole and Eudragit® L100-55 (21) as 
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well as Chokshi et al. for combinations of indomethacin and PVPVA (22).  Utilizing a 
similar approach, Lakshman et al. (23) pre-processed high melting point temperature 
sensitive active ingredients by spray drying to render the material amorphous prior to 
processing at significantly reduced temperatures to minimize degradation in order to 
render an amorphous solid solution by melt extrusion.  While these low temperature 
processing approaches have been utilized to facilitate production of various 
compositions, few publications report the direct use of carrier selection to complement 
the manufacture of heat sensitive ingredients using fusion methods. 
 
Fusion manufacturing methods have been well established in academic research 
for the production of solid dispersions, however the primary manufacturing method for 
this class of techniques is hot melt extrusion (13-15).  Having been extensively utilized 
for the production of solid dispersions for bioavailability enhancement, controlled release 
and dosage form design such as films and shaped tablets, hot melt extrusion has emerged 
as one of the premier production methods.  While numerous advantages of this process 
have been cited, the high temperatures required and possibility for extended residence 
times of up to ten minutes (16) can limit the applicability for production with temperature 
sensitive materials.   
 
KinetiSol® Dispersing is a new fusion based manufacturing that utilizes a 
combination of frictional and shear energies to rapidly produce solid dispersions (24, 25).  
This technique has been successfully employed for the production of hydrophilic solid 
dispersions and plasticizer free solid dispersions containing temperature sensitive 
polymers such as Eudragit® L100-55 (24, 25).  In this study it was hypothesized that 
potency of hydrocortisone solid dispersions produced by thermal manufacturing 
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techniques could be improved through the correct identification of carrier materials and 
the application of novel manufacturing technologies such as KinetiSol® Dispersing.  
Under the study design, preclinical characterization of drug and polymeric carriers were 
conducted using differential scanning calorimetry, hot stage microscopy and thermal 
gravimetric analysis.  Following identification of appropriate polymeric carrier materials, 
a design of experiments was conducted to study the effect of hot melt extrusion 
processing variables such as screw speed, residence time and temperature on the finished 
product attributes.  Finally, compositions were also prepared using KinetiSol® Dispersing 
and evaluated for potency, dissolution and crystal character in comparison to hot melt 
extruded material. 
 




Micronized hydrocortisone, USP (HCT) was purchased from Spectrum Chemical 
Co. (Gardena, CA).  Kollidon® VA64, a vinylpyrrolidone-vinylacetate copolymer (6:4) 
(PVPVA 64) and hydroxypropyl methylcellulose (2910 grade) (HPMC E3) were donated 
by BASF Corporation (Florham Park, NJ) and Dow Chemical Corporation (Midland, 
MI), respectively.  HPLC grade acetonitrile and methanol were purchased from EMD 






6.3.2.1 KinetiSol® Dispersing (KSD) 
 
KinetiSol® Dispersing was performed using a custom built compounder designed 
for pharmaceutical processing applications by DisperSol Technologies, L.L.C. (Austin, 
TX) as described previously (24, 25).  Prior to processing, drug and polymer 
compositions were accurately dispensed into an impact mill and premixed for 1 minute 
prior to being charged into the compounder.  During processing, temperature and 
rotational speeds were monitored with material discharged immediately upon achieving 
the target processing temperature.  During production, PVPVA 64 and HPMC E3 
compositions were prepared using maximum rotational speeds of 3,200 rpm and 2,200 
rpm, respectively. Following discharge the material was quench pressed, as necessary, 
between two chilled plates, ground using an impact mill (Capresso Inc., Closter, NJ) and 
passed through a 60 mesh (250 micron) screen prior to further testing.  In-process 
temperature profiles were smoothed using a five point mean value algorithm and plotted 
using Microsoft Excel 2003 (Microsoft Corporation, Redmond, WA). 
 
6.3.2.2 Hot Melt Extrusion (HME) 
 
Hot melt extrusion was conducted using a co-rotating conical (5/14 mm diameter) 
twin screw HAAKE Minilab II Microcompounder (Thermo Electron Corporation, 
Newington, NH).  Compositions using PVPVA as a carrier were prepared using the 2 mm 
round opening die, while no die was used for compositions produced with HPMC E3.  
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Prior to processing, materials were accurately weighed, premixed in an impact mill for 1 
minute (Capresso Inc., Closter, NJ) and manually charged into the extruder during 
processing to provide a continuous feed.  As necessary, recirculation was used to achieve 
required residence time.  Powder blends and appropriate manufacturing conditions for 
each batch are detailed in Table 6.1.  Following extrusion, extrudates were milled using 
an impact mill (Capresso Inc., Closter, NJ) and screened using a 60 mesh sieve to yield a 
final powder for analysis. 
 
6.3.2.3 Residence Time Studies 
 
To assess the residence time of hydrocortisone and PVPVA formulations, a dye 
tracer was utilized to visually identify the residence time of material in the barrel.  For 
these studies, a spike blend containing 10% hydrocortisone, PVPVA 64 and yellow tracer 
dye (Sensient, Milwaukee, WI) having a bright orange color was prepared by replacing 
approximately 2% of PVPVA 64 with dye and thoroughly mixing in a glass mortar and 
pestle.  During testing the extruder was preset to the required conditions. HCT:PVPVA 
64 powder in a 1:9 ratio was mixed and charged into the extruder hopper.  At a 
predetermined time, approximately 500 mg of dye containing mixture was charged into 
the extruder hopper followed by continued charging of the dye free powder blend.  Upon 





6.3.2.4 Thermal Gravimetric Analysis (TGA) 
 
Thermal gravimetric analysis was conducted using a Perkin-Elmer 7-Series 
Thermogravimetric Analyzer (Norwalk, CT) operated at a ramp rate of 10oC/min from a 
temperature of 50oC to 350oC.  Samples were prepared by degassing under desiccated 
vacuum for 72 hours at room temperature prior to analysis and accurately measuring a 
sample of approximately 10 mg.  Data were analyzed using Perkin-Elmer control 
software and plotted using Microsoft Excel. 
 
6.3.2.5 Differential Scanning Calorimetry Screening Studies 
 
Differential scanning calorimetry (DSC) testing was conducted using a TA 
Instruments Model 2920 DSC (New Castle, DE) and analyzed using TA Universal 
Analysis 2000 Software. Prior to testing, physical mixtures of drug and carrier were 
prepared in a glass mortar and pestle by accurately dispensing the components and 
manually mixing for two minutes. Samples were accurately weighed to 15 ± 2 mg in 
aluminum crimped pans (Kit 0219-0041, Perkin-Elmer Instruments, Norwalk, CT).  
Testing was performed from 50 to 250 °C at a ramp rate of 10 °C/min under nitrogen 
purge at a flow rate of 40 mL/min. 
 
6.3.2.6 Hot Stage Microscopy Screening Studies 
 
Characterization of HCT solubility in the molten carrier was assessed using hot 
stage microscopy.  Polymer samples were prepared by dissolving PVPVA in acetone and 
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HPMC E3 in purified water.  The solutions were pipetted onto a glass slide and allowed 
to dry at 25 oC for a minimum of 24 hours prior to testing.  Prior to testing HCT was 
spread onto the polymer coated surface of the slides.  As a control, HCT was also tested 
by spreading across an uncoated slide and observed under heating.  During testing, an 
Olympus BX60 microscope (Olympus Corp., Center Valley, PA) with Insight QE camera 
(Diagnostic Instruments, Inc., Sterling Heights, MI) was used to visually observe samples 
while a FP82HT hot stage controlled by a FP 90 central processor (Mettler Toledo, 
Columbus, OH) maintained temperatures at 160 oC for 15 minutes followed by an 
additional 15 minutes at 180oC.  Images were captured under visible and polarized light 
using Spot Advance Software (Diagnostic Instruments, Inc.) after reaching 160 oC ± 2 oC, 
after 15 minutes at 160 oC ± 2 oC and after an additional 15 minutes while being 
maintained at 180 oC ± 2 oC. 
 
6.3.2.7 X-Ray Diffraction (XRD) 
 
XRD testing was performed using a Philips Model 1710 X-ray diffractometer 
(Philips Electronic Instruments Inc., Mahwah, NJ) to assess crystallinity in conjunction 
with thermal techniques.  Processed powders were tested after screening through a 60 
mesh screen, as described previously.  Physical mixtures were prepared by premixing 
HCT and polymer in the appropriate ratio prior to analysis.  Samples of powder were 
placed into channeled stages and the diffraction profile was measured from 5o to 50o 
using a 2θ step size of 0.05o and dwell time of 3s. 
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6.3.2.8 Assay Testing 
 
Finely ground powder samples were accurately weighed to 100.0 ± 3.0 mg and 
transferred directly into a 100 ml volumetric flask.  Measured powder samples were 
dissolved using a 1:1 methanol:water solution and diluted to 100 ml total volume.  
Samples were then filter using 13mm 0.2mm PTFE filters (Whatman, Piscataway, NJ) 
and transferred into HPLC vials for analysis (VWR International, West Chester, PA) for 
analysis.   
 
6.3.2.9 In Vitro Dissolution 
 
Dissolution testing (USP XXIX, Apparatus II) was performed using a VK 7010 
dissolution apparatus (Varian, Inc., Palo Alto, CA) operated at 50 rpm paddle speed and 
VK 8000 autosampler (Varian, Inc., Palo Alto, CA).  An equivalent amount of 25.0 mg ± 
0.3 mg of Hydrocortisone (theoretical drug loading) was accurately weighed and added to 
the dissolution vessel containing 900 mL of 0.1N HCl media preheated to 37oC.  During 
testing 5 mL samples were removed from the dissolution vessels without replacement 
after 5, 10, 15, 30, 45 and 60 min.  Samples were immediately filtered using 0.2 m 
PTFE membrane, 13mm filters (Whatman, Piscataway, NJ) and transferred into 1 mL 





6.3.2.10 HPLC Analysis 
 
Assay and dissolution samples were analyzed using a Waters (Waters 
Corporation, Milford, MA) high performance liquid chromatography (HPLC) system 
consisting of dual Waters 515 Syringe Pumps, a Waters 717 Autosampler and a Waters 
996 Photo Diode Array extracting at a wavelength of 254 nm and 242 nm, respectively.  
The system was operated under isocratic flow at 1 mL/min using a mobile phase 
consisting of 2:1:1 water:acetonitrile:methanol.  For assay testing a Phenomenex Luna 5 
μm C18(2) 100 Å, 250 mm x 4.6 mm (Phenomenex®, Torrance, CA) HPLC column was 
used to facilitate separation of major impurities, while a Phenomenex Luna 5 m C18(2) 
100 Å, 250 mm x 4.6 mm (Phenomenex®, Torrance, CA) was used for dissolution 
testing.  Sample injection volumes of 50 μL were used during testing.  Data were 
collected and analyzed using Empower® Version 5.0 software and all analytical tests 
maintained system suitability linearity and reproducibility of r2 ≥ 0.999 and % RSD ≤ 
2.0%, respectively. 
 
6.3.2.11 Statistical Analysis 
 
Factorial design of experiments and statistical analysis was conducted using 
Minitab Release 14 (Minitab, Inc., State College, PA).  For analysis, experimental 
designs were analyzed using Minitab analyzer modules. Additional analysis was 
conducted using ANOVA with Tukey post-hoc testing.  A p-value of ≤ 0.05 was 
considered statistically significant. 
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6.3.2.12 Solubility Parameter Calculations 
 
Hansen solubility parameters for compositions not referenced from literature were 
calculated based on molecular structure and melting point using Molecular Modeling Pro, 
v 6.2.8 (ChemSW, Fairfield, CA). 
 
6.4 RESULTS & DISCUSSION 
 
6.4.1 Preclinical Characterization 
 
Material stability at elevated temperatures is an essential pre-requisite for 
successful solid dispersion production using fusion processing and several techniques can 
be employed to assess material stability under elevated conditions.  One such technique is 
TGA, which can be utilized to determine the weight loss of a material measured under 
isothermal or dynamic temperature conditions and has been frequently applied to assess 
the thermal stability of materials prior to hot melt extrusion.  Hydrocortisone and the 
polymeric carriers HPMC E3 and PVPVA 64 were tested using TGA to assess their 
thermal stability, as shown in Figure 6.1.  As shown in the weight loss profiles, all 
materials exhibited minimal weight loss through temperatures of approximately 200oC, 
although the calculated degradation onset temperature based on weight loss for 
hydrocortisone was approximately 180oC.  It is important to note that this method of 
decompositional measurement is only effective for materials which exhibit a change in 
weight during reaction.  Samples of hydrocortisone were also maintained under 
isothermal conditions for 20 minutes at 160oC, 180oC and 200oC in order to assess 
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potency changes.  Potency measurements showed limited decomposition at temperatures 
below 200oC, supporting the TGA results.  At temperatures above 200oC, rapid 
decomposition of all materials was observed which indicated that maximum processing 
temperatures should not exceed 200oC for extended durations and would ideally be 
maintained below 180oC. 
 
Selection of appropriate drug:polymer combinations was performed on 
representative physical mixture preparations using differential scanning calorimetry and 
hot stage microscopy as shown in Figures 6.2 and 6.3, respectively.  Physical mixtures 
tested using DSC were compared to unprocessed polymer samples and examined for the 
presence of melting and drug dissolution events associated with hydrocortisone.  For 
combinations of hydrocortisone and L-HPC an endothermic event was observed at 
220oC, having an associated transition energy of 11.27 J/g.  Noting that the formulation 
contained 10% hydrocortisone, which had a transition energy of 136 J/g, this value 
represents approximately 82% recovery of crystalline hydrocortisone from the test.  
Additionally, minimal depression of the hydrocortisone melting point is observed, 
indicating that L-HPC would not be a suitable carrier for processing hydrocortisone at 
temperatures significantly below its melting point.  For HPMC, a similarly high recovery 
of crystalline hydrocortisone is observed at approximately 103%, however a significant 
reduction in melting temperature is observed, having an onset of 171oC.  This suggests 
that HPMC would be more effective than L-HPC for processing hydrocortisone below 
the melting temperature and could potentially be achieved at temperatures as low as 
170oC.   Physical mixtures of hydrocortisone and PVPVA 64 also tested by DSC did not 
exhibit a melting endotherm for hydrocortisone.  In comparison to the unprocessed 
polymer sample a downward drift in baseline above 130oC was observed, which may be 
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due to the dissolution of hydrocortisone in the molten PVPVA 64.  The absence of a 
defined melting endotherm and the possible dissolution of hydrocortisone evidenced by 
the change in baseline suggest that the PVPVA 64 would function as an optimum carrier 
for solid dispersion processing, allowing for production at temperatures significantly 
below the melting point of the active ingredient. 
 
In order to verify the data generated by DSC, hot stage microscopy studies were 
conducted to visually determine the onset, rate and extent of drug dissolution within the 
carrier.  Images taken under optical and polarizing light are shown in Figure 6.3.  
Samples of HCT layered directly onto the glass slide showed minimal change following 
heating through 180oC, which was characteristic of the DSC that showed melting did not 
occur until approximately 220oC.  Since similar results were obtained in the DSC study 
for L-HPC which showed no solubilization or melting point depression benefit, this 
combination was not tested.  In strong agreement with the DSC data, HCT layered onto 
HPMC E3 showed minimal API dissolution until reaching temperatures of 180oC and 
thereafter showed extensive solubilization of the drug.  For combinations of 
hydrocortisone and PVPVA 64 optical imaging showed that the drug was extensively 
solubilized at temperatures as low as 160oC, again being well correlated with the results 
obtained by DSC testing. 
 
Examination of the solubility parameters for each of the components was also 
conducted to rationalize the behavior observed during screening.  Based on the molecular 
structure, the Hansen solubility parameter for hydrocortisone was calculated to be 22.6 
MPa1/2.  For the carriers, solubility parameters of 22.9 MPa1/2 and 30.0 MPa1/2 for 
PVPVA (17) and HPMC 2910 (26) have been reported previously.  Miscibility between 
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components is commonly predicted when the difference between the solubility 
parameters of the materials is less than 7 MPa1/2 and immiscibility to occur if the 
difference is greater than 10 MPa1/2.  Examination of the solubility parameters for the 
HCT:PVPVA 64 composition showed minimal difference indicating similar interaction 
energies during mixing, while solubility parameters for the HCT:HPMC composition 
provided differences greater than 7 MPa1/2 which may indicate potential hindered 
dissolution and immiscibility.  Results from the screening studies indicated that PVPVA 
provided more efficient solubilization of hydrocortisone upon exposure to elevated 
temperatures, suggesting that solubility parameters may also provide good indicators for 
the ability of a drug to be solubilized within a material. Similar behavior was also 
observed for itraconazole and Eudragit® L100-55, which have solubility parameters of 
26.1 MPa1/2 and 27.0 MPa1/2, respectively.  It is interesting to note that in a previous 
study by DiNunzio and co-workers (25), hot stage microscopy failed to predict drug 
dissolution within the polymer, however subsequent production by hot melt extrusion and 
KinetiSol® Dispersing yielded amorphous product.  This indicated that consideration of 
material properties and preformulation screening can provide insight into the melt 
behavior, however may also be prone to the indication of false negatives due to the lack 
of shear provided by the characterization techniques presented here.  It should also be 
noted that this behavior will depend on properties such as polymer molecular weight and 
drug diffusivity, and results gained during this stage of development should be leveraged 





6.4.2 HME Process Variable DOE 
 
Previous studies of HCT solid dispersion production have shown that under 
thermal processing, degradation can occur (12).  In order to verify the behavior of the 
selected carrier materials, PVPVA 64 and HPMC E3, in terms of thermal processability 
and overall HCT decomposition profile, batches were prepared using the Haake minilab 
at different temperatures with a constant screw speed of 50 rpm and no additional 
recirculation.  Samples were collected for assay analysis following extrusion and 
grinding, with measured potency values and in-process parameters presented in Figure 4 
and Table 1 respectively.  During processing, HPMC E3 compositions were observed to 
have a lower overall material throughput and significantly higher torque loads which was 
attributed to the higher melt viscosity of the formulation.  Attempts to manufacture this 
composition below 180oC were unsuccessful and resulted in clogging.  Conversely, 
formulations prepared by PVPVA exhibited better flow characteristics, however could 
not be processed at temperatures above 200oC due to insufficient viscosity of the 
material.  Furthermore, differences in the potency profiles of the two formulations were 
also observed.  Figure 4 shows that the PVPVA 64 formulation provided minimal 
decomposition over the temperature range studied, while decomposition of the HPMC 
formulation was significantly influenced by the processing temperature.  This disparity in 
potency at equivalent temperatures suggests the possibility of a specific drug:carrier 
interaction.  In the previous work of Repka and co-workers they identified the 
decomposition of hydrocortisone in HPC, which was attributed to an oxidation pathway.  
Examination of the molecular structure for HPMC shows similarity to HPC, specifically 
an abundance of hydroxyl groups which could potentially contribute to oxidation as free 
radicals.  In a recent study by Basumallick et al. (27), it was shown that radical 
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concentration of HPMC 2910 increased at temperatures above 120oC, suggesting that the 
processing conditions of melt extrusion could facilitate propagation of oxidation during 
production.  Examination of the potency chromatograms shows that the degradation 
products produced during extrusion of the PVPVA 64 composition also differ from those 
of the HPMC E3 composition.  For the HPMC E3 formulation, one major impurity peak 
was observed similar to that reported by Repka and co-workers which confirmed an 
oxidative decomposition.  For compositions of HCT and PVPVA 64, three impurities 
were observed to form which were similar to those of thermally stressed HCT during 
TGA analysis and indicated that a second thermal mechanism was responsible for the 
decomposition.   Differences in melt behavior were also observed and attributed to the 
thermoplastic characteristics of the carrier material used.  PVPVA 64 exhibits a 
significant reduction in viscoelastic properties upon heating, while HPMC E3 is a non-
thermoplastic polymer (28) and therefore required the presence of molten drug to 
lubricate flow.  Since partially dissolved drug was required to achieve the requisite flow 
characteristics, higher temperatures were needed for processing.  Flow resistance of the 
HPMC formulation also contributed to an observed reduced material output rate for this 
composition, increasing the residence time and further effecting decomposition.  Based 
on the combined factors of specific drug:polymer interactions facilitating oxidation, 
requirements for elevated processing temperatures and the reduced product throughput, 
the HPMC E3 composition was not selected for the process study DOE.  Instead the 
PVPVA 64 composition, which provided higher potency and enhanced processing 
characteristics, was selected in order to determine the effect of processing variables 
including screw speed, temperature and residence time on finished product attributes.   
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During fusion production of solid dispersions the overall thermal energy exposure 
as a function of temperature and residence time within the production equipment can play 
a significant role on the impurity profile of the finished product.  HME is a continuous 
process and currently the preferred unit operation for the thermal production of 
amorphous solid dispersions in the pharmaceutical industry; however the residence time 
of the material in the extruder barrel can be upwards of 10 minutes.  During the process 
design phase it is possible to reduce residence times within the equipment through proper 
screw design, screw speeds and material feed rates, as well as selection of appropriate 
equipment.  For example, co-rotating twin screw extruders have been reported to provide 
shorter material residence times as a result of the self-wiping nature of the process (13).  
Additional examples of process modulation include the replacement of mixing elements 
with conveying elements or increasing the screw speed to improve material transit.  In 
order to better understand the effect of manufacturing process variables on the residence 
time of the HCT:PVPVA 64 formulation, a tracer dye was added to the formulation to 
allow for visual determination of material transit.  Surface plots of the residence time and 
torque are presented in Figure 5 and both characteristics were shown to be strongly 
affected by screw speed and processing temperature.  Torque provides an indication of 
the compositional viscosity during the extrusion process, and is both a function of 
temperature and flow velocity for non-newtonian polymer melts.  The equation below 
shows the relationship between melt viscosity, which is proportional to torque, and 
temperature; where η is viscosity, K’ is a constant, Ea is the activation energy of melt 




e K'=η                                                                    Equation 6.1 
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As temperature increases, the exponential relationship with viscosity provides 
improved material flow through a reduced viscosity.  Similarly, increases in screw speed 
results in greater shear which drives a reduction in melt viscosity.  Since viscosity is 
proportional to torque, the reduction of this metric can be correlated with the viscoelastic 
behavior of the material.  Flow characteristics of the material within the extruder will be 
directly related to the viscosity of the melt and the conveying time which is a function of 
screw design and rotational speed.  The behavior of residence time exhibited similar 
characteristics to that of torque, showing reductions of residence time due to increases in 
temperature and speed.  For residence time the major control variable was the screw 
speed.  Material residence time was directly related to the screw speed as a result of 
extruder design, which regulates flow through screw flight, pitch angle and rotational 
speed (29).  In a fixed system, such as the Haake minilab, a three-fold increase in 
rotational speed resulted in a corresponding increase in linear flow velocity.  At lower 
screw speeds a more pronounced effect of temperature on screw speed was observed due 
to the higher viscosity of material.  For higher temperature and lower viscosity 
formulations, residence time became limited only by the feed rate and slip which resulted 
from low material viscosity.  These results indicated that it was possible to control 
residence time by maximizing screw speed and temperature, although elevation of 
temperature would also accelerate thermal decomposition. 
 
A factorial design of experiments, presented in Table 6.1, was also conducted to 
examine the effect of processing variables on the potency of melt extruded compositions, 
specifically evaluating screw speed, temperature and residence time through the use of 
the recirculation collar.  Figure 6.6 shows the surface plots of potency as a function of 
critical variables in the study.  Statistical analysis of the data, with p-values presented in 
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Table 6.2, revealed that residence time and temperature provided a statistically significant 
effect on product potency.  Additionally, an interaction between residence time and 
temperature resulted, which indicated that the cumulative thermal energy exposure was 
responsible for the decomposition of hydrocortisone in the system.  Examination of 
batches with five minute residence time revealed that screw speed, as well as the 
interaction of screw speed with temperature, did not have a statistically significant impact 
on product potency (p > 0.05).  Shear during hot melt extrusion can also negatively 
impact product potency, and these results indicated that the HCT:PVPVA 64 system was 
not shear sensitive within the ranges studied in the Haake minilab. 
 
During the development of a drug product, formulation and process development 
function synergistically to produce a system with optimum characteristics.  For hot melt 
extrusion of a heat sensitive active, control of the process variables can significantly 
impact the characteristics of the materials.  By modulating the extruder processing 
conditions such as temperature, screw speed and geometry, it is possible to limit product 
residence time, which is essential since degradation is directly related to thermal 
exposure.  While potency values for compositions without additional recirculation 
showed acceptable assay values above 95.0%, the addition of five minute residence time 
resulted in further degradation.  During scale-up, residence time within the extruder will 
generally increase relative to barrel length and may result in potency issues at the 
production scale which were not observed during laboratory scale manufacture.  Further 
control of process variables may mitigate residence time and improve potency, however 
it is important to have a detailed understanding of the product behavior at both scales in 
order to develop an optimized manufacturing procedure. 
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6.4.3 Comparison of HME and KSD Production 
 
Study results identified during the DOE revealed that the combined effect of 
residence time and temperature contributed to the observed product potency of the 
HCT:PVPVA 64 solid dispersion.  While small scale extrusion without recirculation 
provided acceptable potency, achieving similar residence times on large scale equipment 
may not be feasible due to differences in equipment geometry.  KSD is a fusion process 
for the production of solid dispersions during which cycle times are generally less than 
thirty seconds and achieve the elevated temperatures only briefly.  Additionally, as a 
result of the high shear involved it may also be possible to process materials at reduced 
temperatures relative to hot melt extrusion.  While geometric changes during scale-up 
associated with hot melt extrusion drive differences in residence time between scales, 
KSD is a semi-continuous process that provides nearly identical cycle times between the 
laboratory and production scale.  In order to assess the effectiveness of KSD for the 
production of heat sensitive solid dispersions, compositions of HCT in either PVPVA 64 
or HPMC E3 were prepared and evaluated for potency, crystallinity and dissolution 
behavior using both manufacturing technologies. 
  
Characteristic of the previously reported solid dispersions prepared by KSD, rapid 
cycle times were observed which minimized thermal exposure (24, 25).  Processing 
profiles for the batches produced are presented in Figure 6.7.  For both formulations, 
solid dispersions were rapidly prepared in under 30 s, with exposure to temperatures 
above 130 oC experienced for less than 5 s.  Similar to hot melt extrusion, decomposition 
in KSD would be regulated by mechanical and chemical decomposition accelerated by 
temperature.  During the extrusion studies, decomposition of the formulations was shown 
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to be independent of shear rate which suggested that mechanical decomposition would 
not be significant.  Utilizing the reduced thermal exposure provided by KSD it was 
hypothesized that degradation could be minimized.  Examination of product potency 
values presented in Table 6.3 showed that KSD provided improvements for both 
formulations, with a significant benefit observed for HPMC E3 solid dispersions.  During 
extrusion studies, residence times of PVPVA 64 formulations were shown to be a strong 
function of the processing conditions and many processing conditions were substantially 
longer than the 10 second processing cycle of HCT:PVPVA 64 formulations 
manufactured by KSD.  For formulations prepared using HPMC E3, residence time 
studies were not conducted, however material flow was observed to be more limited 
compared to the PVPVA 64 solid dispersions indicating longer residence times.  
Additionally, elevated temperatures were required to achieve flow resulting in greater 
thermal exposure of the product during processing.  Using KSD, HPMC E3 formulations 
were processed in less than 30 seconds and were able to be processed at temperatures as 
low as 160 oC due to the combination of shear and frictional energy applied.  The 
combination of lower temperatures and reduced residence times minimized thermal 
exposure and provided greater product potency. 
  
The ability of the manufacturing process to render materials amorphous is 
essential for the development of solid dispersions for oral bioavailability enhancement.  
As demonstrated in the preformulation study, both carriers exhibited partial solubilization 
of the drug below the melting point of the API which limited the ability to assess 
amorphous character by DSC.  For assessment of crystal content within the dispersion, 
XRD was implemented and the results are presented in Figure 6.8.  HCT exhibits several 
strong characteristic crystalline peaks, of which those at 14.5 and 17.5 2θ are easily 
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identifiable in representative physical mixtures.  This allowed for an assessment of 
crystallinity within the solid dispersions produced.  For all compositions, the diffraction 
patterns show an amorphous halo and no crystalline peaks were detected, which indicated 
that HCT was present as an amorphous material within the carrier. 
  
In order to assess the dissolution rate enhancement provided by these 
compositions, dissolution testing of the powders was conducted under sink conditions.  
Results for dissolution testing of the HCT:PVPVA 64 and HCT:HPMC E3 compositions 
are presented in Figure 6.9a and Figure 6.9b respectively.  Examination of the profiles for 
each composition show that the absolute release was strongly affected by the potency of 
the formulation, with all formulations providing faster release rates than unprocessed 
HCT.  For compositions produced with PVPVA 64, higher potencies were achieved and 
therefore the magnitude of dissolution was also substantially greater than that observed 
with the HPMC E3 compositions.  Also, compositions prepared with PVPVA carrier 
showed more rapid release than their HPMC counterparts, releasing nearly all material in 
under 10 minutes while cellulosic solid dispersions provided slightly lower release rates.  
If the solid dispersion release HCT via a polymer mediated process, the dissolution rate 
of the carrier will become the rate limiting step (30).  The disparity in release rates, 
although minor, was most likely due to the gelling nature of HPMC which impedes 
carrier dissolution due to the formation of a diffusion barrier at the bulk interface.  
  
While both manufacturing methods were capable of producing amorphous solid 
dispersions, carrier selection and mode of manufacture significantly influenced product 
potency.  Formulations prepared by KSD exhibited higher potency values and the 
magnitude of improvement between the two processes would be expected to increase for 
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scaled-up systems having increased extruder residence times.  Dissolution rate was also 
impacted by the selection of the carrier, although the magnitude of the difference between 
carriers was not significant when evaluated in comparison to the un-processed crystalline 
API.  These results indicate that both KSD and HME are acceptable techniques for the 
production of amorphous solid dispersions; however formulation and process 
optimization must be performed to ensure maximization of critical product attributes.  
Utilization of KSD processing for the production of solid dispersions can also provide 
critical advantages in terms of reduced processing temperatures and shortened residence 




 The limitation of fusion processing of heat sensitive active ingredients due to 
elevated temperatures is one of the major perceived drawbacks in applying these 
techniques to solid dispersion production.  One effective method for producing solid 
dispersions of such compounds is to select carriers which limit decompositional behavior 
at elevated temperatures and also facilitate processing at reduced temperatures to limit 
thermal exposure.  As shown in the process parameters study, residence within the 
equipment was strongly influenced by operational conditions and was also shown to 
directly impact product potency.  While the design of melt extruders can be configured to 
reduce residence time, issues on scale-up with increased residence times may also lead to 
greater degradation.  KSD provided improved product potencies for both formulations in 
comparison to HME which was attributed to the reduced residence time of the 
compositions.  This novel manufacturing technology also allowed for production of 
amorphous solid dispersions at lower temperatures, providing greater flexibility for 
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processing heat sensitive components.  Since production cycle times are not significantly 
increased on scale-up, this technology may provide a viable platform for producing solid 
dispersions of thermally labile active ingredients when used in combination with 
formulations developed to facilitate processing at reduced temperatures and minimize 
degradation.  By applying proper formulation techniques and novel manufacturing 
processes such as KSD, it is possible to produce amorphous solid dispersions of 
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Figure 6.2 Excipient Screening by Differential Scanning Calorimetry.  Physical mixtures 
were prepared in a 1:9 ratio using a mortar and pestle.  Testing conducted at 





Figure 6.3 Hot Stage Microscopy Analysis of HCT Dissolution in Polymer Samples by 




Figure 6.4 Effect of Temperature on Product Assay for HME Processed Solid 
Dispersions Containing Hydrocortisone, n = 3 Samples Analyzed at Each 




Figure 6.5 Surface Plot of the Effect of Process Conditions on Critical Extrusion 











Figure 6.7 KinetiSol® Dispersing Manufacturing Temperature Profiles for 






Figure 6.8 XRD Profiles of HCT, HCT:Polymer Physical Mixtures and HCT:Polymer 





Figure 6.9 Dissolution Profiles of Hydrocortisone Solid Dispersions Prepared by KSD 
and HME for Compositions Containing PVPVA 64 (a.) and HPMC E3 (b.)  
Key: HCT - Crystalline(♦),HCT:PVPVA 64, KSD, 160oC (■),HCT:PVPVA 
64, HME, 160oC (▲),HCT:PVPVA 64, HME, 180oC (●),HCT:PVPVA 64, 
HME, 200oC, Recirculation = 5 minutes (X), HCT:HPMC E3, KSD, 160oC 
(□),HCT:HPMC E3, KSD, 180oC (Δ),HCT:HPMC E3, HME, 180oC 
(◊),HCT:HPMC E3, HME, 200oC (○) Each vessel (n=3) contained 25.0 mg 
of HCT theoretical equivalent without adjustment for assay and was 
conducted in 900 ml of 0.1 N HCl at 37.0oC using a paddle speed of 50 rpm 


















001 HPMC 160 50 0 290 ± 35 NA 
002 HPMC 180 50 0 114 ± 30 75.0 ± 0.4 
003 HPMC 200 50 0 49 ± 5 50.6 ± 0.3 
004 HPMC 230 50 0 20 ± 5  17.3 ± 0.8  
005 PVPVA 160 50 0 24 ± 4 97.4 ± 0.3 
006 PVPVA 160 50 5 27 ± 4 96.7 ± 0.4 
007 PVPVA 160 150 0 83 ± 7 97.7 ± 0.8 
008 PVPVA 160 150 5 86 ± 7 95.8 ± 1.0 
009 PVPVA 180 50 0 15 ± 3 95.7 ± 1.1 
010 PVPVA 180 50 5 15 ± 3 95.4 ± 0.8 
011 PVPVA 180 150 0 58 ± 11 96.6 ± 1.3 
012 PVPVA 180 150 5 53 ± 5 93.6 ± 0.7 
014 PVPVA 200 50 0 11 ± 3 94.6 ± 0.4 
015 PVPVA 200 50 5 11 ± 4 88.6 ± 1.0 
016 PVPVA 200 150 0 35 ± 4 94.8 ± 2.6 
017 PVPVA 200 150 5 37 ± 5 89.4 ± 2.9 
 
Table 6.1 HME Manufacturing Conditions of Batches Produced for Screening Studies 




Temperature (oC) 0.000 
Screw Speed (rpm) 0.777 
Residence Time (min) 0.000 
Temperature (oC) x Screw Speed (rpm) 0.504 
Temperature (oC) x Residence Time (min) 0.000 
Screw Speed (rpm) x Residence Time (min) 0.216 
Temperature (oC) x Screw Speed (rpm) x Residence Time (min) 0.286 
 









KSD HPMC E3 160 -- 91.9 ± 0.8 
KSD HPMC E3 180 -- 83.0 ± 0.3 
HME HPMC E3 180 -- 75.0 ± 0.4 
KSD PVPVA 64 160 -- 98.3 ± 0.2 
HME PVPVA 64 160 -- 97.4 ± 0.3 
HME PVPVA 64 180 -- 95.7 ± 1.1 
HME PVPVA 64 200 -- 94.6 ± 0.4 
HME PVPVA 64 200 5 88.6 ± 1.0 
 
Table 6.3 Comparison of Hydrocortisone Solid Dispersions Prepared by KSD and HME 
Processing 
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Chapter 7:  Production of Advanced Solid Dispersions for Enhanced 
Bioavailability of Itraconazole Using KinetiSol® Dispersing 
7.1 ABSTRACT 
 
Formulation design research of solid dispersions for enhanced oral bioavailability 
has shifted from maximizing the magnitude of supersaturation to achieving stabilized 
concentrations for prolonged duration in order to improve absorption.  In this study, solid 
dispersions containing hydroxypropyl methylcellulose acetate succinate (LF, MF and HF 
grades) and carbopol 974P were prepared by KinetiSol® Dispersing to characterize oral 
bioavailability enhancement.  As part of the formulation development process, primary 
carrier stabilization of itraconazole was studied by the addition of a small water miscible 
solvent loaded solution of drug into a pre-dissolved polymer media.  Results showed that 
stabilization was related to molecular weight and degree of hydrophobic substitution on 
the polymer such that HF > MF ≈ LF, indicating that stabilization was achieved through a 
combination of steric hinderance and hydrophobic interaction, supplemented by the 
amphiphilic nature and ionization state of the polymer.  Solid dispersions prepared by 
KinetiSol® Dispersing exhibited amorphous solid state behavior and provided neutral 
media supersaturation using a surfactant free pH change supersaturated dissolution 
method such that LF > MF > HF.  Addition of carbopol 974P increased acidic media 
dissolution, while providing a lower magnitude of supersaturation in neutral media due to 
swelling of the high viscosity gel with low pH media which affected microenvironmental 
pH.  In vitro testing of selected compositions using biosimilar fasted state simulated 
intestinal fluid (FaSSIF) media showed greater similarity of formulation release profiles 
compared to surfactant free media.  When compositions were dosed in Sprague Dawley 
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rats, improvements in mean oral bioavailability were observed compared to Sporanox® 
pellets, although both compositions displayed erratic absorption which was attributed to 
the variability of gastrointestinal pH in the animals.  These results showed that production 
of amorphous solid dispersions containing concentration enhancing polymers via 
KinetiSol® Dispersing can provide improved oral bioavailability, however additional 
formulation techniques must be developed to minimize variability associated with natural 




Oral bioavailability limitations for developmental drugs are becoming more 
frequent and it has been reported that upwards of 90% of the developmental compounds 
today exhibit properties which can limit absorption (1).  To this end, solubility 
enhancement techniques have emerged as a primary method for improving 
pharmacokinetic behavior.  The term solubility enhancement refers to the capability of a 
composition to improve the apparent solubility of an active ingredient and can be 
achieved by two specific mechanisms: alteration of equilibrium solubility and temporary 
establishment of elevated metastable solubility.  Alteration of equilibrium solubility is 
achieved by the addition of solubilizing excipients which modify the thermodynamic 
properties of the system to increase the equilibrium solubility of the drug substance.  
Such techniques include formulation of emulsions (2, 3) or addition of complexing agents 
such as cyclodextrins (4-7).  In such systems, the active component becomes dispersed 
within the oil phase or complex and results in an equilibrium between the concentration 
of the two phases (oil/complex and aqueous).  For such systems, oral absorption may still 
be limited as a result of partitioning of the drug between the oil and aqueous phase or the 
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analogous complexed and non-complex form.  The development of such systems have 
been successfully applied to a variety of molecules including: itraconazole (8), paclitaxel 
(9) and cyclosporine (10).  Alternatively, drug products may be developed to achieve a 
greater metastable solubility through modification of the component morphology or 
change in the material properties.  Such techniques include the development of 
nanoparticles (11-16) to provide increased surface area for dissolution and the generation 
of amorphous solid dispersions (17-21) to alter the free energy of the system.  Numerous 
studies of such compositions have described their use in dissolution rate enhancement 
and oral bioavailability improvement; however it is important to note that solubility gains 
for such processes are transient and equilibrium solubility will eventually be reached. 
 
The application of amorphous pharmaceutical production techniques has been 
gaining increased industrial acceptance, with several commercially marketed 
formulations currently available and numerous others in development. Effectively 
designing such formulations requires optimization of both magnitude and duration of 
supersaturation.  Special consideration must also be given to account for the 
physicochemical properties of the moiety administered and the primary site of absorption 
for the compound.  While many studies have described techniques for maximizing the 
magnitude of supersaturation, several other studies have detailed techniques for providing 
site targeted delivery (22, 23) and stabilized supersaturation (13, 21).  Molecular 
properties, such as acid/base nature of the compound, play a significant role in the design 
of such compositions.  Many pharmaceutically active molecules can be classified as weak 
acids or weak bases, although the majority of ionizable compounds are classified as weak 
bases.  For weakly acidic compounds greater solubility will generally be achieved in the 
later stages of the gastrointestinal tract where biological design facilitates absorption.  
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This may limit the need for solubility enhancement, although this will also be a function 
of the pKa and magnitude of solubility in the given environments.  For weakly acidic and 
weakly basic compounds having a pKa above the physiological range, solubility behavior 
within the gastrointestinal tract will be similar to the behavior of neutral compounds.  In 
such cases, formulations may be designed to supersaturate in acidic or neutral pH 
environments of the intestinal tract without concern for changing solubility as a function 
of regional pH.  Stabilization and site targeting components for such systems may also be 
included based on the precipitation kinetics and regional absorption behavior of the 
moiety.  Weak bases exhibiting low pKa values (< ~ 5) present a unique situation, since 
such compounds will exhibit a substantial decrease in equilibrium solubility during 
intestinal transit.  The anatomical construction of the body is designed to facilitate 
absorption of most nutrients at the upper small intestine, which presents a significant 
surface area relative to other regions as a result of villi and microvilli which compose the 
intestinal surface (24-28).  Designing such systems to rapidly supersaturate in the acidic 
environment of the stomach may provide the greatest dissolution rate and magnitude of 
supersaturation as a result of the greater solubility in these conditions, however this will 
also result in an over saturation resulting in higher crystallization driving force during 
transit.  As a result, when reaching the primary site of absorption, the rate of nucleation 
and growth will be amplified, resulting in a rapid precipitation of the drug from solution.  
For such systems, site targeting of supersaturation can be an effective method of limiting 
the over saturation of the system.  Kondo et al. (22), demonstrated that this approach 
could successfully be applied to improve the oral bioavailability of HO-221, an 
experimental anticancer compound, by preparing solid dispersions of the drug in enteric 
hydroxypropyl methylcellulose phthalate (22).  In a similar study Miller et al., prepared 
enteric solid dispersions of itraconazole and Eudragit® L100-55 to improve the oral 
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bioavailability of the antifungal agent (23).  Although mean bioavailability improvements 
were observed in the Miller et al study, significant variability was also noted and 
attributed to the rapid precipitation of the drug from solution.  Designing formulations by 
incorporation of concentration enhancing polymers for extended durations of 
supersaturation can also be an effective method of improving oral bioavailability of all 
classes of pharmaceutical actives.  The presence of these materials reduce precipitation 
rates by physical, chemical or a combination thereof of interactions which can affect 
component solubility, solid-liquid boundary layer viscosity, molecular mobility, and 
interfacial solvation to thereby alter the nucleation and growth rates.  Expanding on 
previous studies, Miller et al. (29) incorporated Carbomer 974P, a cross linked high 
viscosity acrylic acid polymer, into solid dispersion formulations of itraconazole and 
Eudragit® L100-55.  In vitro dissolution testing showed lower magnitudes and longer 
durations of supersaturation from compositions containing Carbomer 974P following pH 
change, suggesting a concentration enhancing potential of the formulations.  Oral 
bioavailability assessed in a Sprague Dawley rat model showed that bioavailability was 
improved and variability reduced in comparison to the previous formulation.  In another 
study, DiNunzio et al. (21) demonstrated that engineered particle formulations of 
amorphous itraconazole dispersed in cellulose acetate phthalate, a concentration 
enhancing polymer, could provide improved oral bioavailability compared to the 
commercially marketed solid dispersion.  Similar studies have shown incorporation of 
concentration enhancing excipients strategy to be an effective technique to improve oral 
bioavailability for marketed and developmental compounds including; tacrolimus (13, 
20), paclitaxel (9), celecoxib (30), PNU-3125 (31) and RS-8359 (32). 
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For this study itraconazole (ITZ), a weakly basic triazole antifungal agent, was 
selected to serve as the model poorly water soluble active ingredient and has been 
extensively studied in a variety of bioavailability enhancing platforms.  Owing to the 
extremely low and pH dependent solubility, which has been reported to be as low as 4 
μg/ml in acidic media and 5 ng/ml in neutral media, ITZ exhibits low and variable 
absorption (6, 33, 34).  Absorption of ITZ is also affected by extensive metabolism of the 
molecule due to cytochrome P 450 enzymes in the intestinal wall and liver (35).  In this 
study, it was hypothesized that the production of ITZ solid dispersions containing 
Hypromellose Acetate Succinate (HPMCAS) by KinetiSol® Dispersing could provide 
enhanced oral bioavailability.  Additionally, incorporation of Carbomer 974P (C974) was 
included to confirm if previously reported concentration enhancing properties or 
secondary properties of the material such as mucoadhesion or paracellular transport 
increases (36-38).  In order to assess the behavior of ITZ concentration enhancing 
polymer systems, solid dispersions of were prepared by KinetiSol® Dispersing following 
preformulation assessment of polymer stabilization.  Solid state characterization and in 
vitro dissolution testing were conducted to identify lead compositions which were 
administered to Sprague Dawley rats to assess oral bioavailability in comparison to 












Itraconazole, BP micronized (ITZ) was purchased from Hawkins, Inc. 
(Minneapolis, MN). Hydroxyitraconazole was purchased from BDG Synthesis 
(Wellington, New Zealand).  Hypromellose acetate succinate (HPMCAS) was generously 
donated in three grades (LF, MF and HF) by Shin Etsu Chemical Co (Tokyo, Japan).  
Carbomer® 974P (C974) was generously provided by Lubrizol Advanced Materials Inc. 
(Cleveland, OH). Hypromellose (HPMC) was generously donated in three grades (E3, 
E50, F50) by the Dow Chemical Company (Midland, MI). HPLC grade acetonitrile and 
methanol were purchased from EMD chemicals (Darmstadt, Germany). Lecithin and 
sodium taurocholate were purchased from Spectrum Chemicals (Gardena, CA).  All other 




7.3.2.1 KinetiSol® Dispersing (KSD) 
 
KinetiSol® Dispersing was performed using a custom built compounder designed 
for pharmaceutical processing applications by DisperSol Technologies, L.L.C. (Austin, 
TX) as described previously (39, 40).  Prior to processing, drug and polymer 
compositions were accurately dispensed into an impact mill and premixed for 1 minute 
prior to being charged into the compounder.  During processing, temperature and 
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rotational speeds were monitored with material discharged immediately upon achieving 
the target processing temperature.  During production, all compositions were prepared 
using a maximum rotational speed of 2,200 rpm. Following discharge, the material was 
quench pressed between two chilled plates, ground using an impact mill (Capresso Inc., 
Closter, NJ) and passed through a 60 mesh (250 micron) screen prior to further testing.  
In-process temperature profiles were smoothed using a five point mean value algorithm 
and plotted using Microsoft Excel 2003 (Microsoft Corporation, Redmond, WA). 
 
7.3.2.2 Potency Testing 
 
Processed powder samples were accurately weighed to 10.0 ± 0.1 mg theoretical 
equivalent of ITZ and transferred to a 100 ml volumetric flask.  Powder samples were 
dissolved in a 70:30:0.05 acetonitrile:water:diethanolamine solution and diluted to 
volume.  Samples were analyzed by HPLC for potency by comparing to a known 
standard and adjusting for recorded sample weight.  HPLC analysis was conducted as 
described in the HPLC Analytical Method section. 
 
7.3.2.3 X-Ray Diffraction (XRD) 
 
XRD testing was conducted using a Philips Model 1710 X-ray diffractometer 
(Philips Electronic Instruments Inc., Mahwah, NJ) operating at an accelerating voltage of 
40 kV and 30 mA.  Samples of powder were placed into channeled stages and the 
diffraction profile was measured from 2.5o to 60o using a 2θ step size of 0.04o and dwell 
time of 2s. 
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7.3.2.4 Modulated Differential Scanning Calorimetry (mDSC) 
 
Modulated differential scanning calorimetry testing was performed using a TA 
Instruments Model 2920 DSC (New Castle, DE) and analyzed using TA Universal 
Analysis 2000 Software. Samples were weighed to 15 ± 2 mg in aluminum crimped pans 
(Kit 0219-0041, Perkin-Elmer Instruments, Norwalk, CT) and tested under a ramp rate of 
10 °C/min from 5 to 215 °C using a modulation temperature amplitude of 0.5 ºC and a 
modulation period of 40 s under nitrogen purge at a flow rate of 40 mL/min.  For 
unprocessed polymer samples, the second run was analyzed to remove the thermal 
history of the material. 
 
7.3.2.5 Supersaturation Stabilization Studies 
 
Polymer supersaturation stabilization studies were conducted by accurately 
weighing 75 ± 1 mg of selected polymers (HPMC E3, HPMC E50, HPMC F50, 
HPMCAS-LF, HPMCAS-MF, HPMCAS-HF) into 1000 ml of pH 6.8 phosphate media 
prepared by the addition of 250 ml of 0.2M Na3PO4 buffer into 750 ml of 0.1N HCl 
followed by neutralization with 1N sodium hydroxide.  ITZ was dissolved into 1,4 
dioxane at a concentration of 18.75 mg/ml.  Testing was conducted by preheating the 
dissolution apparatus to 37.0 ± 0.3 oC using a VK 7010 dissolution apparatus (Varian, 
Inc., Palo Alto, CA).  For testing, 2 ml aliquots of the ITZ solution were injected by 
pipette into the 1000 ml dissolution vessels containing pre-dissolved polymer.  Samples 
of approximately 5 mL were taken after 5, 10, 15, 30, 45, 60, 90, 120, 180, 240 and 1440 
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minutes without replacement using a VK 8000 autosampler (Varian, Inc. Palo Alto, CA), 
immediately filtered using 0.2 μm 13mm PVDF membrane filters (Whatman 
Corporation, Florham Park) and diluted 1:1 with 70:30:0.05 
acetonitrile:water:diethanolamine mobile phase.  Filtered and diluted samples were then 
transferred to 1 ml HPLC vials (VWR International, West Chester, PA) for analysis, 
using the procedure described in the HPLC Analytical Method section. 
 
7.3.2.6 Supersaturated Dissolution Testing 
 
Supersaturated dissolution testing was performed based on the USP XXIX 
method A enteric dissolution test using a VK 7010 dissolution apparatus and VK 8000 
autosampler.  An equivalent amount of solid dispersion having 37.5 mg ± 0.4 mg ITZ 
(~10x 0.1N HCl media equilibrium solubility) was weighed and added to the dissolution 
vessel containing 750 mL of 0.1N HCl media.  After two hours, 250 mL of 0.2M Na3PO4 
solution was added to the dissolution vessel to achieve a pH of approximately 6.8.  
During testing, 5 mL samples were removed from the dissolution vessels without 
replacement after 60, 120, 125, 130, 135, 150, 180, 240, 300, 360 and 1440 min.  
Samples were immediately filtered using 13mm 0.2μm PVDF membrane filters, diluted 
in a 1:1 ratio with mobile phase, vortex mixed and transferred into 1 mL vials for HPLC 
analysis. 
 
7.3.2.7 Biosimilar Media Dissolution Testing 
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Biosimilar media, fasted state simulated intestinal fluid (FaSSIF), was prepared 
using a method adapted from the method presented by Cellarets et al.(41).  Briefly, 6.96 g 
of NaOH, 123.72 g of NaH2PO4·H2O were dissolved in 20L of purified water.  Additional 
1N NaOH was added as necessary to achieve a pH of 6.5.  To a 1.2L aliquot of pH 6.5 
phosphate buffer 9.66 g of sodium taurocholate and 3.54 g of lecithin were added and 
allowed to mix overnight.  Prior to testing, 200 ml of the sodium taurocholate were 
brought to 1000 ml volume by addition of the pH 6.5 phosphate buffer.  The diluted 
solutions were added to the dissolution apparatus and this procedure was repeated as 
necessary to prepare dissolution media.  Dissolution testing was performed based on the 
USP XXIX apparatus II test using a VK 7010 dissolution apparatus and VK 8000 
autosampler.  An equivalent amount of solid dispersion having 37.5 mg ± 0.4 mg ITZ 
was weighed and added to the dissolution vessel containing 1000 mL of biosimilar media 
maintained at approximately 37.0oC.  During testing 5 mL samples were removed from 
the dissolution vessels without replacement after 5, 10, 15, 30, 45, 60, 90, 120, 180, 240 
and 1440 min.  Samples were immediately filtered using 0.2μm PVDF membrane, 13mm 
filters, diluted in a 1:1 ratio with methanol, vortex mixed and transferred into 1 mL vials 
for HPLC analysis.  Preliminary studies indicated that the method of media preparation 
(i.e. dichloromethane emulsion or mixing overnight) did not provide a significant 
difference in release profile. 
 
7.3.2.8 HPLC Analytical Analysis 
 
Dissolution samples were analyzed using a Waters (Waters Corporation, Milford, 
MA) high performance liquid chromatography (HPLC) system consisting of dual Waters 
515 Syringe Pumps, a Waters 717 Autosampler and a Waters 996 Photo Diode Array 
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extracting at a wavelength of 263 nm.  The system was operated under isocratic flow at 1 
mL/min using a mobile phase consisting of 70:30:0.05 acetonitrile:water:diethanolamine 
equipped with a Phenomenex Luna 5 μm C18(2) 100Å, 150 mm x 4.6 mm 
(Phenomenex®, Torrance, CA) HPLC column.  Samples collected in the 0.1N HCl media 
and neutralized media were injected in volumes of 50 μL and 200 μL respectively during 
testing.  Data were collected and analyzed using Empower® Version 5.0 software.  The 
retention time of ITZ was approximately 6 min.  All analytical tests maintained system 
suitability limits for linearity from 0.024 to 100 μg/mL (r2 ≥ 0.999) and reproducibility of 
replicate injections (% RSD ≤ 2.0%). 
 
7.3.2.9 In Vivo Studies 
 
Institutionally approved in vivo studies were conducted using jugular vein pre-
catheterized CD® IGS Sprague-Dawley rats (Charles River Laboratories, Inc., 
Wilmington, MA) weighing approximately 300 g. Throughout the study the animals were 
stored in individual cages, subjected to 12hr-12hr cycles of light and darkness, with 
access to food and water ad libitum.  The catheters were flushed daily with 300 μL of 50 
U/mL heparinized normal saline. A minimum of 72 hours was allowed for 
acclimatization, after which time the rats were administered the formulations at a dose of 
15 mg ITZ / kg body weight (n = 6).  Solid dispersion formulations were dispersed in 
deionized water prior to dosing at a concentration of 4.5 mg ITZ / 400 μL and dosed by 
oral gavage. Blood samples of approximately 300 μL were collected from the jugular 
vein catheter at 0, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12 and 24 hr after dosing, placed into pre-
heparinized 1.5 mL microcentrifuge tubes and replaced with equal volumes of 
heparinized saline. Blood samples were centrifuged at 3000g for 15 min and the plasma 
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transferred to a clean 1.5 mL microcentrifuge tube.  All samples were stored at -20oC 
until HPLC analysis. 
 
Prior to HPLC analysis, plasma samples were removed from frozen storage, 
allowed to equilibrate to room temperature and a measured volume of plasma was 
transferred to a clean 1.5 mL microcentrifuge tube.  To each microcentrifuge tube, 50 μL 
of 0.3 N barium hydroxide and 50 μL 0.4 N zinc sulfate heptahydrate solutions were 
added.  Samples were then vortex mixed for 30 s and 1 mL of acetonitrile containing 
1200 ng/mL ketoconazole as an internal standard was added to each plasma sample.  
Samples were vortex mixed for an additional 90 s and centrifuged at 3000g for 15 min. 
From each vial the supernatant was extracted, transferred to a clean 1.5 mL centrifuge 
tube and dried in an aluminum heating block (70 °C) under a stream of nitrogen gas. 
Samples were reconstituted with 250 μL mobile phase, vortex mixed for 60 s and 
centrifuged for an additional 15 min.  An aliquot of the supernatant was extracted and 
filled into 150 μL HPLC vial inserts. Samples were analyzed at a wavelength of 263nm 
using the previously described Waters HPLC system equipped with a Phenomenex® Luna 
5 μm C-18(2) 100Å HPLC column (250 mm × 4.6 mm) maintained at a temperature of 
37 °C using a 38:62 0.05M phosphate buffer : acetonitrile mobile phase operated under 
isocratic flow of 1 mL/min.  Sample injection volumes of 100 μL were utilized for testing 
and the retention times of KTZ, OH-ITZ and ITZ were approximately 5.5 min, 7.5 min 
and 14.7 min, respectively.  All analytical tests maintained system suitability limits for 
linearity (r2 ≥ 0.999) and reproducibility of replicate injections (% RSD ≤ 2.0%).  The 
limit of detection and quantitation for both ITZ and OH-ITZ was 10 ng/mL and 30 
ng/mL, respectively. 
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7.3.2.10 Pharmacokinetic Analysis 
 
Plasma data was analyzed with WinNonlin v4.1 (Pharsight Corporation, 
Mountain View, CA) using non-compartmental analysis for extravascular input.  
Specifically, Tmax and Cmax were determined directly from empirical data, AUC was 
calculated by the linear trapezoidal method, and t½ was determined by calculation of the 
lambda z parameter.   
 
7.3.2.11 Statistical Analysis 
 
 Statistical analyses were conducted by ANOVA with Tukey comparison test 
using Minitab® Release 14.  For all tests, p ≤ 0.05 was used as the criteria to assess 
statistical significance. 
 
7.4 RESULTS AND DISCUSSION 
 
7.4.1 Precipitation Inhibition Studies 
 
Successful development of formulations utilizing concentration enhancing 
polymers requires identification of the carrier excipient which will provide the greatest 
degree of stabilization, however only limited works have discussed preformulation 
techniques for assessing maintenance of supersaturation.  Screening was conducted using 
two major classes of polymers, HPMC and HPMCAS, each having three distinct types of 
material.  The HPMC group consisted HPMC E3, HPMC E50 and HPMC F50 in order to 
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study the effect of molecular weight and functional group contributions to stabilization of 
supersaturation.  For the HPMCAS group, three grades consisting of LF, MF and HF 
having varying ratios of succinoyl:acetyl groups were used.  During testing, rapid 
precipitation of all formulations was observed due to the significant magnitude of 
supersaturation which was estimated to be approximately 10,000 times equilibrium 
solubility.  Following rapid nucleation and initial growth, measured concentrations of the 
formulations reached a period of gradual decrease and continued to decrease over the 24 
hour testing period.  Concentration data measured during the study was used to calculate 
area under the dissolution curve (AUDC), as presented in Table 7.1. Data showed that the 
HPMCAS polymers as a group provided greater stabilization of supersaturation than the 
HPMC polymers.  Further examination showed that the stabilization within each group 
was directly related to the number of hydrophobic functional groups on the polymer.  
Within the HPMCAS category, the HF grade provided significantly greater stabilization 
than either the LF or MF grade materials.  Differences in molecular weight could not 
explain this behavior since all grades have been reported to have similar molecular 
weights (42).  Examination of the molecular structure for these materials revealed that the 
level of methoxyl and hydropropoxyl substitutions are nearly the same, however acetyl 
substitutions (ACS) increase and succinoyl substitutions (SUS) decrease when comparing 
the LF grade (ACS ~ 7, SUS ~ 16) to MF grade (ACS ~ 9, SUS ~ 12) to HF grade (ACS 
~ 12, SUS ~ 6) (43).  This indicated a correlation between hydrophobic functional groups 
on the polymer and stabilization of supersaturation.  A comparison of HPMC E50 to 
HPMC F50 revealed similar behavior.  For E chemistry, HPMC functional substitutions 
are 29% methoxyl and 8.5% hydropropoxyl while F chemistry is composed of 28% 
methoxyl and 5% hydropropoxyl.  The common behavior across polymer classes of 
increasing stabilization with greater hydrophobicity suggested a hydrophobic interaction 
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between the drug and polymer which contributed to the observed concentration 
enhancing effect.  Further comparison of the different E chemistry molecular weight 
grades showed that higher molecular weight polymers provided superior stabilization 
compared to the lower molecular weight analogs.  This indicated that a component of the 
stabilization was also due to steric hinderance.  In a previous study investigating the use 
of polyvinyl acetate phthalate (PVAP) and cellulose acetate phthalate (CAP) as 
concentration enhancing polymers for ITZ, it was shown that CAP provided superior 
stabilization to PVAP, which was partially attributed to differences in polymer backbone 
(21).  Combining this information, one can hypothesize that the mechanism of 
stabilization of ITZ in solution is due to the combination of steric hinderance and 
hydrophobic interaction, supported by the capability of the polymer to also interact with 
water due to the presence of hydrophilic groups.  In such a scenario, polymers which 
orient at the solid-liquid boundary layer provide an increased diffusional barrier due to 
molecular weight and entropic restrictions limiting molecular motion resulting from 
backbone rigidity.  Additional intermolecular interactions which could result in 
precipitation are further hindered by partial shielding due to polymer backbone.  
Increasing the hydrophobic component of the polymer results in greater drug-polymer 
interactions as the ITZ molecules diffuse to the solid surface for recrystallization.  Further 
stabilization of the ionic polymer class may also be explained by the ionization state of 
the polymeric stabilizers, which prevent the rapid collapse of the colloidal precipitate.  
Using such a model, it is possible to explain stabilization behavior observed in this study, 
as well as previous studies of ITZ supersaturation stabilization. 
 
Results from this study allowed for selection of the primary carrier for prototype 
formulation development based on stabilization; however they did not provide 
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information on the dissolution behavior of the amorphous solid dispersions.   In a recent 
paper by Vandecruys et al. (44), they examined the stabilization potential of multiple 
carriers on a set of 25 active ingredients of varying physicochemical properties in a high 
throughput setting by applying a similar technique in which drug was dissolved in an 
organic solvent and added dropwise to the aqueous polymer solution until precipitation 
was observed.  Samples were subsequently measured periodically to establish the 
magnitude of supersaturation and ability to stabilize supersaturation.  While this 
technique provided additional information on the magnitude of supersaturation that could 
be achieved from such compositions it did not account for kinetic factors associated with 
the solid dispersion.  Similarly, the method applied within this study did not account for 
such factors and therefore the development of prototype formulations was necessary to 
establish supersaturation behavior.  For prototype formulation development, HPMCAS 
was selected since these polymers provided greater stabilization of supersaturation in 
neutral media.   
 
7.4.2 Solid State Characterization 
 
Prototype solid dispersions were prepared using KinetiSol® Dispersing.  This 
technology is classified as a fusion production process, which has recently been reported 
for a range of applications including hydrophilic solid dispersion production, plasticizer 
free solid dispersion manufacture and solid dispersion processing of temperature sensitive 
active ingredients (39, 40, 45).  During processing, material temperatures were rapidly 
raised through the generation of frictional energy within the equipment while being 
thoroughly mixed as a result of the shear developed.  The process resulted in rapid cycle 
times, as shown in Figure 7.1, with all batches produced in under 20 s.  Exposure to 
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elevated temperature conditions was also minimized due to the rapid temperature 
increase, measured to be approximately 35oC/s during the primary working phase, 
followed by cooling application of a quench press technique after material discharge 
upon reaching approximately 160oC.  Interestingly, during production of HPMCAS solid 
dispersions a rank order behavior of frictional processing duration was observed. 
Frictional processing occurs during the initial stage of production prior to entering the 
working phase where heat is rapidly generated as viscoelastic material properties change.  
The time required for frictional energy generation to enter the working phase, was 
observed such that LF > MF > HF.  This indicated a potential variation in underlying 
material feed properties which may impact processing profiles.  Compositions containing 
C974 showed extremely short frictional and working stages similar to behavior observed 
in previously reported studies (40), further suggesting material properties play a role in 
the duration of these stages during KinetiSol® Dispersing.  Product potency testing also 
revealed that compositions provided prepared by KinetiSol® Dispersing exhibited values 
between 95.0% and 105.0%, as shown in Table 7.2, conforming to the acceptance criteria 
listed in the USP.  
 
Processed powders were examined by mDSC and XRD to study the solid state 
characteristics of these systems.  Thermal analysis was performed to identify the presence 
of residual crystalline ITZ in the dispersion and also identify the formation of an 
amorphous glass solution, indicated by single phase behavior of the system.    In Figure 
2a, crystalline ITZ exhibited a strong melting endotherm at 170oC which was not present 
in the processed solid dispersions.  This indicated that the compositions were amorphous, 
which was further confirmed using XRD. As presented in figure 7.2, XRD profiles 
showed that all compositions yielded an amorphous halo with no crystalline peaks of ITZ 
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visible, verifying the amorphous nature of the compositions.  Total and reversing heat 
flow profiles for the compositions tested are presented in Figure 7.3a and 7.3b, 
respectively.  Reversing heat flow profiles were utilized to deconvolute thermal events 
associated with specific heat that are characteristic of glass transition events.  Amorphous 
ITZ, prepared as a second heating sequence of crystalline ITZ as described in the 
methods section, revealed a glass transition at approximately 58.5oC and subsequent 
rearrangement of the liquid crystalline phase at 75oC and 90oC.  While the temperature 
magnitude for these events were similar to those reported by Six et al. (46), the 
exothermic behavior of the chiral nematic mesophase to isotropic liquid conversion 
observed in the present study was due to the mDSC heating rate.  At reduced heating 
rates, this event is endothermic and similar to the results presented by Six and coworkers.  
HPMCAS polymer samples also exhibited amorphous behavior, providing glass 
transition temperatures of approximately 120oC.  Previously reported studies on C974 
have shown a glass transition temperature of approximately 130oC (29).  For all 
processed compositions a single primary Tg value was observed at approximately 85oC.  
This indicated the formation a homogeneous amorphous solid dispersion and was similar 
to control compositions prepared by hot melt extrusion using a Haake minilab which also 
exhibited single phase behavior. 
 
7.4.3 In Vitro Dissolution Studies 
 
Application of screening studies provided insight into the stabilization properties 
of the polymers selected, however issues regarding dissolution rate behavior accounting 
for kinetic factors could not be assessed using the screening technique employed.  In 
order to assess the behavior of the solid dispersions prepared, samples were subjected to 
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pH change supersaturated dissolution testing using surfactant free media.  Dissolution 
profiles comparing the behavior of compositions containing LF, MF and HF grade of 
HPMCAS are presented in Figure 7.4, with critical formulation metrics presented in 
Table 7.3.  During the acidic period, all compositions exhibited partial release, achieving 
approximately 50% of the equilibrium solubility value during the two hour period, which 
was most likely due to the presence of accessible amorphous ITZ located in the surface 
region of the particles.  Following pH change, particle dissolution was observed, with the 
rate of dissolution (LF > MF > HF) and extent of supersaturation (LF ≈ MF > HF) being 
correlated to the grade of HPMCAS used in solid dispersion production.  This release 
behavior was most likely due to the ratio of succinoyl:acetyl functional groups on the 
polymer which increased with greater dissolution rates and also contributed to the pH 
onset of dissolution, which has been reported by the manufacturer as pH 5.5, pH 6.0 and 
pH 6.8, respectively.  The extent of supersaturation in neutral media also showed similar 
performance of the LF and MF formulations, as indicated by the AUCdissolution in neutral 
media.  This behavior was most likely due to a combination of factors, including the 
similar stabilization properties reported during screening, as well as the lower maximum 
concentration in solution observed for the MF grade which provided a reduced driving 
force for nucleation and growth. For compositions prepared using LF and MF grade 
material, maximum amounts of drug in solution were observed following pH change 
within 60 minutes, however the HF grade material which provided the greatest 
stabilization of supersaturation failed to provide adequate release to substantially 
supersaturate neutral media.  As a result of the superior dissolution rate of the LF grade 
and the similar stabilization properties of the LF and MF grade material, Amax and 
AUCdissolution values showed that the LF composition provided the greatest magnitude of 
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supersaturation with similar extents of supersaturation observed for LF and MF 
formulations. 
 
The effect of incorporation of C974 into the solid dispersions on in vitro 
dissolution performance was also assessed.  In a previous study by Miller et al. (29), 
C974 was observed to provide concentration enhancing properties to ITZ in solution 
when used in solid dispersions and this in vitro behavior was attributed to the improved 
oral bioavailability of the formulation.  Carbomer has been reported to provide other 
functions in vivo, specifically yielding mucoadhesive properties and facilitating transport 
through GI membranes (37, 38).  Incorporation of this material as an additive into a solid 
dispersion composed of a concentration enhancing polymer carrier would allow study of 
the contribution of these secondary properties.  In vitro dissolution profiles of 
formulations prepared containing 20% C974 on a polymer weight basis are presented in 
Figure 7.5, along with the profile for the HPMCAS-LF composition as reference.  Critical 
dissolution metrics for these formulations are also provided in Table 7.3.  The presence of 
C974 in the dispersion increased the release in acidic media, resulting in slightly 
supersaturated media (~ 2x equilibrium solubility).  Previous reports incorporating C974 
into solid dispersions have shown greater drug release in acidic media due to increased 
permeability resulting from swelling and erosion (47).  Swelling and interfacial erosion 
of the particles would provide a larger quantity of accessible amorphous ITZ, 
contributing to the release in acidic media.  The presence of C974 also affected 
supersaturation behavior in neutral media.  Solid dispersions containing HPMCAS-LF 
and C974 showed significantly reduced dissolution rates when compared to C974 free 
material.  Since C974 is a high molecular weight cross-linked polymer, an increase in 
solid-liquid boundary layer viscosity most likely contributed to the muted release by 
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reducing diffusion of elevated pH bulk media to the particle surface while simultaneously 
limiting drug and concentration enhancing polymer diffusion from the solid dispersion 
surface.  As a result of the lower drug release rate, concentrations of drug in solution 
never reached sufficient levels to maximize AUCdissolution values.  In the case of 
HPMCAS-HF and C974 compositions, contribution of swelling and erosion imparted by 
the acrylic acid polymer increased acidic and neutral media drug release.  Since 
HPMCAS-HF has a dissolution onset of approximately pH 6.8, testing in media having a 
pH of 6.8 provides only partial ionization of the polymeric chains and results in slower 
dissolution.  By incorporating the C974, the solid dispersion particles become partially 
swollen and more porous as the polymer swells and diffuses into the bulk media.  This 
allows for greater specific surface to facilitate drug dissolution following pH change.  
Even with this behavior however, this formulation still fails to significantly supersaturate 
the dissolution media. 
 
Application of the surfactant free pH change dissolution method has been applied 
extensively to characterize the dissolution behavior of enteric ITZ solid dispersions; 
however, the media used does not accurately reflect the contents of the upper small 
intestine which contain bile salts and micellular complexes (48, 49).  In order to better 
understand the affect of intestinal contents on the dissolution and supersaturation 
behavior of concentration enhancing polymer solid dispersions, lead compositions 
consisting of ITZ:HPMCAS-LF and ITZ:HPMCAS-LF:C974 were tested in FaSSIF 
media having a pH of 6.5.  Dissolution profiles of both compositions and critical 
statistical metrics are presented in Figure 7.6 and Table 7.4, respectively.  Behavior of 
both formulations in pH 6.5 biosimilar media showed rapid and extensive 
supersaturation, with a high degree of similarity between the two profiles.  In previous 
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studies of other enteric polymer compositions (23), addition of ITZ:L100-55 solid 
dispersions directly into neutral media have shown minimal drug release.  For ITZ:L100-
55 solid dispersions, this behavior was ascribed to the permeability of the matrix under 
acidic conditions which allowed the drug to solvate in the more favorable low pH 
conditions.  HPMCAS solid dispersions however, showed the ability to supersaturate 
biosimilar media having a pH of 6.5, as well as pH 6.5 media without biosimilar 
components.  This suggested that the presence of HPMCAS may also affect the solvation 
of ITZ due to the amphiphilic nature of the polymer, which allowed hydrophobic 
domains of the polymer to interact with ITZ while hydrophilic groups on the polymer 
provided favorable interactions with water that prevented rapid aggregation and 
precipitation of the dissolved drug.  Stabilization properties of the tested formulations 
exhibited greater similarity than observed during the pH change method, although 
AUCdissolution differences were still statistically significant.  The much more rapid 
dissolution of compositions containing C974 in biorelevant media was one of the most 
interesting characteristic differences in material behavior between the two tests.  Under 
biosimilar testing conditions, materials were added directly to pH 6.5 media, which 
prevented gelling of C974 under acidic conditions.  This suggested that the muted release 
after neutralization observed in pH change conditions was primarily due to a residual low 
pH microenvironment as a result of limited diffusion, while a contribution of 
microenvironmental viscosity increase to reduced release of ITZ also could not be ruled 
out.  In both cases compositions tested using biosimilar media showed greater 
AUCdissolution and Amax values.  Intestinal fluids are known to contain bile salt micelles 
which are capable of solubilizing hydrophobic substances.  Improvements in these 
metrics suggested that physiological media would facilitate the solubilization of ITZ, 
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improving the oral bioavailability over what would be predicted from surfactant free 
tests. 
 
Formulation comparison within test methods was also strongly influenced by the 
media and procedure employed in the study.  Application of the pH change method 
without surfactant predicted a significant difference in oral bioavailability of ITZ based 
on formulation, indicating substantial improvements for compositions prepared without 
C974.  Using biosimilar media, differences were again predicted, however the magnitude 
was significantly reduced.  While both methods predicted improvements from 
compositions without C974, the true predictive power of the methods needed to be 
verified using an animal model.   
 
7.4.4 In Vivo Bioavailability 
 
Lead formulations of ITZ:HPMCAS-LF and ITZ:HPMCAS-LF:C974 were 
selected based on in vitro behavior and dosed to Sprague Dawley rats by oral gavage at a 
dose of 15 mg/kg.  During the study, blood samples were taken periodically and analyzed 
for plasma concentration of ITZ and the primary metabolite OH-ITZ.  Plasma levels 
measured during the study are presented in Figure 7, with calculated pharmacokinetic 
data shown in Table 7.5.  Upon oral administration, ITZ was rapidly absorbed from both 
formulations with greater oral bioavailabilities based on AUC values for both 
compositions compared to hydrophilic solid dispersions of ITZ and Sporanox® pellets 
(21, 39).  As predicted by both models, the mean AUC for ITZ:HPMCAS compositions 
was greater than that observed for the C974 formulation, however the extensive 
variability observed in both compositions made it impossible to establish statistical 
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significance.  Similar high variability for pH sensitive solid dispersions was also noted in 
a series of studies by Miller et al. (23, 29), in which formulations containing L100-55 had 
significant AUC variability, measuring over 100%, which was attributed to the absence 
of concentration enhancing polymers.  The variability of the composition was 
significantly reduced to approximately 30% by the addition of C974 and attributed to the 
supersaturation stabilization effect of the material.  In the current study C974 failed to 
improve variability since concentration enhancing polymers were already present in both 
formulations.  This indicated that the behavior of C974 as a concentration enhancing 
polymer, described by Miller et al., was correct and not associated with secondary 
properties of the material, such as mucoadhesion or increased membrane transport.  It 
also suggested that the variability observed in this study was not due to the stabilization 
of supersaturation.  Examination of the in vitro dissolution profiles for C974 free 
formulations showed that the time to achieve maximum concentration was approximately 
45 minutes once entering neutral media.  In the case of the C974 composition measured 
under pH change, maximum concentrations were actually observed in acidic media.  This 
suggested that a kinetic component may be partially responsible for the observed 
variation.  Additionally, examination of rat intestinal physiology shows that pH is 
variable in the duodenum and jejunum, which can be further impacted by the food intake 
of the animal.  In a recent study by McConnell et al.(50) the pH of intestinal fluids were 
measured in fed and fasted rats along various segments of the intestinal tract. Results 
showed duodenal pH values ranging from 5.0 ± 0.3 in the fed state and 5.9 ± 0.3 in the 
fed state, while jejunal values were measured to be 5.1 ± 0.3 and 6.1 ± 0.3 in the fed and 
fasted states, respectively.  Interestingly, these measured values fall within the dissolution 
onset value for the HPMCAS polymer used.  Since rats were administered food ad 
libitum during the study, it was postulated that the intestinal pH values in the primary 
 266
regions of absorption would cover the range reported in the McConnell study.  If so, 
dissolution of some compositions would be hindered as a result of the variable pH 
observed.  An additional contribution may also stem from the extent of metabolic 
conversion of ITZ to OH-ITZ.  Pharmacokinetic profiles of OH-ITZ for both 
formulations exhibited similar behavior and also similar mean values, although high 
variability was again observed.  Since ITZ is extensively metabolized in the gut wall as 
well as the liver (35), the amount of drug in solution will be related to the extent of 
metabolic conversion.  For cases where low concentrations are observed, metabolism is 
expected to be extensive, however if the drug is highly supersaturated the extent of 
metabolic conversion may be limited due to saturation.  Interestingly, these OH-ITZ 
values were also similar in magnitude to those reported by Tsutsumi et al. (51) for enteric 
ITZ solid dispersions prepared by particle engineering technologies, while ITZ levels 
were significantly higher in the current study.  This suggested that the gut wall 
metabolism may be saturated at higher levels of ITZ supersaturation, and it would also 
stand to reason that if supersaturation was highly variable as a result of pH so to would be 
the extent of metabolic conversion thereby contributing to the highly variable AUC 
values. 
 
While in vitro dissolution tests did correctly predict the magnitude of AUC 
improvement, they failed to provide an indication of variability.  Since solid dispersions 
prepared with ionic polymers are highly sensitive to environmental pH, patient to patient 
differences of gastrointestinal physiology may strongly affect pharmacokinetic behavior 
and clinical outcome.  When developing such systems, examination of drug release at 
multiple pH conditions is recommended, in order to establish pharmacokinetic variability 





Oral bioavailability of many developmental compounds can be limited due to 
reduced solubility, however formulation techniques designed to increase and maintain 
metastable solubility can provide improved bioavailability of many poorly water soluble 
drugs.  In this study it was shown that KinetiSol® Dispersing could be used for the 
production of ITZ solid dispersions containing concentration enhancing polymers, a class 
of material which limits drug precipitation.  Under the proposed mechanism of 
stabilization, the hydrophilic domains of the polymer facilitated interaction with water 
while hydrophobic domains interacted with the drug and provided stabilization effects.  
Based on this model, it is possible to identify polymers which may have greater 
stabilization affinity for a particular drug substance.  Furthermore, in vitro testing 
appeared to show general trends of oral bioavailability for pH sensitive solid dispersions, 
however current methods failed to account for physiological variability which affected 
oral bioavailability.  Based on the results presented, it can be concluded that KinetiSol® 
Dispersing is a viable manufacturing technique for producing concentration enhancing 
solid dispersions for improved oral bioavailability, however testing methods must be 
modified to assess the impact of patient to patient variability on formulation performance 
when developing pH sensitive solid dispersions.  Furthermore, continued work is 
necessary to develop formulations capable of providing improved oral bioavailability 
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Figure 7.3 mDSC Profiles for KSD Processed Solid Dispersions, Unprocessed Polymers 




Figure 7.4 – In Vitro Dissolution Testing for Compositions prepared with HPMCAS-LF 
(♦), HPMCAS-MF (■) and HPMCAS-HF (▲)Each vessel (n=3) contained 
37.5 mg ITZ equivalent corresponding to 10 times the equilibrium solubility 
of ITZ in the acid phase. Testing was conducted for 2 h in 750 ml of 0.1 N 
HCl followed by pH adjustment to approximately 6.8 with 250 ml of 0.2 M 
tribasic sodium phosphate solution.  Dashed vertical line indicates the time 






Figure 7.5 In Vitro Dissolution Profiles for Compositions Containing Carbomer 974P. 1:2 
ITZ:HPMCAS-LF (♦), 1:1.6:0.4 ITZ:HPMCAS-LF:C974P (■), 1:1.6:0.4 
ITZ:HPMCAS-HF:C974P (●) Each vessel (n=3) contained 37.5 mg ITZ 
equivalent corresponding to 10 times the equilibrium solubility of ITZ in the 
acid phase. Testing was conducted for 2 h in 750 ml of 0.1 N HCl followed 
by pH adjustment to approximately 6.8 with 250 ml of 0.2 M tribasic 







Figure 7.6 In Vitro Dissolution Profile of Lead Compositions Tested in FaSSIF.  Key: 1:2 
ITZ:HPMCAS-LF (♦), 1:1.6:0.4 ITZ:HPMCAS-LF:C974 (□).  Each vessel 
(n=3) contained 37.5 mg ITZ equivalent. Testing was conducted using 




Figure 7.7 In Vivo Plasma Profile of Hydroxy-Itraconazole (a.) and Itraconazole (b.). 
Key: 1:2 ITZ:HPMCAS-LF(■/□) and ITZ:HPMCAS-LF:C974 (♦/◊).  
Formulations were administered by oral gavage at a dose of 15 mg ITZ / kg 




Polymer Methyl Hydroxypropyl Succinoyl Acetyl AUDC 
(ng·min/ml) 
None -- -- -- -- 152,060 ± 98,350 
HPMC E3 29.0 8.5 -- -- 169,168 ± 26,277 
HPMC E50 29.0 8.5 -- -- 517,434 ± 195,710 
HPMC F50 28.0 5.0 -- -- 201,332 ± 43,338 
HPMCAS-LF 22.0 7.0 16.0 7.0 481,859 ± 28,322 
HPMCAS-MF 23.0 7.0 12.0 9.0 419,661 ± 115,182 
HPMCAS-HF 24.0 8.0 6.0 12.0 2,921,246 ± 371,143 
 
Table 7.1 Polymer Screening Results and Chemical Properties for Selected Polymers and 




Composition Potency (%) 
1:2 ITZ:HPMCAS-LF 104.7 
1:2 ITZ:HPMCAS-MF 101.9 
1:2 ITZ:HPMCAS-HF 102.5 
1:1.6:0.4 ITZ:HPMCAS-LF:C974 102.2 
1:1.6:0.4 ITZ:HPMCAS-HF:C974 98.0 
 




AUCdissolution (mg·min) Composition Amax (mg) 
tmax 
(min) ACID NEUTRAL TOTAL 
1:2 ITZ:HPMCAS-LF 10.6 ± 0.9 170 ± 17 168 ± 4 3,440 ± 1,067 3,608 ± 1,070 
1:2 ITZ:HPMCAS-MF 5.8± 0.1 240 ± 0 139 ± 10 3,021 ± 272 3,160 ± 267 
1:2 ITZ:HPMCAS-HF 1.3 ± 0.1 60 ± 0 110 ± 6 41 ± 15 151 ± 16 
1:1.6:0.4 ITZ:HPMCAS-
LF:C974 5.4± 0.3 130 ± 17 354 ± 32 1,129 ± 194 1,483 ± 186 
1:1.6:0.4 ITZ:HPMCAS-
HF:C974 7.4 ± 0.6 120 ± 0 503 ± 37 665 ± 44 1,167 ± 81 
 
Table 7.3 Summary of In Vitro Dissolution Testing Data with reported maximum 
observed amounts (Amax), observed time to achieve maximum amount (tmax), 
and area under the supersaturation dissolution profile for pH change testing 




Composition Amax (mg) tmax (min) AUCdissolution (mg·min) 
1:2 ITZ:HPMCAS-LF 16.5 ± 0.9 35 ± 9 6,482 ± 603 
1:1.6:0.4 ITZ:HPMCAS-
LF:C974 15.0± 1.0 30 ± 0 5,051 ± 107 
 
Table 7.4 – Summary of in vitro dissolution testing data measured in pH 6.5 biosimilar 
media with reported maximum observed amounts (Amax), observed time to 
achieve maximum amount (tmax), and area under the supersaturation 











1:2 ITZ:HPMCAS-LF 1,003.4 ± 504.5 5.9 ± 1.9 10,546 ± 9,847 7.6 ± 6.3 
OH-ITZ 
1:1.6:0.4 ITZ:HPMCAS-
LF:C974P 675.2 ± 391.5 4.1 ± 1.2 8,586 ± 6,520 8.0 ± 3.1 
1:2 ITZ:HPMCAS-LF 2,288.9 ± 1,018.6 4.4 ± 2.2 13,225 ± 11,368 5.8 ± 3.1 
ITZ 
1:1.6:0.4 ITZ:HPMCAS-
LF:C974P 798.4 ± 731.8 3.8 ± 1.4 7,345 ± 8,126 6.8 ± 5.4 
 
Table 7.5 Calculated Pharmacokinetic Parameters for Formulations Tested In Vivo 
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Chapter 8:  Concluding Remarks 
8.1 DISSERTATION CONCLUSION 
 
Studies using KinetiSol® Dispersing demonstrated the utility of the process for the 
production of a wide range of amorphous solid dispersions, providing unique advantages 
that cannot be achieved using currently available technologies, including: reduced 
thermal burden during processing for temperature sensitive materials, rapid processing 
times for increased manufacturing output, greater mixing yielding homogenous solid 
dispersions and the ability to produce solid dispersions without the aid of a plasticizer.   
These advantages present unique capabilities and the potential to improve drug 
development as well as commercial production. 
 
Investigation of itraconazole solid dispersion formulations containing 
concentration enhancing polymers demonstrated that the approach was a viable method 
for improving the oral bioavailability of the weak base; however significant variability of 
some compositions was observed.  This variability was attributed to inter-animal 
differences in physiological conditions, specifically intestinal pH.  While historical 
examination of the data reveals that engineered particle compositions provided reduced 
variability, solid dispersions prepared by fusion methods still exhibited significant 
variation.  This suggested that the significantly greater surface area helped to reduce 
variability, although substantial release of engineered particle compositions in gastric 
media may have also contributed to the performance.  Ultimately, while additional 
formulation work may be required to reduce variability this research has provided a 
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fundamental qualitative demonstration of the potential of this formulation approach to 
improve oral bioavailability.  
 
The research conducted under this dissertation was intended to demonstrate the 
applicability of concentration enhancing polymer formulation for the enhancement of 
itraconazole oral bioavailability while developing KinetiSol® Dispersing for the 
production of amorphous pharmaceutical compositions.  By presenting the potential of 
these formulation and processing techniques using model compounds, including 
hydrocortisone and itraconazole, it was hoped that this work would lay the foundation for 
continued development in these fields.  Ultimately, this work has successfully shown the 
applicability of both formulation and processing technologies to improving oral 
bioavailability, having academic and industrial applications, which will contribute to the 
development of novel pharmaceutical compositions to improve treatment options and 
enhance the quality of life for people afflicted with a myriad of illness. 
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Appendix A: Solid State Characterization of Sporanox® Pellets  
A.1 PURPOSE 
 
The purpose of this study was to examine the solid state characteristics of 
Sporanox® Pellets, which have previously been reported by Kapsi and Ayers (1) to be a 




Nanocrystalline solid dispersions can theoretically provide significant 
supersaturation as a result of small particle size, described by the Ostwald-Freundlich 
equation.  While theoretically possible, to date no nanocrystalline solid dispersions have 
been prepared and reported using a solvent based fluid bed coating technique.  
Examination of the fluid bed coating technique used for the production of Sporanox® 
Pellets, uses methylene chloride and ethanol to dissolve the drug and carrier, suggesting 
that the inventors were attempting to produce an amorphous solid dispersion (2).  Based 
on this information, a solid state characterization study was conducted to verify the 










Itraconazole, BP was purchased from Hawkins, Inc. (Minneapolis, MN). 
Hypromellose (HPMC E5) was generously donated by the Dow Chemical Company 
(Midland, MI)  Sugar spheres, NF 20 – 25 mesh were donated by Paulaur Corporation 
(Cranbury, NJ)  Polyethylene glycol 20,000 was generously donated by Mallinckrodt 
Baker (Phillipsburg NJ).  Sporanox® capsules (Lot # 6MG457) were purchased from 




A.3.2.1 Material Preparation 
 
Sporanox® Pellets were prepared for physical testing, by manually separating the 
capsule cap and body, followed by removal of the solid dispersion pellets.  These pellets 
were then placed into a glass mortar and pestle and crushed into a fine powder for further 
testing. 
 
Representative physical mixtures were prepared by accurately weighing all 
formulation materials and placing them into a glass mortar and pestle.  The materials and 
respective ratios were: itraconazole (21.74%), HPMC E5 (32.61%), Sugar Spheres 20 – 
25 mesh (41.74%) and polyethylene glycol 20,000 (3.91%).  Powder blends were then 
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prepared by manual mixing to produce a fine powder for further testing.  Single 
component preparations were prepared by mixing in a glass mortar and pestle. 
 
A.3.2.2 Modulated Differential Scanning Calorimetry 
 
Modulated Differential scanning calorimetry testing was performed using a TA 
Instruments Model 2920 DSC (New Castle, DE) and analyzed using TA Universal 
Analysis 2000 Software. Prior to testing samples were accurately weighed to 15 ± 2 mg 
in aluminum crimped pans (Kit 0219-0041, Perkin-Elmer Instruments, Norwalk, CT).  
Testing was performed at a ramp rate of 10 °C/min from 5 to 215 °C using a modulation 
temperature amplitude of 0.5 ºC and a modulation period of 40 s under nitrogen purge at 
a flow rate of 40 mL/min. 
 
A.3.2.3 X-Ray Diffraction 
 
XRD testing was conducted using a Philips Model 1710 X-ray diffractometer 
(Philips Electronic Instruments Inc., Mahwah, NJ).  Samples of powder were placed into 
channeled stages and the diffraction profile was measured from 5o to 50o using a 2θ step 






A.4 RESULTS & DISCUSSION 
 
In the study by Kapsi and Ayers, they established the crystallinity of Sporanox® 
by examining the differential scanning calorimetry profile for the pellets and unprocessed 
crystalline drug substance, which revealed a significant endothermic event at 
approximately the same temperature for both crystalline API and pellets.  Examination of 
the total heat flow profiles, presented in Figure A.1, showed that crystalline itraconazole 
exhibited a strong endothermic event at nearly the same temperature as Sporanox®.  The 
representative physical mixture exhibited two endothermic events at 167 oC and 189 oC, 
associated with the melting of crystalline itraconazole and sugar spheres.  These results 
confirmed what had initially been report by Kapsi and Ayers, however the energy 
associated with the transition was similar in magnitude to the sugar spheres, which could 
also indicate that the melting point of this material was depressed in the Sporanox® 
formulation.  If so, that would suggest that the material was actually amorphous. 
 
In order to confirm the origin of the endothermic event observed in the thermal 
testing, XRD testing was performed as shown in Figure A.2.  Crystalline itraconazole 
exhibited several strong characteristic peaks at 17.7o, 20.6o, 23.6o, 25.5o and 27.3o, all of 
which were absent in the Sporanox® pellet sample.  A clear correlation between peaks 
observed in the Sporanox® pellet sample and those observed in the sugar sphere sample 
was seen, which indicated that the pellets did not contain significant levels of crystalline 
itraconazole.  This would also indicate that the sugar sphere material, present in a 
crystalline form in Sporanox®, would exhibit a melting event, similar to that seen in the 
physical mixture sample.  Since only a single melting event was observed and XRD 
profiles revealed patterns correlated to the sugar sphere component, this indicated that the 
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melting endotherm was a result of the pellet substrate, with Sporanox® having 




Based on these results, one can conclude that Sporanox® is a commercial 
amorphous solid dispersion and that the observed melting endotherm reported Kapsi and 




1. Kapsi SG, Ayres JW 2001. Processing factors in development of solid solution 
formulation of itraconazole for enhancement of drug dissolution and 
bioavailability. Int J Pharm (229):193 - 203. 
 
2. Gilis PM, De Condé VFV, Vandecruys RPG. 1997. Beads Having a Core Coated 
with an Antifungal and a Polymer. United States Patent & Trademark Office, 






Figure A.1 mDSC Total Heat Flow Profiles for Sporanox® Pellets, Representative 






Figure A.2 XRD Profile for Crystalline Itraconazole, Sporanox® Pellets and Sugar 
Spheres 
 299




The purpose of this study was to determine if any significant performance 





The application of biorelevant media in dissolution testing has become more 
common, particularly as drug substances have increasingly shown dissolution limited oral 
bioavailability.  Unlike compendial dissolution media, which is primarily designed to 
provide a quality control assessment of a formulation’s performance, biorelevant media 
incorporates surfactants and bile salts to approximate the contents of the gastrointestinal 
tract and predict material behavior in vivo.  Preparation of the media currently reported in 
literature, uses an emulsion-evaporation sequence to dissolve the lecithin in 
dichloromethane or methylene chloride, followed by addition of the organic solvent 
phase to a larger aqueous phase and then remove residual solvent.  While extensively 
reported in literature, some companies have been reported to use a technique of extended 
conventional mixing to incorporate lecithin in the media.  This study examined the 
dissolution variation of itraconazole solid dispersions in media prepared by solvent 
evaporation and extended mixing. 
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Itraconazole, BP micronized (ITZ) was purchased from Hawkins, Inc. 
(Minneapolis, MN).  Hypromellose acetate succinate (HPMCAS) was generously 
donated in three grades (LF, MF and HF) by Shin Etsu Chemical Co (Tokyo, Japan).  
HPLC grade acetonitrile and methanol were purchased from EMD chemicals (Darmstadt, 
Germany). Lecithin and sodium taurocholate were purchased from Spectrum Chemicals 




B.3.2.1 KinetiSol® Dispersing 
 
KinetiSol® Dispersing was performed using a custom built compounder designed 
for pharmaceutical processing applications by DisperSol Technologies, L.L.C. (Austin, 
TX) as described previously (1, 2).  Prior to processing, drug and polymer compositions 
were accurately dispensed into an impact mill and premixed for 1 minute prior to being 
charged into the compounder.  During processing, temperature and rotational speeds were 
monitored with material discharged immediately upon achieving the target processing 
temperature.  During production, all compositions were prepared using a maximum 
rotational speed of 2,200 rpm. Following discharge, the material was quench pressed 
between two chilled plates, ground using an impact mill (Capresso Inc., Closter, NJ) and 
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passed through a 60 mesh (250 micron) screen prior to further testing.  In-process 
temperature profiles were smoothed using a five point mean value algorithm and plotted 
using Microsoft Excel 2003 (Microsoft Corporation, Redmond, WA). 
 
B.3.2.2 Preparation of Biosimilar Media 
 
Biosimilar media, fasted state simulated intestinal fluid (FaSSIF), was prepared 
using a method adapted from the method presented by Mellaerts et al. (3).  Briefly, 6.96 g 
of NaOH, 123.72 g of NaH2PO4·H2O were dissolved in 20L of purified water.  Additional 
1N NaOH was added as necessary to achieve a pH of 6.5.  For preparation using the 
emulsion technique a 200 mL aliquot of pH 6.5 phosphate buffer was accurately 
measured, along with 5.9 ml of dichloromethane.  To the phosphate buffer 1.61 g of 
sodium taurocholate was and 590 mg of lecithin was added to the dichloromethane.  The 
organic solution was added to the aqueous phase, which was then heated at 80oC for 15 
minutes.  After evaporation of the organic phase, the solution was brought to a total 
volume of 1000 ml using the pH 6.5 phosphate buffer.  For preparation by mixing 
overnight, 1.61 g of sodium taurocholate and 590 mg of lecithin were added into 200 ml 
of pH 6.5 phosphate buffer.  Media was mixed overnight for a minimum of 12 hours.  
The mixed solution was then reconstituted to 1000 ml by addition of pH 6.5 phosphate 






B.3.2.3 Dissolution Testing 
 
Dissolution testing was performed based on the USP XXIX apparatus II test using 
a VK 7010 dissolution apparatus and VK 8000 autosampler.  An equivalent amount of 
solid dispersion having 37.5 mg ± 0.4 mg ITZ was weighed and added to the dissolution 
vessel containing 1000 mL of biosimilar media maintained at approximately 37.0oC.  
During testing 5 mL samples were removed from the dissolution vessels without 
replacement after 5, 10, 15, 30, 45, 60, 90, 120, 180, 240 and 1440 min.  Samples were 
immediately filtered using 0.2μm 13 mm PVDF membrane filters, diluted in a 1:1 ratio 
with methanol, vortex mixed and transferred into 1 mL vials for HPLC analysis.   
 
Dissolution samples were analyzed using a Waters (Waters Corporation, Milford, 
MA) high performance liquid chromatography (HPLC) system consisting of dual Waters 
515 Syringe Pumps, a Waters 717 Autosampler and a Waters 996 Photo Diode Array 
extracting at a wavelength of 263 nm.  The system was operated under isocratic flow at 1 
mL/min using a mobile phase consisting of 70:30:0.05 acetonitrile:water:diethanolamine 
equipped with a Phenomenex Luna 5 μm C18(2) 100Å, 150 mm x 4.6 mm 
(Phenomenex®, Torrance, CA) HPLC column using injection volumes of 200 μL.  Data 
were collected and analyzed using Empower® Version 5.0 software.  The retention time 
of ITZ was approximately 6 min.  All analytical tests maintained system suitability limits 
for linearity from 0.024 to 100 μg/mL (r2 ≥ 0.999) and reproducibility of replicate 





B.4 RESULTS & DISCUSSION 
 
Dissolution testing of poorly water soluble compounds is frequently conducted 
under non-sink conditions to determine the behavior of a composition in vivo.  
Frequently, dissolution tests also employee biorelevant media to simulate the conditions 
of the gastrointestinal tract.  The most common method of preparation for systems is via 
an organic solvent emulsion, typically using methylene chloride or dichloromethane 
(DCM) (4, 5).  For this study, as detailed in the methods section, media systems were 
prepared using a DCM emulsion and extended mixing to study differences in 
performance.  During non-sink dissolution testing of itraconazole under pH change 
methods, 10 times equilibrium solubility of acidic media was added to the dissolution 
vessel.  In order to provide a comparative basis, a similar total amount of itraconazole 
was added to biosimilar media, which represented upwards of 10,000 times equilibrium 
solubility.  Equilibrium solubility studies using biosimilar media showed that 
concentrations were maintained below the limit of quantitation for 48 hours, indicating 
minimal itraconazole solubility.  Dissolution profiles for both media preparations, 
presented in Figure B.1 along with critical release and comparison metrics in Table B.1, 
show similar behavior.  Both media provided rapid release of the formulation, with 
maximum amounts of drug in solution observed after 45 minutes.  Maximum 
concentration levels were also comparable and provided less than 5% variation, as shown 
in Table B.1.  Precipitation profiles were similar between the two media used with less 
than 15% variation between the two formulations in terms AUCdissolution.  Given the 
relatively high variability observed with similar non-sink itraconazole tests, such as the 
pH change surfactant free method, this difference was not determined to be significant.  
Finally, statistical comparison was conducted using the f-test metric which has been 
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applied by the United States Food and Drug Administration for the evaluation of 
similarity between dissolution profiles.  For testing, release profiles were converted to 
percentage values, such that 37.5 mg was considered 100% release.  As shown in Table 
B.1 f1 and f2 values met the specific requirements for similarity, being < 15.0 and > 50.0 
for f1 and f2, respectively.  Although this approach has not been previously reported for 
use in the comparison of non-sink testing profiles, this does provide a theoretical basis for 
similarity, further supporting no significant difference between the media preparation 




Results from this study showed that regardless of the media preparation 
technique, in vitro dissolution behavior was similar, having minimal variations in critical 
metrics and also providing f-test similarity.  This indicates that FaSSIF media can be 
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Figure B.1 Dissolution Comparison of Biorelevant Media Preparation Methods.  Key: 
Extended Mixing Method (♦), DCM Emulsion Method (■).  Each vessel 
(n=1) contained 37.5 mg ITZ equivalent. Testing was conducted using 






Composition Amax (mg) tmax (min) 
AUDC 
(mg·min) f1 f2 
DCM Emulsion Method 12.7 45 3,922 -- -- 
Extended Mixing Method 12.1 45 3,450 13.49 72.80 
Differences < 5.0% < 5.0% < 15.0% Meets < 15.00 Meets > 50.00 
 
Table B.1 Biorelevant Dissolution Metrics for Formulations  
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Appendix C: HPLC Method Verification for the Detection of Hydroxy-




The purpose of this study was to verify that the current HPLC method for analysis 





Detection of itraconazole from rat plasma samples was performed based on the 
method reported by Gubbins et al. (1), however was never validated for detection of the 
primary metabolite, hydroxy-itraconazole.  Since itraconazole is extensively metabolized 
by CYP 3A enzymes, conversion occurs in the gut wall as well as the liver, resulting in a 
significant first pass effect.  For oral bioavailability studies using a rat model, conversion 
can be extensive at up to 75%, with decreasing conversions at increasing dose.  Since 
formation of hydroxyl-itraconazole can significantly impact oral bioavailability studies, 
examination of the current analytical method for the detection of this metabolite, as well 








Itraconazole, BP micronized (ITZ) was purchased from Hawkins, Inc. 
(Minneapolis, MN). Hydroxy-itraconazole was purchased from BDG Synthesis 
(Wellington, New Zealand).  HPLC grade acetonitrile and methanol were purchased from 
EMD chemicals (Darmstadt, Germany). All other chemicals utilized in this study were of 




C.3.2.1 Preparation of Known Standard Curve 
 
Known amounts of itraconazole (ITZ), hydroxy-itraconazole (OH-ITZ) and 
ketoconazole (KTZ) were dissolved into 100 ml flasks using 38:62 0.05M phosphate 
buffer : acetonitrile mobile phase.  Samples were combined into known volumes and 
serially diluted to establish a linear calibration curve. 
 
C.3.2.2 Preparation of Spiked Plasma Samples 
 
Prior to HPLC analysis, plasma samples were removed from frozen storage, 
allowed to equilibrate to room temperature and a measured volume 250 μl of mouse 
serum was transferred to a clean 1.5 mL microcentrifuge tube and spiked with ITZ and 
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OH-ITZ in 10 μl of methanol to provide a theoretical concentration of 500 ng/ml.  To 
each microcentrifuge tube, 50 μL of 0.3 N barium hydroxide and 50 μL 0.4 N zinc sulfate 
heptahydrate solutions were added.  Samples were then vortex mixed for 30 s and 1 mL 
of acetonitrile containing 1200 ng/mL KTZ as an internal standard was added to each 
plasma sample.  Samples were vortex mixed for an additional 90 s and centrifuged at 
3000g for 15 min. From each vial the supernatant was extracted, transferred to a clean 1.5 
mL centrifuge tube and dried in an aluminum heating block (70 °C) under a stream of 
nitrogen gas. Samples were reconstituted with 250 μL mobile phase, vortex mixed for 60 
s and centrifuged for an additional 15 min.  An aliquot of the supernatant was extracted 
and filled into 150 μL HPLC vial inserts.  
 
C.3.2.3 High Performance Liquid Chromatography Analysis of Samples 
 
Samples were analyzed at a wavelength of 263nm using a Waters (Waters 
Corporation, Milford, MA) high performance liquid chromatography (HPLC) system 
consisting of dual Waters 515 Syringe Pumps, a Waters 717 Autosampler and a Waters 
996 Photo Diode Array extracting at a wavelength of 263 nm. The system was equipped 
with a Phenomenex® Luna 5 μm C-18(2) 100Å HPLC column (250 mm × 4.6 mm) 
maintained at a temperature of 37 °C using a 38:62 0.05M phosphate buffer : acetonitrile 
mobile phase operated under isocratic flow of 1 mL/min.  Sample injection volumes of 





C.4 RESULTS & DISCUSSION 
 
The current method used within the Division of Pharmaceutics for quantifying 
ITZ levels from animal tissue and plasma samples was based on that reported by Gubbins 
et al. (1), and had been successfully employee in several studies within the group (2-6).  
Previous reports using this method however, failed to identify the primary metabolite, 
OH-ITZ in the chromatograms even though the original method was shown to provide 
appropriate separation.  As such, identification and quantification of this metabolite 
needed to be established using the already validated method. 
 
Standard samples of the individual components, as well as combined standards 
having all three components (ITZ, OH-ITZ and KTZ) were injected to establish linearity 
and reproducibility of the method, as well as verify appropriate separation of analyte 
peaks.  A representative chromatogram, shown in Figure C.1, indicated that there was 
sufficient separation of the peaks using the validated method, with resolution values of 
4.04 and 13.71 for KTZ:OH-ITZ and ITZ:OH-ITZ, respectively. 
 
Linearity and reproducibility of the analytes were also determined, as shown in 
Figure C.2 and Table C.1.  For all three analytes, excellent linearity was observed with r2 
values greater than 0.9999.  Additionally, similar absorbance profiles were presented for 
both ITZ and OH-ITZ, suggesting the potential of using only the ITZ calibration curve to 
quantitate both materials if necessary.  Similar absorbance profiles for these materials 
were also demonstrated across the UV spectrum, as shown in Figure C.3.  This was 
anticipated since the materials are structurally similar and would present the same 
chromophores in nearly identical levels on a per mass basis.   Furthermore, 
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reproducibility of OH-ITZ samples was demonstrated to be acceptable, meeting the 
system suitability requirements of NMT 2.0%.  These results indicated that the existing 
analytical method could be utilized to assess the level of OH-ITZ and ITZ from samples 
using KTZ an internal standard. 
 
To verify the recovery of OH-ITZ from plasma samples, a mouse serum matrix 
was spiked with a known concentration of analyte (460 ng/ml theoretical) and analyzed 
using the method described previously.  The calculated plasma concentration determined 
using this method was measured to be 443 ng/ml, representing 96% recovery.  This 
indicated that the method provided a high recovery of the target analyte and would be 
acceptable for use in assessing plasma concentrations during oral bioavailability studies.   
        
C.5 CONCLUSIONS 
 
Results indicated that the HPLC method could be utilized to quantify the 
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